Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
07/2010 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions July category listing 07/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
07/29/2010 > patent applications in patent subcategories. category listing

20100190684 - Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity: The invention generally concerns inhibition of a molecule that has a role in post-translational modification of a receptor for antiproliferative factor (APF) of bladder epithelial cells, thereby modulating the APF. In particular, inhibition of DHHC2 activity and/or ZDHHC2 expression results in modulation of APF receptor activity, and in specific aspects... Agent: Fulbright & Jaworski, LLP

20100190685 - Prognostic factor in sarcoma, and metastasis inhibitor: The present invention relates to uses of sarcopodin as a gene associated with distant metastasis or prognosis for survival in tumors. Specifically, the present invention provides a method of determining the risk of distant metastasis or prognosis for survival in a tumor, comprising measuring the expression level of sarcopodin in... Agent: Leydig Voit & Mayer, Ltd

20100190686 - Novel secreted proteins of adipocytes for diagnostic purposes: The present invention relates to the discovery of polypeptide biomarkers excreted into the blood stream (serum or plasma) and/or urine from adipocytes and their use to determine the existence of metabolic syndrome (prediabetic) and/or diabetic conditions (including type 2 diabetes) including insulin resistance and/or glucose intolerance, their use to monitor... Agent: Coleman Sudol Sapone, P.C.

20100190687 - Pyrimidinone derivatives and methods of use thereof: The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 (“GPR119”) in a patient.... Agent: Merck Patent Department (k-6-1, 1990)

20100190690 - Biomimetic particles and films for pathogen capture and other uses: The identification and immobilization of glycosylated molecules having biomimetic properties, more particularly naturally-occurring, tissue-derived, non-immunological glycan sequences or functional equivalents thereof, on solid state surfaces and films or on membranes arising at the interface between non-polar and polar materials is described herein. The biomimetic glycosylated films and particles constructed therefrom... Agent: Smith Patent Consulting, LLC

20100190689 - Compositions and methods related to protein displacement therapy for myotonic distrophy: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of... Agent: Ballard Spahr LLP

20100190691 - Delivery of nucleic acids using cell-penetrating peptides: The present invention is based on the innovative concept of conjugating a cell-penetrating peptide (CPP), including a protein transduction domain, to a nucleic acid molecule to provide a nucleic acid-protein conjugate exhibiting enhanced cellular uptake. Accordingly, the invention provides a method of producing a cell permeable nucleic acid molecule conjugate... Agent: Dla Piper LLP (us)

20100190692 - Methods for reducing gnrh-positive tumor cell proliferation: A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore a method for reducing degenerate GnRH-positive tumor cells... Agent: Grund Intellectual Property Group

20100190688 - Tetrapeptide analogs: Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided.... Agent: Scully, Scott, Murphy & Presser, P.C.

20100190695 - Liquid crystal emulsion type pharmaceutical composition containing cyclosporine, and therepeutic method of treating cutaneous disease therewith: A dermal external pharmaceutical composition that excels in feeling at application or after application and that by enhancing of the transdermal absorption of cyclosporine, exerts medicinal benefits at low concentration. There is provided a liquid crystal emulsion-type pharmaceutical composition comprising cyclosporine, a hydrophilic nonionic surfactant, a lipophilic nonionic surfactant, an... Agent: Muncy, Geissler, Olds & Lowe, PLLC

20100190693 - Method for screening compounds & uses therefor: In accordance with the present invention, it has been discovered that glucose and incretin hormones promote pancreatic islet cell survival via the calcium and cAMP dependent induction, respectively, of the transcription factor CREB. Specifically, a signaling module has been identified which mediates cooperative effects of calcium and cAMP on islet... Agent: Foley & Lardner LLP

20100190694 - Methods for identifying patients who will respond well to cancer treatment: The invention provides methods for identifying patients who will respond well to cancer treatment with a therapeutic regimen that comprises the use of a histone deacetylase inhibitor (HDACi) and one or more further chemotherapeutic agents. The invention also relates to methods of treating such patients with a therapeutic regimen comprising... Agent: Klauber & Jackson

20100190696 - Treatment of t-cell mediated diseases: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides... Agent: Sheridan Ross PC

20100190709 - Angiogenic composition: e

20100190711 - Big gastrin i as a therapeutic agent: The present invention is directed to the use of the peptide compound Pyr-Leu-Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp-Pro-Ser-Lys-Lys-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100190708 - Composition for amelioration of body lipid: e

20100190702 - Compositions and methods of treating neoplasia: The invention features compositions and methods that are useful for the treatment of neoplasia by reducing base excision repair (BER). Such compositions are useful, for example, for enhancing the efficacy of known chemotherapeutics, such as DNA alkylating agents. In particular, the invention features agents that mimic the interaction of APC... Agent: Edwards Angell Palmer & Dodge LLP

20100190699 - Glucagon analogs exhibiting enhanced solubility in physiological ph buffers: Modified glucagon peptides are disclosed having improved solubility while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or... Agent: Barnes & Thornburg LLP

20100190701 - Glucagon/glp-1 receptor co-agonists: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of... Agent: Barnes & Thornburg LLP

20100190710 - Il-23 receptor antagonists and uses thereof: The present invention relates to IL-23 receptor antagonists and agonists. The use of IL-23 receptor antagonists in treating autoimmune and inflammatory disorders, as well as methods of identifying IL-23 receptor antagonists and agonists.... Agent: Choate, Hall & Stewart LLP

20100190700 - Methods and compositions for treating hypoglycemic disorders: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-I) receptor, e.g. a GLP-I fragment or analogue thereof.... Agent: Pearl Cohen Zedek Latzer, LLP

20100190698 - Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor: The present invention provides AP-1 signaling inhibitory peptides comprising the amino acid sequences of SEQ ID NOS: 28-31, 36-39, 45-48, 54-57 and 62-65, compositions comprising one or a plurality of said peptides, and methods of treatment of neurological disorders comprising the administration of the peptide(s) or compositions.... Agent: Fenwick & West LLP

20100190707 - Novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20100190703 - Peptides specific for human blood outgrowth endothelial cells: Provided herein are compositions and methods for binding outgrowth endothelial cells (OEC). The compositions consist of peptide ligands capable of binding OEC with high affinity and specificity. The compositions of the invention include peptides set forth in SEQ ID NO: 1-38 and variants and derivatives thereof. Compositions also include the... Agent: Alston & Bird LLP

20100190714 - Rnai inhibition of alpha-enac expression: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100190715 - Stable formulations of peptides: Method for increasing the shelf-life of a pharmaceutical formulation comprising a glucagon-like peptide.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100190706 - Stable non-aqueous pharmaceutical compositions: The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia, comprising insulinotropic peptide and semi-polar protic organic solvent.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100190704 - Structure comprising chitosan and collagen: It is an object of the present invention to provide a structure comprised of a mixture of chitosan and collagen, which achieves both degradability and tissue adhesiveness. The present invention provides a structure comprised of a mixture of chitosan and collagen, wherein (i) the deacetylation degree of chitosan is 50%... Agent: Sughrue Mion, PLLC

20100190705 - Suppression of glial fibrillary acidic protein: Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell. Also provided are compounds useful for the treatment of Alexander disease in subjects at risk of or diagnosed with Alexander... Agent: Foley & Lardner LLP

20100190697 - Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass: The present invention relates to methods and compositions for treating and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway involving gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not limited to, metabolic syndrome, glucose intolerance, diabetes types 1 and 2, atherosclerosis and obesity.... Agent: Kenyon & Kenyon LLP

20100190712 - Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine: The present invention is directed to the use of the peptide compound Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100190713 - Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent: The present invention is directed to the use of the peptide compound Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH or its combination with the peptide Lys-Trp-Lys-Leu-Phe-Lys-Lys-Ile-Glu-Lys-Val-Gly-Gln-Asn-Ile-Arg-Asp-Gly-Ile-Ile-Lys-Ala-Gly-Pro-Ala-Val-Ala-Val-Val-Gly-Gln-Ala-Thr-Gln-Ile-Ala-Lys as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.... Agent: Winstead PC

20100190718 - Methods for preventing or treating mitochondrial permeability transition: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of... Agent: Foley & Lardner LLP

20100190716 - Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents: The present invention is directed to the use of the peptide compound Pro-Ser-Hyp-Gly-Asp-Trp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100190717 - Use of melanin concentrating hormone and met-enkephalin as therapeutic agents: The present invention is directed to the use of the peptide compound Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100190720 - Compositions and methods for preventing or treating cancer: The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer.... Agent: Dann, Dorfman, Herrell & Skillman

20100190719 - Peptides as antimicrobial agents towards campylobacter spp: The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.... Agent: Graybeal Jackson LLP

20100190721 - Peptide whitening agents and cosmetic compositions comprising the same: The present invention relates to novel peptide compounds having the following formula [R1R2N—CH(Ra)—CO]a-(AA1)m-(AA2)b—X1—X2—X3—Y1—Y2—Y3—X4-(AA3)n—[NH—CH(Rb)—COOR3]c. It also pertains to cosmetic and dermatological compositions comprising one or more of these peptide compounds and to their uses in the cosmetic whitening of human skin and for the manufacture of a dermatological preparation intended to... Agent: Young & Thompson

20100190722 - Substance p and thyrotropin releasing hormone for therapeutic applications: The present invention is directed to the use of the peptide compound Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100190723 - Preventive or therapeutic composition for liver disease: This invention provides a composition having preventive and/or therapeutic effects on liver disease, which is highly effective, free of side effects, easily ingestible, and capable of long-term ingestion from the viewpoint of a cost and safety. This invention relates to a peptide having the amino acid sequence represented by the... Agent: Sughrue Mion, PLLC

20100190724 - Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection: The present invention is directed to the use of the peptide compound Pro-Leu-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100190725 - Amino acid derivatives: Compounds of formula (I) or formula (II) have dopaminergic activity: wherein: R1 is a carboxyl, carboxyl ester, or carboxamide group; R2 is a group —C(═O)—NR3R4, or —S(═O)2—NR3R4; R3 and R4 are independently selected from hydrogen, optionally substituted C1-C6 alkyl, (C1-C5 fluoroalkyl)-CH2—, -Q, and —CH2Q, wherein Q is an optionally substituted... Agent: Banner & Witcoff, Ltd.

20100190726 - Novel phyllanthus extract: A method is described for producing an extract of Phyllanthus comprising the steps of: (a) extracting Phyllanthus components with a solvent; (b) fractionating the extract obtained in the preceding step on the basis of hydrophobicity; (c) collecting and combining fractions that correspond in hydrophobicity to elute fractions resulting from 10-50%... Agent: Mdip LLC

20100190727 - Use of monosaccharides and composition therefor: The present invention relates to the use, especially the cosmetic use, of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, for reducing or preventing the signs of ageing of the skin or its integuments. The present invention also relates to a cosmetic composition and a device... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100190728 - Synthesis of metabolically stable analgesics, pain medications and other agents: Disclosed are analgesic-related compositions and methods of using the compositions for modulation of analgesic receptor activity. The compositions and methods are useful for reducing pain, as well as for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling.... Agent: Techlaw LLP

20100190730 - Application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression: The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20100190729 - Composition for treating atopic dermatitis comprising hirsutanonol or oregonin as an active ingredient: The present invention relates to a composition for treating atopic dermatitis comprising hirsutanonol as an active ingredient. Hirsutanonol or oregonin as the active ingredient of the present composition decreases the number of eosinophil increased in atopic dermatitis and regulates expression amounts of immune regulatory cytokines, IL-4, IL-5, IL-10 and IL-13... Agent: Clark & Elbing LLP

20100190731 - Methods for treating acute myocardial infarctions and associated disorders: The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.... Agent: Marshall, Gerstein & Borun LLP (intermune)

20100190732 - Use of pterosin compounds for treating diabetes and obesity: This invention relates to the use of pterosin compounds of formula I for treating diabetes including type I and type II. Also disclosed is the use of the pterosin compounds for treating obesity.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100190733 - Methods of treating muscular dystrophies: The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100190734 - Method of treating dry eye disease with azithromycin: The present invention relates to a method for treating dry eye disease. The method comprises identifying a subject suffering from dry eye disease, and administering to the subject an amount of azithromycin effective to reduce dry eye symptoms and/or signs ands to improve tear film quality. Azithromycin is preferably administered... Agent: Howery LLP

20100190735 - Mouthwash and method of using same for the treatment of mucositis or stomatitis: An oral rinse formulation for the treatment or prophylaxis of mucositis or stomatitis comprises one or more of the following components in combination with pharmaceutically acceptable excipients or additives: a) at least one corticosteroid; b) at least one anti-histamine; c) at least one topical anaesthetic; and, d) at least one... Agent: Adorno & Yoss, LLC

20100190736 - Morpholinyl anthracycline derivative combined with protein kinase inhibitors: The present invention provides the combined use of a morpholinyl anthracycline derivative of formula (I) as defined in the specification or a pharmaceutically acceptable salt thereof, such as nemorubicin hydrochloride, and a protein kinase (PK) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations... Agent: Scully Scott Murphy & Presser, PC

20100190837 - 5'-substituted-2-f' modified nucleosides and oligomeric compounds prepared therefrom: The present invention provides 5′-substituted-2′-F nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In one preferred embodiment the nucleoside analogs have either (R) or (5)-chirality at the 5′-position. These nucleoside analogs are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance.... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20100190838 - Connective tissue growth factor fragments and methods and uses thereof: The present invention is directed to CTGF fragments comprising at least exon 2 or exon 3 of CTGF and having the ability to induce extracellular matrix synthesis, in particular, collagen synthesis and myofibroblast differentiation. The present invention is further directed to methods using said CTGF fragments to identify compositions which... Agent: Dla Piper LLP (us)

20100190841 - Genetic suppression and replacement: The invention relates to gene suppression and replacement. In particular, the invention relates to enhanced expression of suppression agents for suppressing gene expression in a cell and in vivo and replacement nucleic acids that are not inhibited by the suppression agent. Regulatory elements are included in expression vectors to optimize... Agent: David S. Resnick

20100190842 - Influenza polynucleotides, expression constructs, compositions, and methods of use: The invention provides isolated RNA molecules containing a stretch of nucleotides from a conserved Influenza sequence, and provides complementary RNA molecules thereto. The RNA molecules of the invention are also substantially non-homologous to human sequences. The RNA molecules of the invention include double-stranded RNAs comprising a first region that is... Agent: David S. Resnick

20100190839 - Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats: Telomere-encoding nucleic acid nanocircles, methods for their preparation, and methods for their use are disclosed. The nanocircles can be constructed containing multiple repeats of the complement of telomere repeat sequences. The telomere-encoding nanocircles are useful for extending telomeres both in vitro and in vivo, for treating macular degeneration, the effects... Agent: Howrey Simon Arnold & White, LLP

20100190840 - Tissue specific gene therapy treatment: The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca2+]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium... Agent: David S. Resnick

20100190737 - Compositions comprising inosine and orotic acid and methods of use thereof for the treatment of certain heart conditions and enhancement of work capacity: The invention comprises a composition of inosine and orotic acid or a salt thereof, and its methods of use in treating, maintaining and enhancing the health of the heart, and specifically the integrity of the myocardium. The effective combination of inosine and orotic acid/orotate effectively improves various medical parameters that... Agent: Scully Scott Murphy & Presser, PC

20100190738 - Use of aalkylphophocholines in combination with antitumor medication for the treatment of benign and melignant oncoses in humans and mammals: e

20100190739 - Rapidly dissolving vitamin formulation and methods of using the same: Rapidly dissolvable nutritional compositions and methods of providing nutritional supplementation to candidates for, patients undergoing, or patients having undergone bariatric surgery, to patients suffering renal disease, and to candidates for or patients undergoing dialysis. The compositions generally comprise one or more vitamins and optionally minerals and dissolve in less than... Agent: Senniger Powers LLP

20100190740 - Oil-in-water emulsion: The present invention relates to a composition in the form of an emulsion of the oil-in-water type formed of oily globules which are each provided with a lamellar liquid crystal coating and which are dispersed in an aqueous phase, wherein it has a pH ranging from 3 to 5.5 and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100190742 - Cosmetic/pharmaceutical compositions comprising hyaluronic acid and administration thereof for reducing signs of aging: Cosmetic/pharmaceutical compositions contain, formulated into a physiologically acceptable medium, at least (i) hyaluronic acid and/or one of its derivatives and (ii) a C-glycoside compound, at least one of the constituents (i) and (ii) advantageously being in a form suitable for administration by injection, and administration thereof for filling depressions on... Agent: Buchanan, Ingersoll & Rooney PC

20100190741 - Injectable cross-linked polymeric preparations and uses thereof: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic... Agent: Hoffmann & Baron, LLP

20100190743 - Method and composition for treatment of a mucosal tissue disorder: Methods of treating a subject suffering from a disorder in a mucosal tissue, such as interstitial cystitis; cancer in a mucous membrane such as bladder or vaginal cancer; Crohn's disease; inflammatory bowel disease or colitis, by administering a medicament containing a sulfated chitinous polymer administered topically are described. Pharmaceutical compositions... Agent: Edwards Angell Palmer & Dodge LLP

20100190744 - Compositions and methods of treating viral infections: The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing... Agent: Casimir Jones, S.c.

20100190747 - Fused ring compound and use thereof: e

20100190745 - Heterocyclic urea derivatives and methods of use thereof: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20100190746 - Quinazolinones as potassium channel modulators: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia,... Agent: Townsend And Townsend And Crew, LLP

20100190749 - Benzoxazole kinase inhibitors and methods of use: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or... Agent: Wilson, Sonsini, Goodrich & Rosati

20100190748 - Boron-containing small molecules: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part... Agent: Morgan, Lewis & Bockius LLP (sf)

20100190750 - Gpr119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto: The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a... Agent: Fish & Richardson P.C.

20100190751 - Novel combination of neramexane for treatment of nerordegeneratie disorders: The present invention relates to combinations comprising neramexane and a Glutamate Release Inhibitor (GRI) and the use of such combinations in the treatment of neurodegenerative disorders.... Agent: The Firm Of Hueschen And Sage

20100190752 - Pharmaceutical combination: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b)... Agent: Crowell & Moring LLP Intellectual Property Group

20100190753 - Methods and compositions for treating amyloid-related diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.... Agent: Mccarter & English/ Neurochem

20100190754 - Azolylmethylidenehydrazine derivative and use thereof: wherein Ar is an aryl group optionally having substituent(s) or a heteroaryl group optionally having substituent(s), R1 and R2 are the same or different and each is an alkyl group, a cycloalkyl group, an aralkyl group optionally having substituent(s), an aryl group optionally having substituent(s), a heteroarylalkyl group optionally having... Agent: Leydig Voit & Mayer, Ltd

20100190756 - 3, 10, and 12a substituted tetracycline compounds: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100190755 - Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment: The present invention pertains, at least in part, to substituted tetracycline compounds. The present invention also pertains to methods for treating rheumatoid arthritis in a subject, comprising administering to the subject a tetracycline compound of the invention.... Agent: Mintz Levin Cohn Ferris Glovsky And Popeo, P.C.

20100190757 - Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same: The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or <3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units,... Agent: Millen, White, Zelano & Branigan, P.C.

20100190759 - Nk 1 antagonists: e

20100190758 - Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding: Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100190760 - Process for making crystals: A process for preparing an emulsion or a dispersion comprising crystalline particles of at least one active principal that comprises contacting a solution of at least one solute in a solvent or mixture of solvents in a first flowing stream with a non-solvent in a second flowing stream wherein the... Agent: Tod T. Tumey

20100190763 - Poly (adp-ribose) polymerase (parp) inhibitors: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and... Agent: Takeda San Diego, Inc.

20100190764 - Novel compounds: This invention relates to novel Spiro cyclopentane derivatives of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100190766 - Antibacterial agents: i

20100190767 - Compounds for the treatment of inflammatory diseases: and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100190765 - Dihydrodiazepines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20100190761 - Diphenyl substituted alkanes: The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.... Agent: Merck

20100190762 - Triazolyl phenyl benzenesulfonamides: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of... Agent: Brinks Hofer Gilson & Lione

20100190771 - Amino-heterocyclic compounds: m

20100190770 - Compositions and methods for inhibition of the jak pathway: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.... Agent: Weaver Austin Villeneuve & Sampson LLP

20100190768 - Novel fused pyrole derivative: wherein R1 is aralkyl, etc.; R2 is H, etc.; —W4═W5—W6═W7— is a group of the formula: —CR4═CR5—CR6═CR7— (in which R4, R5, R6 and R7 are independently a group of the formula: -E-A (E is a single bond, etc., A is H or nitro, etc.)), etc.; R8 is a group of... Agent: Birch Stewart Kolasch & Birch

20100190769 - Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R is H or C1-C6 alkyl;... Agent: Genentech, Inc.

20100190772 - Substituted azepine derivatives as serotonin receptor modulators: The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT)... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100190773 - Anti-cytokine heterocyclic compounds: Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100190774 - Inhibitors of c-met and uses thereof: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.... Agent: Vertex Pharmaceuticals Inc.

20100190775 - Pyrimidodiazepinone derivative: [wherein n represents 1 or 2, Z represents a hydrogen atom or the like, R1 and R2 may be the same or different, and each represents a hydrogen atom or the like, A represents a bond, (CH2)m (wherein m represents an integer of 1 to 4), optionally substituted phenylene, optionally... Agent: Edwards Angell Palmer & Dodge LLP

20100190776 - Thiazoline and oxazoline derivatives and their methods of use: The invention relates to a series of thiazoline and oxazoline derivatives, compositions thereof, and methods of treating conditions and disorders using such compounds.... Agent: Paul D. Yasger Abbott Laboratories

20100190777 - Compounds and methods for kinase modulation, and indications therefor: Compounds of formula I active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (I) wherein Ar is optionally substituted heteroaryl; R2 is hydrogen, lower alkyl or halogen; U is selected from the... Agent: Alexander R Schlee SchleeIPInternational P.C.

20100190778 - 3,4-dihydrobenzo[1,2,3]thiadiazine-1,1-dioxide derivatives, process for preparation thereof, medicaments containing said derivatives and their use: The present invention is related to new 3,4-dihydroberizo[1,2,3]thiadiazine-1,1-dioxide derivatives of the Formula (I), medicaments containing said new compounds, process for the preparation thereof and the use of said derivatives in the medicine. The compounds according to the present invention are suitable for the treatment or prevention of disorders of the... Agent: Kf Ross PC

20100190780 - Sigma receptor inhibitors: The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20100190781 - Sigma receptor inhibitors: The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20100190779 - Viral polymerase inhibitors: e

20100190782 - Compounds and methods of use: in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for... Agent: Jones Day

20100190783 - Triazolone derivatives:

20100190785 - Method for the purification of mycophenolate mofetil: The present invention provides a method for the preparation of mycophenolate mofetil wherein mycophenolic acid or an amine salt of mycophenolic acid is esterified with 2-morpholinoethanol, the resulting mixture is extracted into water at a pH-value between 1.0 and 3.0, and mycophenolate mofetil is back-extracted in a water-immiscible solvent at... Agent: Nixon & Vanderhye, PC

20100190784 - Organic compounds: e

20100190786 - Indolin-2-ones and aza-indolin-2-ones: The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to certain indolin-2-ones and aza-indolin-2-ones which possess anti-tumour activity and are accordingly useful in methods of treatment of the human or animal body,... Agent: Philip S. Johnson Johnson & Johnson

20100190787 - Modulators of mitotic kinases: The invention relates to compounds of Formula (I), a prodrug, a polymorph, a tautomer, an enantiomer, a stereoisomer, a solvate, an N-oxide, or a pharmaceutically acceptable salt thereof: (formula should be inserted here) which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100190788 - Amide derivatives as kinase inhitors: The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar1, Ar2, R1, R3, p and n have the meaning defined in the claims. In particular, the... Agent: Wolf Greenfield & Sacks, P.C.

20100190789 - Piperidine/piperazine derivatives: hydrogen, C1-12alkyl, C2-6alkenyl or R3; provided that if X represents —O—C(═O)—; the R2 O represents R3; and provided that (A) is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as... Agent: Philip S. Johnson Johnson & Johnson

20100190790 - Sigma receptor inhibitors: The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20100190791 - Compounds and methods for inhibiting the interaction of bcl proteins with binding partners: The present invention relates to heterocyclic compounds that bind to Bcl proteins and inhibit Bcl function, compositions comprising such compounds, and methods for treating and modulating disorders associated with hyperproliferation, such as cancer.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100190792 - Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds: Disclosed herein are methods of treating a patient suffering from a cognitive disorder using the following compounds (I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII).... Agent: Allergan, Inc.

20100190793 - Compositions for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are... Agent: Knobbe Martens Olson & Bear LLP

20100190794 - Herbicidally active composition: s

20100190795 - Betulin derived compounds useful as antiprotozoal agents: The invention relates to betulin derivatives, and to the use thereof as agents against protozoa of the genus Leishmania and against leishmaniasis in applications of pharmaceutical industry.... Agent: Birch Stewart Kolasch & Birch

20100190796 - Methods for identifying inhibitors of solute transporters: Provided herein are methods for identifying and characterizing agents that alter the volume of a cell. Methods are provided for rapid screening and identification of an agent that alters the capability of a small, neutrally charged solute transporter to transport the solute across a cell membrane. The methods described herein... Agent: Seed Intellectual Property Law Group PLLC

20100190797 - Crystalline polymophic forms of zopiclone, processes for their preparation and their pharmaceutical compositions: Disclosed are processes for the preparation of crystalline polymorphic forms of zopiclone and their pharmaceutical compositions for use as a sedative.... Agent: Volpe And Koenig, P.C.

20100190798 - Pharmaceutical composition comprising racemic aminopterin: There is disclosed a pharmaceutical composition comprising racemic aminopterin or pharmaceutically acceptable salts thereof. There is further disclosed a method to treat a disorder in a patient comprising administering a therapeutically effective amount of racemic aminopterin or pharmaceutically acceptable salts of racemic aminopterin. More particularly, there is disclosed a method... Agent: Syntrix Biosystems, Inc.

20100190799 - Phenazine compounds and use thereof in autoimmune and inflammatory diseases: The invention discloses compounds, compositions and methods useful for preventing and/or treating autoimmune diseases and inflammatory diseases. The methods and compositions utilize water-soluble phenazine compounds, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent autoimmune diseases and inflammatory diseases... Agent: Fenwick & West LLP

20100190800 - Combinaton of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases: e

20100190801 - Triazolopyridine derivatives as inhibitors of lipases and phospholipases: The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100190802 - Carboxamide compounds and methods for using the same: e

20100190803 - Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingred:

20100190804 - Macrocyclic compounds and their use as kinase inhibitors:

20100190805 - Preparation for the treatment of equine laminitis: Disclosed is the use of active substances known from human medicine for treating gout in order to pharmaceutically treat equine laminitis, especially the use of a preparation containing at least allopurinol and/or hydrocortisone and/or powdered opium and/or prednisolone and/or prednisone.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100190806 - Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives: The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of... Agent: Notaro, Michalos & Zaccaria P.C.

20100190807 - Cdki pathway inhibitors and uses thereof to regulate expression to tau protein: The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting increases in MAPT expression induced by the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.... Agent: Preti Flaherty

20100190808 - Tricyclic compounds as modulators of tnf-alpha synthesis: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.... Agent: High Point Pharmaceuticals, LLC

20100190809 - Combination formulations: This invention relates to solid oral dosage forms of the HIV inhibitors containing a combination of TMC114 and TMC125.... Agent: Philip S. Johnson Johnson & Johnson

20100190810 - Composition and method for treatment of warts: Provided is a composition comprising 5-FU and salicylic acid. This composition is useful as a treatment for warts. As opposed to conventional compositions and methods, this composition need only be applied once a day. Also provided are methods for the preparation and use of the composition for treatment of warts.... Agent: Nyemaster, Goode, West, Hansell & O'brien, P.C.

20100190812 - Nilotinib hcl crystalline forms: Crystalline forms of Nilotinib HCl are described.... Agent: Merchant & Gould PC

20100190811 - Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors: The invention provides a novel class of pyrimidine derivatives, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.... Agent: Genomics Institute Of The Novartis Research Foundation

20100190813 - Spiro [piperidine-4- 4' -thieno [3,2-c] pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis: The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to some thieno-pyrano-pyrazole derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis or pain.... Agent: Cooper & Dunham LLP

20100190814 - Spiroindolinone derivative prodrugs: e

20100190815 - Hypertension-ameliorating agent:

20100190816 - Kinase inhibitors:

20100190817 - Large substituent, non-phenolic amine opioids:

20100190818 - Novel salts of 6-heterocycle substituted hexahydrophenanthridine derivatives: The invention relates to salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical composition for use, e.g., in treatment of airway disorders.... Agent: Nath & Associates PLLC

20100190819 - Alpha-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof: The present application is related to compounds represented by Formula I, which are novel allosteric modulators of α7nAChR. The application also discloses the treatment of disorders that are responsive to modulation of acetylcholine action on α7nAChR in a mammal by administering an effective amount of a compound of Formula I.... Agent: Cooley LLP Attn: Patent Group

20100190820 - Modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I): its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group... Agent: Louis J. Wille Bristol-myers Squibb Company

20100190821 - 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors: v

20100190822 - Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv): The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.... Agent: Paul D. Yasger Abbott Laboratories

20100190823 - Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds: Disclosed herein is a compound of the formula (I) therapeutic methods, compositions, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20100190824 - Novel substituted piperidones as hsp inducers: The present invention relates to novel compounds of formula (I) or (II), their pharmaceutically acceptable salts and their hydrates, solvates, stereoisomers, conformers, tautomers, polymorphs and prodrugs and also pharmaceutically acceptable compositions containing them Wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification. The compounds... Agent: Jacobson Holman PLLC

20100190826 - Benzimidazole derivative: Provided is a novel and excellent method for treating and/or preventing benign prostatic hyperplasia, prostate cancer, and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an indole or benzimidazole derivative, where a nitrogen atom of the indole ring or benzimidazole ring is substituted... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100190825 - Benzimidazoles which have activity at m1 receptor and their uses in medicine: o

20100190827 - Polymorphic form of rimonabant, method for preparing it and pharmaceutical compositions containing it: The present invention relates to a novel crystalline polymorph of rimonabant, its method of preparation and the pharmaceutical compositions containing this novel polymorph.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100190828 - Thiazolyl oxime ethers and hydrazones as crop protection agents: in which the symbols A, L1, L2, Y, W, X, R1, R2, R3, R4, R5, R6 and R7 have the meanings given in the description, and also agrochemically active salts thereof, and their use for controlling phytopathogenic harmful fungi, and also methods for controlling phytopathogenic harmful fungi and processes for... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100190829 - Renin inhibitors: Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100190830 - (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives: The present invention relates to (3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic acid derivatives of Formula (I) wherein R1, R2, R3, R4, R5 and R6 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical... Agent: Hunton & Williams LLP Intellectual Property Department

20100190831 - Gpr120 receptor agonists and uses thereof: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.... Agent: Metabolex, Inc. C/o Swiss Tanner, P.C.

20100190832 - Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates: Transthyretin (TTR), a tetrameric thyroxine (T4) carrier protein, is associated with a variety of amyloid diseases. Derivative of biphenyl ethers (BPE), which are shown to interact with a high affinity to its T4 binding site thereby preventing its aggregation and fibrillogenesis. They prevent fibrillogenesis by stabilizing the tetrameric ground state... Agent: Ladas & Parry LLP

20100190833 - Pharmaceutical containing ppara agonist: A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100190834 - Composition for ophtalmic disease associated with hypoxia or ischemia: According to the present invention, a composition containing a VAP-1 inhibitor as an active ingredient, which is effective for ophthalmic diseases associated with hypoxia or ischemia can be provided. According to the present invention, moreover, an angiogenesis inhibitor that suppresses pathologic angiogenesis associated with hypoxia or ischemia can be provided.... Agent: Leydig Voit & Mayer, Ltd

20100190835 - Pharmaceutical composition comprising aleglitazar: The invention relates to a pharmaceutical composition comprising aleglitazar and to the process of manufacture and uses thereof.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100190836 - Compounds, screens, and methods of treatment: The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described.... Agent: Clark & Elbing LLP

20100190843 - Tubulin isotype screening in cancer therapy using halichondrin b analogs: Chemotherapeutic agents that interfere with microtubule assembly or disassembly in the cell are potent inhibitors of cell replication. Examples of such agents include halichondrin B analogs. It has been shown that the susceptibility of certain cancers to analogs of halichondrin B correlates with the expression of particular tubulin isotypes or... Agent: Clark & Elbing LLP / Eisai

20100190845 - Method of treating cancer using atp synthase inhibitors: The present invention is directed to a method of treating cancer in a subject in need of such a treatment by administering an inhibitor of ATP synthase in a pharmaceutically effective amount, preferably, the inhibitor contains one pyrone ring. The present invention also provides for a pharmaceutical composition comprising an... Agent: Wpat, PC Intellectual Property Attorneys

20100190846 - Microbicidal agent and microbicidal composition: A method for suppressing the growth of microorganism comprises the steps of providing a microbicidal agent comprising 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, and contacting the agent with the microorganism, wherein said microorganism is selected from the group consisting of Salmonella sp., and Pseudomonas aeruginosa.... Agent: Sughrue Mion, PLLC

20100190844 - Process for preparation of aglucone isoflavones: The present invention provides a process for producing a composition containing a high concentration of aglucone isoflavones, which comprises adding glucone isoflavones to the fermentation of microorganisms which are generally recognized as safe, and can express or produce β-glycosidase on a soy-based substrate. The present invention also provides a composition... Agent: Wpat, PC Intellectual Property Attorneys

20100190847 - Oral composition with an antiageing effect on the skin: A composition which is adapted for oral consumption and which comprises: (i) a PPAR ligand; such as EPA or DHA (ii) an oestrogen receptor binding agent; such as soy isoflavones (iii) an agent that is involved in the post-translational modification of collagen; such as ascorbic acid and (iv) a carotenoid,... Agent: Unilever Patent Group

20100190848 - Cysteine-protease inhibitors: Substantially pure diastereoisomeric compounds of formula Ia, alternatively Ib, or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, including hydrates, wherein PG is a protective group; R1 is a radical selected from the group consisting of phenylmethyl, 4-hydroxyphenylmethyl, (1H-indol-3-yl)methyl and (1H-imidazol-4-yl)methyl; R2 is a radical selected from... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20100190849 - Novel clerodanes and methods for repelling arthropods: in which R1 is H, halogen, formyl, a straight chain or branched C1-4 saturated alkyl, a straight chain or branched C2-4 unsaturated alkyl, or an aryl containing 6-10 carbon atoms in the ring skeleton thereof, wherein R1 is unsubstituted or substituted with one or more substituents, which are the same... Agent: Usda, Ars, Ott

20100190850 - Water-soluble binuclear nitrosyl iron complexes with natural aliphatic thiolyls possessing cytotoxic, apoptotic and no-donor activity: wherein R is sulfur-containing aliphatic ligands of natural origin, preferably, cystamine or penicillamine, to a method for the preparation thereof, to use thereof as an anticancer agent, to an apoptosis inducer, to a pharmaceutical composition comprising said complexes in an effective amount, and to a kit useful for the treatment... Agent: Osha Liang L.L.P.

20100190852 - Short acting phenylalkylamine calcium channel blockers and uses thereof: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle... Agent: Clark & Elbing LLP

20100190851 - Use of entacapone in cosmetic, dermatological and pharmaceutical compositions: A compound of formula (I), a salt of this compound or an isomeric or polymorphic form thereof can be used for the preparation of a cosmetic or dermatological composition, which is useful for the treatment or prophylaxis of itching or skin ageing caused by a combination of intrinsic and extrinsic... Agent: J.a. Lindeman & Co. PLLC

20100190853 - Topical application of travoprost for combating hair loss: Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over... Agent: Buchanan, Ingersoll & Rooney PC

20100190854 - Composition and method to treat mastitis: A method is provided to produce a treatment composition which is sprayed externally on to the udder of a cow to treat mastitis.... Agent: Tod R Nissle

20100190855 - Organic compounds: A compound of formula (I) wherein Y is oxygen or sulfur, and X1, X2 and X3 are independently of each other hydrogen, halogen, hydroxy or linear or branched (C1-6)-alkoxy, or hydroxy-(C1-6)alkyl or (C1-6)alkoxy-(C1-6)alkyl, mono- or dihalogenated (C1-6)-alkyl, amino(C1-6)-alkyl, hydroxy(C1-6)-alkyl, with one of the two provisos that: (1) at least of... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100190856 - Novel polyhydroxylated compounds as fatty acid synthase (fasn) inhibitors: The present invention relates to new polyhydroxylated compounds and, in particular, to its activity as fatty acid synthase (FASN) inhibitors and to their use for the treatment of pathological states for which an inhibitor of this enzyme is indicated. The invention further relate to pharmaceutical compositions containing them and to... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20100190857 - Lipid-improving agent and composition containing lipid-improving agent: A lipid-improving agent containing a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of a triglyceride(s).... Agent: Drinker Biddle & Reath (dc)

20100190858 - Pharmaceutical formulations containing lipoic acid derivatives: Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.... Agent: Goodwin Procter LLP Patent Administrator

20100190859 - Citrate salt of rasagiline: The subject invention provides rasagiline citrate, its compositions and processes for the manufacture thereof.... Agent: Cooper & Dunham, LLP

20100190860 - Methods for selectively enhancing antinociceptive potency of local anesthetics: This document features methods related to selectively inducing nociceptor blockade. For example, methods of treating pain by administering antinociceptor agents are provided.... Agent: Fish & Richardson PC

20100190861 - Cycloalkylamines as monoamine reuptake inhibitors: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as... Agent: Morgan, Lewis & Bockius LLP (sf)

20100190862 - Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient: The present invention relates to a composition for treating atopic dermatitis comprising hirsutenone as an active ingredient. Hirsutenone as the active ingredient of the present composition decreases the number of eosinophil and the level of IgE increased in atopic dermatitis and remarkably reduces expression amounts of immune regulatory cytokine (e.g.,... Agent: Clark & Elbing LLP

20100190863 - Method of stabilizing an aldehyde: A method of manufacturing a stable aldehyde-surfactant complex solution wherein at least one aldehyde is added to a surfactant in a first aliquot of water, at a temperature of between 40° C. to 50° C., the aldehyde is allowed to interact with the surfactant or detergent, in a complexing reaction,... Agent: Young & Thompson

20100190864 - Alkylene oxide derivative and skin external preparation containing the same: (In the formula, Z is the residue obtained by removing hydroxyl groups from the dimer diol, EO is an oxyethylene group, AO is an oxyalkylene group having 3 to 4 carbon atoms, and the addition form is block-type. The symbols a and b are the average addition mole numbers of... Agent: Rankin, Hill & Clark LLP

20100190865 - Methods and compositions for control of gypsy moths, lymanria dispar: n

20100190866 - Advanced antimicrobial carbon black dispersion: Disclosed is an antimicrobial carbon black dispersion which exhibits excellent dispersant properties and also inhibits microbial contamination when used in consumer products such as cosmetic formulations. Also disclosed are methods for producing and using the antimicrobial carbon black dispersion.... Agent: Handal & Morofsky, LLC

20100190867 - Stable and bioavailable compositions of isomers of lycopene for skin and hair: The present invention relates to a method of manufacturing a stable composition enriched in cis-lycopene (z-isomers) by prolonged heating in solvents of tomatoes, parts of tomatoes, derivative thereof or tomato extracts in solvents.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20100190868 - Photochromic and electrochromic compounds and synthesis and use thereof: Novel photochromic and electrochromic hexadiene compounds are described. The compounds are reversibly convertible between ring-open and ring-closed isomeric forms as indicated in structures I(o) and I(c) below. (See formula in original abstract of application) The conversion between the different isomeric forms may be induced by light or electricity. In one... Agent: Barnes & Thornburg LLP

20100190869 - Process for the isolation of dodecatrienal and its use as aroma substance: v

20100190870 - Polymer comprising water soluble units and lcst units, and aqueous composition comprising same: The invention concerns a polymer comprising water soluble units and LCST units consisting of ethylene oxide and propylene oxide random copolymers, or one of its salts. The invention also concerns an aqueous composition in particular thickened, even gelled, comprising such a polymer or one of its salts and an aqueous... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100190871 - Gel composition and cosmetic: The present invention provides a gel composition having improved texture in use. A gel composition consisting of an organosiloxane derivative represented by the following formula (1) or (3), a monohydric aliphatic alcohol having 10 to 30 carbon atoms, and water.... Agent: Rankin, Hill & Clark LLP

20100190872 - Production of beta-glucans and mannans: Disclosed are methods for producing yeast β-glucan and mannan preparations. The methods employ an autolysis process, followed by enzymatic treatment with one or more of a protease, glucanase or lipase. The preparations produced may be used in food supplements, pharmaceuticals, cosmetics, animal feeds, and neutraceuticals.... Agent: Michael Best & Friedrich LLP

20100190873 - Extract of the plant ashwaganda (withania somnifera) consisting of the seeds of said plant dried and processed into a flour to be used as an ingredient to be incorporated in tablets and/or capsules for human consumption and/or to be available as a base fo: This patent presents a previously undescribed flour obtained from the seeds of Ashwaganda (Withania Somnifera) to be incorporated into tablets and/or capsules or act as a base for solvent extraction where said extractions will be incorporated into tablets and/or capsules and where said extractions may be incorporated into creams/and/or lotions... Agent: Robert D. Bibb

  
07/22/2010 > patent applications in patent subcategories. category listing

20100184638 - Galanin receptors and brain injury: There is provided the use of a GALR2-specific agonist in the preparation of a medicament for the prevention or treatment of brain injury, damage or disease, wherein the brain injury or damage is caused by one of: embolic, thrombotic or haem-orrhagic stroke; direct or indirect trauma or surgery to the... Agent: Hunton & Williams LLP Intellectual Property Department

20100184636 - Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase d and raptor: The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases... Agent: Marshall, Gerstein & Borun LLP

20100184639 - Nucleic acids and polypeptides specific of the neisseria genus pathogenic strains: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.... Agent: Stites & Harbison PLLC

20100184637 - Pharmaceutical and/or cosmetic composition containing an active antioxydant principle and cell energy activator: A cosmetic or pharmaceutical composition, and particularly dermatological composition, comprising, in a physiologically adapted medium, as active principle, polypeptides or peptides, and methods of administering a composition capable of increasing cell energy and to protect the skin from oxidative damage. Also, a cosmetic treatment procedure aimed at protecting the skin... Agent: Young & Thompson

20100184640 - Dog diabetes: A method a method for diagnosing susceptibility to diabetes in a non-human animal, the method comprising: a) identifying whether or not a polymorphism as defined in Table 4 or a polymorphism which is in linkage disequilibrium with such a polymorphism is present in the genome of the animal; and b)... Agent: Fulbright & Jaworski, LLP

20100184641 - Novel plasma protein affinity tags: Method for increasing half-life of therapeutic agents in plasma and novel polypeptide derivatives.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100184643 - Methods and compounds regulating the erythroid response to iron deficiency: The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment... Agent: University Of Virginia Patent Foundation

20100184644 - Mucosal repair by tff dimer peptides: The present invention relates to the use of trefoil factor 1 (TFF1) and trefoil factor 3 (TFF3) dimers and a pharmaceutical composition comprising TFF dimers for increasing the viscosity of mucin in mucus layers and the repair of damaged mucus layers in the gastrointestinal tract (mouth, oesophagus, stomach, small and... Agent: Clark & Elbing LLP

20100184642 - Transgenic plants expressing cobalamin binding proteins: The present invention relates to the use of transgenic plants for the expression of vitamin B12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin B12 binding proteins. The present invention also relates to the use of recombinant vitamin B12 binding proteins... Agent: Senniger Powers LLP (kvph)

20100184646 - Melanocortin receptor ligands modified with hydantoin: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.... Agent: Alan F. Feeny, Esq.

20100184645 - Stitched polypeptides: The present invention provides inventive stitched polypeptides, pharmaceutical compositions thereof, and methods of making and using inventive stitched polypeptides.... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20100184647 - Use of epinecidin-1 peptides and anti-lipopolysaccharide factor peptides for treating microbial infection: Treatments of trichomonas, propionibacterium, or yeast infection using an epinecidin-1 peptide or an anti-lipopolysaccharide factor peptide.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100184649 - Novel antibacterial agents for the treatment of gram positive infections: The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against Clostridium difficile.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100184648 - Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease: A therapeutic agent for a non-alcoholic fatty liver disease comprising a melanin-concentrating hormone receptor antagonist as an active ingredient, which is developed based on a novel mechanism of action that a melanin-concentrating hormone receptor is involved in non-alcoholic fatty liver diseases. A method for screening a drug candidate compound for... Agent: Merck

20100184650 - Treating post-seizure patients: Patients are subject to a post-seizure treatment regime to separately inhibitor consecutive targets of an epileptogenic cascade comprising neurotransmitter receptor signaling, kinase/phosphatase activity, protein translation, and apoptosis or inflammation.... Agent: Richard Aron Osman

20100184668 - method of treating abnormal angiogenesis via the bai family of proteins and their protein fragments: The present disclosure encompasses the protein BAI1, and two cleavage products thereof, Vstat120 and Vstat40. The disclosure also describes the use of BAI1, and two cleavage products thereof, Vstat120 and Vstat40, as an anti-angiogenic and anti-tumorigenic therapy for gliomas as well as its other types of cancer and conditions involving... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100184654 - Anti-microbial targeting chimeric pharmaceutical: The present invention is based on the discovery of a composition that provides targeted anti-microbial effect. Specifically the composition contains a targeting moiety which recognizes a target microbial organism and an anti-microbial peptide moiety which has anti-microbial activity. In addition, the present invention provides methods of treating a microbial infection,... Agent: Townsend And Townsend And Crew, LLP

20100184681 - Antibacterial and antifungal peptides: This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.... Agent: Weaver Austin Villeneuve & Sampson LLP

20100184683 - Antibacterial and antifungal peptides: This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.... Agent: Weaver Austin Villeneuve & Sampson LLP

20100184684 - Antibacterial and antifungal peptides: This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.... Agent: Weaver Austin Villeneuve & Sampson LLP

20100184670 - Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis: Provided are methods and compositions, including topical compositions, for inducing tolerance to a sensitizing agent known to provoke contact hypersensitivity in a subject. Included are methods of topically applying to the subject an effective amount of an antisense composition targeting the start site or splice site of a CFLAR mRNA.... Agent: Seed Intellectual Property Law Group PLLC

20100184671 - Binding molecules for the treatment of myeloid cell malignancies: Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type... Agent: Traskbritt, P.C.

20100184690 - Combined use of a glp-1 compound and a modulator of diabetic late complications: Methods and uses for treatment of diabetic late complications comprising administration of a GLP-1 compound and a modulator of diabetic complications.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100184682 - Composition and methods for the inhibition of membrane fusion by paramyxoviruses: Fusion of the membrane of enveloped viruses with the plasma membrane of a receptive host cell is a prerequisite for viral entry and infection and an essential step in the life cycle of all enveloped viruses, such as paramyxoviruses. The instant invention is directed to providing polypeptides which are a... Agent: Morgan Lewis & Bockius LLP

20100184669 - Compositions and methods for cancer treatment using targeted carbon nanotubes: The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to carbon nanotubes such as single-walled carbon nanotubes (SWNTs) to form a... Agent: Dunlap Codding, P.C.

20100184658 - Compositions and methods for diagnosis and treatment of type 1 diabetes: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics... Agent: Leena Karttunen

20100184688 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone: Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.... Agent: Eckman Basu LLP

20100184661 - Conjugate comprising angiostation or its fragment, the method for producing the conjugate and use thereof: The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as... Agent: Millen, White, Zelano & Branigan, P.C.

20100184653 - Derivates of polyethylene glycol modified thymosin alpha 1: Pharmaceutical compositions that include thymosin alpha 1 peptide derivatives modified at the C-terminal of the peptide chain with polyethylene glycol, and their pharmaceutical acceptable salts, are generally disclosed. Also, new methods used to prepare these thymosin alpha 1 peptide derivatives modified at the C-terminal of the peptide chain with polyethylene... Agent: Dority & Manning, P.A.

20100184665 - Method for activating receptor by cofactor and method for utilizing ligand activity: Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and... Agent: Ladas & Parry LLP

20100184662 - Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (gp2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis: The invention relates to a method for the detection of antibodies from body fluids via immune reaction with GP2 from pancreatic zymogenic granules, immunoreactive sequences or analogs thereof, excluding tissue sections.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20100184663 - Methods and compositions related to inhibition of viral entry: Disclosed are compositions and methods for inhibiting viral entry.... Agent: Ballard Spahr LLP

20100184657 - Methods of treating epithelial lesions outside the stomach and intestines: Intestinal trefoil factors and nucleic acids encoding intestinal trefoil factors are disclosed. The intestinal trefoil factors disclosed are resistant to destruction in the digestive tract and can be used for the treatment of peptic ulcer diseases, inflammatory bowel diseases, and other insults.... Agent: Clark & Elbing LLP

20100184655 - Modified erythropoietin: This invention relates to novel protein conjugates, in particular, to novel pegylated proteins, and their methods of making and use. One aspect of the present invention relates to pegylated-erythropoietin having greater clinical efficacy and stability during shipment and storage than current erythropoietin formulations.... Agent: King & Spalding

20100184667 - Modified plasminogen activator inhibitor type-1 molecule and methods based thereon: The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays CN an increased in vivo half-life of the active form of PAI-1, but is deficient in one or more functional activities as compared to the wild-type PAI-1 protein. The modified PAI-1 molecule that displays an... Agent: Frommer Lawrence & Haug

20100184666 - Novel use of cocoa extract: A cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment for no more than three days, having a polyphenol content of more than 25% by weight, may be used in weight management.... Agent: Hoxie & Associates LLC

20100184664 - Ophthalmic compositions useful for improving visual acuity: The present invention provides a method of improving the visual acuity of a person in need thereof which comprises topically administering to said person, in an effective amount, an ophthalmic composition comprising an aqueous carrier component; and an effective amount of a tonicity component comprising a material selected from a... Agent: Allergan, Inc.

20100184656 - Pantropic neurotrophic factors: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.... Agent: Arnold & Porter LLP (24126) Attn:IPDocketing Dept.

20100184652 - Peptide inhibitors of abl kinases: Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a... Agent: K&l Gates LLP

20100184689 - Pharmaceutical composition containing botulinum neurotoxin: o

20100184674 - Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100184672 - Protein c for use in maintaining hemostasis: It is disclosed herein that protein C functions as a hemostatic agent. Thus, provided is a method of preventing, treating or ameliorating abnormal bleeding in a subject, comprising administering to the subject a protein C polypeptide or polynucleotide. Abnormal bleeding can result from a bleeding disorder, such as hemophilia or... Agent: Klarquist Sparkman, LLP

20100184687 - Purification of glucagon-like peptides: Method for purifying a glucagon-like peptide by reversed phase high performance liquid chromatography.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100184660 - Single exon genes encoding for novel bio-active peptides: The present invention relates to novel bio-active peptide hormone, process for the production of the same, and use of the same. The present invention identified novel bioactive peptide precursor and salts thereof which can be used as drugs, for example therapeutic polypeptides, ligands to discover relevant targets (e.g. GPCRs) or... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100184659 - Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents: The present invention is directed to sustained release formulations of biologic agents which permit persistent bioavailability. Preferred biologic agents include bone morphogenetic proteins. Diseases susceptible to amelioration and/or treatment with the formulations of the present invention include skeletal tissue diseases such as, but not limited to, osteoarthritis and other osteochondral... Agent: K&l Gates LLP

20100184685 - Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein: Systems, and methods for the use of such systems, are described that allow for the administration of a combination of a sustained release local anesthetic compound (such as bupivicaine) through a catheter based administration device and direct visualization or percutaneous injection of a neurotoxic protein compound (such as botulinum toxin)... Agent: Jackson Walker LLP

20100184651 - Targeted fusion proteins for cancer therapy: The invention relates to fusion proteins useful as therapeutics against cancer. The fusion protein comprises of cell-targeting moiety and apoptosis-inducing moiety. Cell-targeting moiety and apoptosis-inducing moiety are linked by a flexible linker, which are specifically recognized by cancer specific protease and cleaved in situ to release the apoptotic domain. In... Agent: Schwegman, Lundberg & Woessner, P.A.

20100184680 - Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43: The present invention is directed to the use of the peptide compound Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His as a therapeutic agent for the pro-phylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100184679 - Use of a combination of cart peptides as a therapeutic agent: The present invention is directed to the use of the combination of the Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-OH and Val-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.... Agent: Winstead PC

20100184676 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100184678 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the combination of the His-Pro-Leu-Gln-Lys-Thr-Tyr-OH and His-Ser-Asp-Gly-lle-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2 as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.... Agent: Winstead PC

20100184675 - Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent: The present invention is directed to the use of the peptide compound His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100184686 - Use of inhibitors for the treatment of rtk-hyperfunction-induced disorders, particularly cancer: The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this... Agent: Leydig Voit & Mayer, Ltd

20100184673 - Use of parathyroid hormone ( 1-34 ) as anti-hiv agent: The present invention is directed to the use of the peptide compound Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100184677 - Use of the human pancreatic polypeptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp- Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to... Agent: Winstead PC

20100184692 - Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.... Agent: Crowell & Moring LLP Intellectual Property Group

20100184691 - Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange: The present invention discloses a method of enhancing cardiac contractility in a subject with heart failure. The method consists of administering a compound that inhibits the sarcolemmal sodium/calcium exchanger, whose activity is elevated in heart failure. This method results in correction of cellular calcium handling and enhancement of cardiac contractility... Agent: Edwards Angell Palmer & Dodge LLP

20100184693 - Methods and systems for generating and evaluating peptides: A method has been developed to create databases of peptides having a desirable property, such as antimicrobial activity, based on analyzing a database of known peptides for a pattern statistically associated with an activity. One can determine a set of patterns that may be representative of a peptide having a... Agent: Pabst Patent Group LLP

20100184697 - Peptide-based stat inhibitor: A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT... Agent: Leydig, Voit & Mayer, Ltd.

20100184696 - Peptides and their use: The present invention relates to peptides for use as antifungal agents. The peptides comprise a sequence of 5 to 15 basic amino acids wherein substantially all of the amino acids in said sequence are the same.... Agent: Speckman Law Group PLLC

20100184694 - T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.... Agent: Fennemore Craig

20100184698 - Use of a deslorelin and mastoparan as a therapeutic agent: The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100184695 - Vascular endothelial cell-binding peptide: A peptide consisting of an amino acid sequence represented by any one of SEQ ID Nos. 1 to 76 of the present invention, a peptide consisting of an amino acid sequence in which one or several amino acids are substituted, deleted, inserted or added in these amino acid sequences, and... Agent: Birch Stewart Kolasch & Birch

20100184699 - Peptide derived from prostate-related protein as cancer vaccine candidate for prostate cancer patient who is positive for hla-a3 super-type allele molecule: According to the present invention, a peptide, which is a prostate-related protein derived peptide, capable of binding to an HLA-A3 supertype allele and recognized by the cellular and/or humoral immune system is provided. The peptides of the present invention make feasible the peptide-based anti-cancer vaccine therapy for prostate cancer patients... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100184700 - Preprocalcitonin antigen t epitopes: The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy.... Agent: Morgan Lewis & Bockius LLP

20100184701 - Beta-arrestin effectors and compositions and methods of use thereof: This application describes a family of compounds acting as β-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100184702 - Selective high-affinity polydentate ligands and methods of making such: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or... Agent: Llns/foley & Lardner Lawrence Livermore National Security, LLC

20100184705 - Therapeutic peptides and vaccines: Compositions are disclosed that induce broadly HIV therapeutic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide... Agent: Kile Goekjian Reed & Mcmanus

20100184703 - Use of peptide derivatives for treating pathologies resulting from ischemia: The inventors have studied the kinetic and hierarchy of activation of apoptogenic caspases during myocardial ischemia and have found that caspase 2 plays a major role during the cardiac pathology by a very fast activation after an ischemic episode. Experiments were carried out on animal models of transitory or permanent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100184704 - Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent: The present invention is directed to the use of the peptide compound Gly-Arg-Gly-Asp-Asn-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100184707 - Anticonvulsive pharmaceutical compositions: The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an... Agent: Young & Thompson

20100184706 - Fap-activated chemotherapeutic compounds, and methods of use thereof: One aspect of the present invention relates to compounds for delivering chemotherapeutic agents to cancerous cells to reduce discomfort and deleterious side effects associated with systemic administration of such agents. Another aspect of the invention relates to methods of treating a subject with cancer by administering a therapeutically effective amount... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100184708 - Use of gly-pro-glu-oh (gpe) as a therapeutic agent: The present invention is directed to the use of the peptide compound Gly-Pro-Glu-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100184709 - Malt1 specific cleavage in assay and screening method: The present invention is based on the surprising finding of a proteolytic cleavage function of human Malt1. More particularly, the present invention relates to enzyme and screening assays, methods for assessing cleaving activity, methods for screening, isolated polypeptides, antibodies and inhibitors of Malt1. The present invention also relates to the... Agent: K&l Gates LLP

20100184710 - Therapeutic bifunctional compounds: The invention generally relates to systems and methods for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using a bifunctional compound that inhibits both fatty acid metabolism and glycolysis. Thus, the invention links a fatty acid metabolism inhibitor to a glycolysis inhibitor. More particularly, the invention... Agent: Wolf Greenfield & Sacks, P.C.

20100184711 - Alpha-glycosyl thiols and alpha-s-linked glycolipids: The present invention relates to stereoselective methods for the preparation of α-glycosyl thiols and α-S-linked glycosylceramides.... Agent: David S. Resnick

20100184712 - Hyperbranched polymers based on cyclodextrins and poly (amidoamines) for the controlled release of insoluble drugs: Hyperbranched, water-soluble polymers, obtainable by Michael polyaddition of α-, β-, or γ-cyclodextrins and amines to bisacrylamides.... Agent: Arent Fox LLP

20100184713 - Pesticidal composition: wherein A, B, R, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description, and 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether as active ingredients, and also provides a pest control method which comprises the step of applying an effective amount of the compound represented by the above formula (I)... Agent: Birch Stewart Kolasch & Birch

20100184714 - Compositions for delivering a drug: A composition comprises a mixture of a silicone and a first solvent, a drug, such as a hydrophilic or lipophilic pharmaceutical agent, a salt of a dialkyl sulfosuccinate, such as dioctyl sodium sulfosuccinate (DOSS), and a second solvent, such as an alcohol. The salt of a dialkyl sulfosuccinate solubilizes the... Agent: Howard & Howard Attorneys PLLC

20100184820 - Combinations comprising staurosporines: The present invention relates to a method of treating myelodysplastic syndromes, lymphomas and leukemias, and also solid tumors with a pharmaceutical combination of a FLT-3 kinase inhibitor and an antisense oligonucleotide or a mcl-1-specific RNAi construct. It also relates to the use of a pharmaceutical combination of a histone deacetylase... Agent: Novartis Corporate Intellectual Property

20100184821 - Compositions and methods for modulating angiogenesis: The invention generally features compositions and methods that are useful for modulating angiogenesis.... Agent: Edwards Angell Palmer & Dodge LLP

20100184823 - Dsrna for treating viral infection: The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each... Agent: Novartis Institutes For Biomedical Research, Inc.

20100184822 - Method of modulating the activity of a nucleic acid molecule: The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising... Agent: Nixon & Vanderhye, PC

20100184826 - Methods and compositions for enhancing the efficacy and specificity of rna silencing: The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100184827 - Methods and compositions for enhancing the efficacy and specificity of rna silencing: The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100184828 - Methods and compositions for enhancing the efficacy and specificity of rna silencing: The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100184824 - Rna interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin... Agent: Merck

20100184825 - Rna interference mediated inhibition of protein tyrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression... Agent: Merck C/o Sirna Therapeutics, Inc.

20100184829 - Rnai modulation of scap and therapeutic uses thereof: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a... Agent: Fulbright & Jaworski L.L.P.

20100184839 - Allelic polymorphism associated with diabetes: The invention relates to the identification of allelic polymorphism in a diabetes associated gene, particularly in a gene encoding phosphofructokinase (PFK) and use thereof for diagnosing diabetes predisposition and state and for predicting the response to a therapeutic agent.... Agent: Fennemore Craig

20100184838 - Compositions and methods for retinal transduction and photoreceptor specific transgene expression: Adenovirus (Ad) vectors are here provided for treatment of ocular tissues as are suitable methods to transduce photoreceptor (PR) cells, the tissue associated with degeneration. Expression from CMV or chicken beta actin (CBA) promoters in neural retina were compared, and CBA was found to be 173-fold more potent than CMV.... Agent: Lawson & Weitzen, LLP

20100184830 - Compositions and methods for the diagnosis and therapy of bcl2-associated cancers: The invention provides methods and compositions for the treatment of cancers associated with overexpression of a BCL2 gene and/or gene product in a subject, and methods and compositions for the improvement of anti-cancer therapy, such as chemotherapy and radiation therapy. The invention also encompasses methods for determining the efficacy of... Agent: Macmillan Sobanski & Todd, LLC

20100184832 - Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins: The invention provides viral vectors, such as chimeric flavivirus vectors, including foreign peptides inserted into the target proteins of the vectors, methods of making and using these vectors, and compositions including the vectors.... Agent: Clark & Elbing LLP

20100184835 - Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna: The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions... Agent: Kenneth J. Collier - C/o Kathy Illg Medtronic, Inc.

20100184841 - Extended dicer substrate agents and methods for the specific inhibition of gene expression: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a pattern... Agent: Edwards Angell Palmer & Dodge LLP

20100184843 - Identification of a pin specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer: The invention relates to nucleic acids encoding a mammalian ABCA5 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, PIN. Further, the invention relates to diagnostic assays for identifying the DNA-binding protein ABCA5 (also known as PIN-1). The invention... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100184834 - Immunostimulatory sequence oligonucleotides and methods of using the same: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.... Agent: Morrison & Foerster LLP

20100184844 - Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates: The present invention is directed to oligonucleotide-modified nanoparticle conjugates and methods of inhibiting bacterial protein production.... Agent: Marshall, Gerstein & Borun LLP

20100184831 - Materials and complexes for the delivery of biologically-active materials to cells: The invention provides a peptide derivative of formula A-B-C wherein A is a polycationic nucleic acid-binding component; B is a spacer element peptide that is susceptible to cleavage within a cell; and C is a cell surface receptor binding component. The invention also provides a lipid derivative of general formula... Agent: Leon R. Yankwich

20100184833 - Methods and means for treating dna repeat instability associated genetic disorders: The current invention provides for methods and medicaments that apply oligonucleotide molecules complementary only to a repetitive sequence in a human gene transcript, for the manufacture of a medicament for the diagnosis, treatment or prevention of a cis-element repeat instability associated genetic disorders in humans. The invention hence provides a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100184845 - Myeloid colony stimulating factor and uses thereof: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in... Agent: Dla Piper LLP (us)

20100184840 - Primary micro rna expression cassette: This invention relates to inhibition of hepatitis gene expression. More specifically, the invention relates to a method of using RNA sequences to inhibit Hepatitis B and C Virus replication. Expression cassettes that include DNA sequences derived from endogenous micro RNAs (miRs) are used in the method and are transcribed by... Agent: Ratnerprestia

20100184837 - Small-molecule nucleotide aptamer for hepatitis c virus, preparation method and use thereof: A DNA aptamer specific for HCV having a nucleotide sequence as shown in SEQIDNO.1-29, and a method of preparing the same including the steps of: (1) constructing a single-stranded DNA library; (2) constructing a double-stranded DNA library; (3) screening by SELEX; (4) amplifying by PCR; (5) cloning and sequencing; and... Agent: Matthias Scholl

20100184842 - Ultraconserved regions encoding ncrnas: Described herein are methods for differentiate human cancers comprising using one or more transcribed ultraconserved regions (T-UCR) expression profiles where the association between the genomic location of UCRs and the analyzed cancer-related genomic elements is highly statistically significant and comparable to that reported for miRNAs.... Agent: Macmillan Sobanski & Todd, LLC

20100184836 - Vaccine: This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100184715 - Stable salts of s-adenosylmethionine and process for the preparation thereof: The present invention refers to new salts of S-adenosyknethionine (SAMe) with improved stability and containing at least 70% by weight of SAMe.... Agent: Dykas, Shaver & Nipper, LLP

20100184716 - Pharmaceutical compositions with superior product performance and patient compliance: The present invention provides novel formulations of isobutyric acid (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-fluoro-2-isobutyryloxymethyl-4-methyl-tetrahydro-furan-3-yl ester) and hydroxypropylcellulose that provide high bulk density, low particle size better suited for improved compression and flow, good compression, and fast dissolution profiles.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100184717 - Treatment of statin side effects using uridine derivatives: The invention relates generally to treatment of muscle pain and/or fatigue and to methods of treatment of side effects of statin therapy which involve the administration of uridine, biological precursors or derivatives or uridine or salts, esters, tautomers or analogues thereof, which are collectively referred to as uridine related compounds.... Agent: Scully Scott Murphy & Presser, PC

20100184718 - Compositions and methods for double-targeting virus infections and targeting cancer cells: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine... Agent: Morgan Lewis & Bockius LLP

20100184719 - Cetp inhibitors derived from benzoxazole arylamides: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.... Agent: Merck

20100184721 - Extract of lentinus for its action on cellulite and accumulations of fat: The present invention relates to the use of an extract of Lentinus, as well as the pharmaceutical composition that contains it, within the scope of combating cellulite and subcutaneous accumulations of fat.... Agent: Fulbright & Jaworski L.L.P.

20100184720 - Use of a natural polysaccharide gel for the preparation of an injectable formulation for treatment of articular degeneration: A sterile injectable aqueous formulation in the form of a gel is made up of hyaluronic acid (or one of the salts thereof) with or without other natural polysaccharide(s) and one or more polyols. The formulation is of intra-articular application in the treatment of joint degeneration, in some cases having... Agent: Young & Thompson

20100184722 - Inclusion complexes of alpha-cyclodextrin and sildenafil salt: Provided are inclusion complexes comprising a sildenafil salt (e.g., sildenafil citrate) and alpha-cyclodextrin. The complexes may be useful treating various conditions, such as male erectile dysfunction and pulmonary hypertension. In some instances the inclusion complexes increase the solubility of sildenafil. Also provided are methods of producing the inclusion complexes, as... Agent: Morrison & Foerster LLP

20100184723 - Carbohydrate-lipid constructs and their use in preventing or treating viral infection: The invention relates to selected carbohydrate-lipid constructs and their use as mimics of ligands for receptors expressed by virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for use... Agent: Nixon & Vanderhye, PC

20100184724 - Compositions for treating and/or preventing diseases characterized by the presence of metal ions: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some... Agent: Wolf Greenfield & Sacks, P.C.

20100184725 - Method and composition for treating alzheimer's disease and dementias of vascular origin: A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans.... Agent: Marshall, Gerstein & Borun LLP

20100184726 - Method of combatting sea lice: The invention provides a method of treatment of farmed fish to combat infestation by multicellular ectoparasites with exoskeletons, which method comprises topically exposing farmed fish, especially salmon in sea cages, to a first and a second sea lice treatment agent, said first sea lice treatment agent being a carbamate or... Agent: Iphorgan, Ltd.

20100184728 - Materials and methods for treatment and diagnosis of disorders associated with oxidative stress: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema.... Agent: Lucas & Mercanti, LLP

20100184729 - New pharmaceutical compositions for treatment of thrombosis: The present invention relates to novel pharmaceutical compositions comprising at least one direct thrombin inhibitor and at least one additional active compound selected from the groups consisting of platelet inhibitors, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, fibrinogen... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100184727 - Treatment of excess sebum production: A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100184730 - Fatty acid acylated salicylates and their uses: The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.... Agent: Wilmerhale/boston

20100184731 - Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation: The present invention relates to the use of a steroid in the manufacture of a pharmaceutical composition for use in the therapeutic or prophylactic treatment of a hypertensive disorder of pregnancy (HDP) or fetal growth retardation, said treatment comprising administering to a female mammal a steroid selected from the group... Agent: Foley And Lardner LLP Suite 500

20100184732 - Method of long-term treatment of graft-versus-host disease using topical active corticosteroids: A method of long-term therapy using corticosteroids to treat tissue damage associated with graft-versus-host disease in a patient having undergone hematopoietic cell transplantation, and host-versus-graft disease in a patient having undergone organ allograft transplantation. The method includes orally administering to the patient a therapeutically effective amount of a topically active... Agent: Lewis Kohn & Fitzwilliam LLP

20100184734 - Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy: Described herein are various lipid mixtures, more particularly special mixtures of fatty acids esters, which may be phytosterol esters and/or glyceride esters. Said mixtures are evaluated in the context of their ability to, upon consumption, affect the levels of circulating LDL and HDL particles, and their therapeutic effect on conditions... Agent: Cooper & Dunham, LLP

20100184733 - Skin treatment composition: The invention discloses skin treatment compositions consisting essentially of a mixture of ceramides, cholesterol, free fatty acids—the mixture being able to mimic skin identical lamellar structures—and nonionic emulsifiers. These compositions are liquid and pumpable at room temperature which means that they can be incorporated easily into cosmetic formulations with no... Agent: Scully Scott Murphy & Presser, PC

20100184735 - Locally active \"soft\" antiandrogens: The present invention relates to antiandrogenic compounds which may be administered for the treatment of androgen excess in the skin and by way of consequence, the treatment of acne, baldness or hirsuitism in subject or patient. These compounds have the general chemical structure (I, II, III or IV):... Agent: Coleman Sudol Sapone, P.C.

20100184736 - Treatment of meconium aspiration syndrome with estrogens: One aspect of the present invention relates to the use of an estrogen in the treatment of Meconium Aspiration Syndrome (MAS) in a newborn infant, said treatment comprising administering an effective amount of estrogen to said newborn infant within 7 days after birth. The present treatment offers the advantage that... Agent: The Webb Law Firm, P.C.

20100184738 - Uses of cinnoline compounds to treat schizophrenia: e

20100184737 - Imidazole compounds for the treatment of neurological disorders: wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds... Agent: Pfizer Inc

20100184739 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100184740 - Substituted oxazolidinones and their use: The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100184741 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates, and pharmaceutically... Agent: Cooley LLP Attn: Patent Group

20100184742 - Polymorphisms in abcb1 associated with a lack of clinical response to medicaments: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100184743 - Use of cholinesterase inhibitors for treating vascular depression: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.... Agent: Novartis Corporate Intellectual Property

20100184744 - Method of preparing a pharmaceutical co-crystal composition: The present invention relates to a method of preparing a pharmaceutical co-crystal composition, said method comprising the steps of: a. simultaneously contacting a supercritical or liquefied gas with solid particles of a pharmaceutically active component and with solid particles of a co-builder to form a co-crystallisation medium containing dissolved pharmaceutically... Agent: Foley And Lardner LLP Suite 500

20100184745 - Use of parthenolide derivatives as antileukemic and cytotoxic agents: e

20100184746 - Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient: An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R1 represents aryl or a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100184748 - Compounds and compositions as itpkb inhibitors: The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B... Agent: Genomics Institute Of The Novartis Research Foundation

20100184747 - Indoline derivatives and their use in treating disease-states such as cancer: The present invention encompasses compounds of general formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100184749 - Benzothiadiazine compounds and their use: Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.... Agent: Goodwin Procter LLP Patent Administrator

20100184750 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent: Paul D. Yasger Abbott Laboratories

20100184751 - Heterocyclic compounds for the treatment of tuberculosis: s

20100184752 - Phenothiazine compounds for treating mild cognitive impairment: The present invention relates generally to methods and materials based on diaminophenothiazines for use in the treatment of Mild Cognitive Impairment (MCI).... Agent: Foley And Lardner LLP Suite 500

20100184753 - Ion channel modulators and methods of uses: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100184754 - Quinolinone derivatives: Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according... Agent: Foley & Lardner LLP

20100184755 - Protein kinase c inhibitors and uses thereof: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these... Agent: Rigel Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20100184756 - Herbicide composition for lawn: A herbicide composition for lawn characterized by containing iodosulfuron-methyl or its salt, and at least 1 kind of herbicidal compound selected from the group consisting of oxaziclomefone, fentrazamide, oxadiargyl, ethoxysulfuron, cafenstrole, indanofan, asulam, fenoxaprop, clethodim, ethofumesate, tribenuron-methyl, metsulfuron-methyl, thifensulfuron-methyl, bromoxynil, MCPA, 2,4-D, dicamba as effective components.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100184757 - Fungicidally active compound combinations: Active compound mixtures comprising ipconazole and at least one further fungicidally active compound are highly suitable for protecting industrial materials against colonization and destruction by microorganisms.... Agent: Lanxess Corporation

20100184758 - Beta carboline derivatives as antidiabetic compounds: Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also... Agent: Merck

20100184761 - 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile derivatives: t

20100184760 - Benzoxazole kinase inhibitors and methods of use: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or... Agent: Wilson, Sonsini, Goodrich & Rosati

20100184759 - Pyrano-pyrazole-amines: The present invention relates to compounds having the structural formula below and pharmacological activity towards the sigma (σ) receptor, and more particularly to pyrano-pyrazole-amines, to processes of preparing such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis.... Agent: Cooper & Dunham LLP

20100184762 - Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof: The present invention relates to compounds that are suitable for treatment of disease states and influence cellular vesicular systems, especially the formation and/or function of lipid droplets, said compound having the general formula I (I) wherein X are each independently hydrogen, halogen, —C1-20-alkyl, —C2-20-alkenyl, —C2-20-alkinyl, —C5-6-cykloalkyl, aryl, aralkyl, adamantyl, heterocyclic,... Agent: Olson & Cepuritis, Ltd.

20100184763 - Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof: This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one... Agent: Jones Day

20100184764 - Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to... Agent: Eli Lilly & Company

20100184766 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent: Paul D. Yasger Abbott Laboratories

20100184765 - Protein kinase inhibitors and methods for using thereof: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or... Agent: Novartis Institutes For Biomedical Research, Inc.

20100184767 - Substituted oxazolidinones and use thereof: The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100184768 - Isoprenyl compounds and methods thereof: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present... Agent: Choate, Hall & Stewart LLP

20100184769 - Pde inhibitors for the treatment of hearing impairment: The invention provides pharmacological compositions comprising PDE-5 inhibitors for the treatment of hearing impairment i.e. hearing loss and tinnitus. The invention also provides methods of screening for such PDE-5 inhibitors for use in the preparation of medicaments for the treatment of hearing impairment i.e. hearing loss and tinnitus.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100184771 - Bicyclic heterocyclic compound: e

20100184770 - Compounds:

20100184773 - Germline polymorphisms in the angiogenic pathway predict tumor recurrence in cancer therapy: The invention provides compositions and methods for determining the likelihood of successful treatment with pyrimidine based antimetabolites and platinum-based alkylating agents. The methods comprise determining the identity of one or more genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive... Agent: Foley & Lardner LLP

20100184774 - Methods of treatment: This invention relates to a method of treating a disease state selected from: Alzheimer's disease, Down's syndrome, mental retardation, memory defects, memory loss, pancreatic cancer, bone resorption disease, osteoporosis, sickle cell anemia, chronic kidney disease, diabetes, depression, and subsets of depression including: alcoholism, anxiety, obsessive compulsive disorder, panic disorder, chronic... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100184772 - Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators: The present invention relates to substituted pyrazoline compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff, Ltd.

20100184775 - Organic compounds: The present invention relates to compounds of formula (I) wherein n represents 0, 1, 2, 3, 4 or 5, R represents independent from each other hydroxyl, cyano, nitro, halogen, alkyl, alkoxy alkylcarbonyl, alkoxycarbonyl, alkylamine, dialkylamine, alkylcarbonylamine, alkylcarbamate Y represents one of the following groups: (Ia) in free base or acid... Agent: Fanelli Strain & Haag PLLC

20100184776 - Piperidine/piperazine derivatives: alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted; cyano; C1-6alkylcarbonyl; nitro; amino; mono- or di(C1-4alkyl)amino; C1-4alkylcarbonylamino; —S(═O)p-C1-4alkyl; R6R5N—C(═O)—; R6R5N—C1-6alkyl; C3-6cycloalkyl aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—C1-4alkyl; Het-C(═O)—; Het-O—; R9 represents hydrogen, halo, C1-4alkyl, C1-4alkyl substituted with hydroxyl; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.... Agent: Philip S. Johnson Johnson & Johnson

20100184777 - Substituted pyrazinone amides: k

20100184779 - Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors: The present invention relates to a method for evaluating patients to help optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. More specifically, the method comprises the steps of (a) determining the OCT-1 Activity in pre-therapy blood of a warm-blooded animal suffering from CML, and (b)... Agent: Novartis Corporate Intellectual Property

20100184778 - Novel heterocycle compounds and uses thereof: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (Q) or (I), which penetrate the blood-brain barrier, inhibit the formation and accumulation of beta-amyloid, and are useful in the treatment of neurodegenerative diseases, particularly Alzheimer's disease. Further, the compounds of the present invention inhibit certain... Agent: Hoxie & Associates LLC

20100184781 - Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof: The present invention relates to novel oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof, and processes for preparing the same, and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof can... Agent: Sughrue Mion, PLLC

20100184780 - Inhibitors of protein kinases: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).... Agent: Olson & Cepuritis, Ltd.

20100184782 - Fused bicyclic pyrimidines: e

20100184783 - Combination for use in the treatment of inflammatory atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist: There is provided combination products comprising (a) a mast cell inhibitor, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a PPARY agonist, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in atherosclerosis and related conditions.... Agent: Ryan Kromholz & Manion, S.c.

20100184784 - Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor: The present invention relates to pharmaceutical compositions comprising at least one multifunctional phosphodiesterase inhibitor (MPDEI) and at least one adenosine uptake inhibitor. The present invention also relates to compositions comprising cilostazol and dipyridamole and their use.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100184785 - Pharmaceutical formulation for the production of chewable tablets and lozenges: The present invention relates to pharmaceutical formulations for the production of chewable and suckable tablets, comprising agglomerates based on sugar or sugar alcohols and disintegrant and water-insoluble polymers in combination with a viscosity-increasing/gel-forming polymer, and the corresponding chewable and suckable tablets.... Agent: Connolly Bove Lodge & Hutz, LLP

20100184786 - Polar quinazolines: in which, R1, R2, R3, R4, R5, R6, R22, R23, R24, R25, R26, R27, R28, R29, W, W1, W2, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, and n can be as defined anywhere herein. In general, these compounds... Agent: Wyeth LLC Patent Law Group

20100184787 - Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors: The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for... Agent: Abbott Laboratories C/o Polsinelli Shughart PC

20100184788 - Heterocyclic derivatives: The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, and heart failure development.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100184792 - Co-crystals of pyrimethanil and dithianon: e

20100184791 - Compounds and compositions as c-kit and pdgfr kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.... Agent: Genomics Institute Of The Novartis Research Foundation

20100184789 - Inhibitors of protein kinases: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least... Agent: Olson & Cepuritis, Ltd.

20100184790 - Pyrrolo[2,3-b]pyridine compounds, azaindole compounds used for synthesizing said pyrrolo[2,3-b]pyridine compounds, methods for the production thereof, and uses thereof: The invention relates to pyrrolo[2,3-b]pyridine compounds and azaindole compounds used for the synthesis thereof. The invention also relates to methods for the production thereof and the uses thereof. Said novel pyrrolo[2,3-b]pyridine compounds according to the invention have great antiproliferative, apoptotic, and neuroprotective activities. The invention particularly applies to the pharmaceutical... Agent: Oliff & Berridge, PLC

20100184793 - Compositions incorporating sesamin-class compounds and vitamin b1 class compounds: A composition incorporating at least one sesamin-class compound is enhanced in the anti-fatigue action of sesamin class compounds by additionally incorporating at least one vitamin B1 class compound. Also provided is an anti-fatigue agent containing at least one sesamin-class compound and at least one vitamin B1 class compound as the... Agent: Drinker Biddle & Reath (dc)

20100184795 - Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same: Disclosed are aspartic acid salts of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, methods for preparing the same, and antimicrobial pharmaceutical compositions comprising the same.... Agent: Seed Intellectual Property Law Group PLLC

20100184794 - Fused heterocyclic compound: s

20100184796 - Agonists of bitter taste receptors and uses thereof: The present invention relates to agonists of the human bitter-taste receptors hTAS2R46, hTAS2R47 and hTAS2R50 and their role in bitter taste transduction. The invention also relates to methods for identifying molecules that modulate, e.g. suppress, or enhance hTAS2R46, hTAS2R47 and hTAS2R50 bitter taste transduction or bitter taste response.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100184797 - Treatment of dyskinesia: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.... Agent: Nixon & Vanderhye, PC

20100184798 - Methods to predict cholesterol elevations during immunosuppressant therapy: This invention provides methods to predict the degree of elevation of serum cholesterol levels in patients treated with immunosuppressive medication. This invention also provides treatment strategies based on these predictions and kits to carry out these methods.... Agent: Novartis Corporate Intellectual Property

20100184799 - Oxadiazole beta carboline derivatives as antidiabetic compounds: Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also... Agent: Merck

20100184800 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100184801 - Fused amino pyridines for the treatment of brain tumors: The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.... Agent: Elmore Patent Law Group, PC

20100184802 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.... Agent: Klauber & Jackson

20100184804 - Methods for the prevention or treatment of bacterial and fungal infections: The present invention features improved methods for treating, stabilizing, or preventing a bacterial or a fungal infection in a plant or an animal, such as a mammal. In particular, these methods involve the use of a compound, that is controlled by MvfR, and that affects the expression of an MvfR... Agent: Clark & Elbing LLP

20100184803 - Treatment of lysosomal storage diseases: Methods and compositions useful in the treatment or prevention of lysosomal storage diseases, such as Pompe's disease, Fabry's disease, Gaucher's disease, and Niemann-Pick disease, are provided. The treatment includes administering to a subject a farnesyl transferase inhibitor compound. The treatment may also include enzyme replacement therapy or gene therapy.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100184805 - Renin inhibitors: Disclosed are aspartic protease inhibitors represented by the following structural formula: and pharmaceutically acceptable salts thereof. These compounds are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. The present invention is also... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100184806 - Modulation of neurogenesis by ppar agents: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more neurogenic... Agent: Sughrue Mion, PLLC

20100184807 - Methods to inhibit tumor cell growth by using proton pump inhibitors: Methods of treating one or more growth deregulated cells are disclosed: An effective amount of a pharmaceutical composition including a proton pump inhibitor is administered thereby treating a growth deregulated cell outside of the gastric lumen of a subject.... Agent: Traskbritt, P.C.

20100184808 - 3-aza-bicyclo[3.3.0]octane compounds: The invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of the formula (I) wherein R1, R2, R3, and A are as described in the description and their use as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20100184809 - Heterocyclic fxr binding compounds: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding... Agent: Kilyk & Bowersox, P.l.l.c.

20100184810 - Methods and compositions related to riboswitches that control alternative splicing: Disclosed are methods and compositions related to riboswitches that control alternative splicing.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100184811 - Isoniazid mediated healing of wounds and ulcers: The invention relates to the use of a compound(s) selected from isoniazid and isoniazid analogs of formula Ia, wherein R is —C(O)NHNH2, —C(O)NHNHC1-6 alkyl, —C(O)NHN═C1-6 alkenyl, —C(O)NHNHC2-6 alkenyl, —C(O)NHC1-6 alkyl, —C(O)NHC2-6 alkenyl, —C(O)NHNHC(O)C1-6alkyl, —NHC(O)C1-6 alkyl, —NHC(O)C1-6 alkenyl, —NHC(O)NH2, —NHC(O)NHC1-6alkyl, —NHC(O)NHC2-6 alkenyl, or —COOH, and wherein formula (Ia) optionally is further... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20100184812 - Mutual prodrugs and methods to treat cancer: Mutual prodrugs comprising retinoids and histone deacetylase inhibitors, methods for production of the mutual prodrugs, and methods of treatment comprising administration of the mutual prodrugs. The retinoids include all-trans retinoic acid, 13-cis retinoic acid, and retinoic acid analogs that have a substitution at C-4. Further, the mutual prodrugs of the... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100184813 - Chemical compounds 553: t

20100184814 - Ester derivatives of losartan, methods for their preparation, and uses thereof: The present invention relates to compounds represented by the formula (I) as prodrugs of the formula (II) (Losartan) and their salts, solvates, hydrates, polymorphs, optical isomers, enantiomers, and pharmaceutical compositions comprising these compounds and methods of preparing them and administering them for the treatment of circulatory diseases such as hypertension,... Agent: New River Valley Intellectual Property Law

20100184815 - Agonists of peroxisome proliferator activated receptor-alpha: And pharmaceutically acceptable salts thereof, wherein the variables are as defined herein, which are useful in activating PPARα and in treating atherosclerosis hypercholesterolemia, primary hypercholesterolemia or mixed dyslipidemia, hypertriglyceridemia, Frederickson Types IV and V hyperlipidemia. Pharmaceutical compositions, intermediates useful in the preparation of the compounds of formula I and methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100184816 - Method for reducing the phytotoxicity of azoles on dicotyledonous plants by adding additives: The present invention relates to a method for reducing the phytotoxicity of azoles on dicotyledonous plants by addition of additives. Furthermore, the application relates to novel compositions comprising certain triazole fungicides in combination with additives, in particular alkali metal sulphosuccinates, and their use for controlling unwanted phytopathogenic fungi.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100184817 - Methods of treating neuropathy: Methods and compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and methods for administering the compositions to treat various neuropathies.... Agent: Knobbe Martens Olson & Bear LLP

20100184818 - Photosensitizers for targeted photodynamic therapy: The present invention provides photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20100184819 - Method for reducing intracranial pressure: The present invention relates generally to methods for reducing intracranial pressure in a subject. More particularly, the methods of the present invention include administering to the subject an effective amount of a substance P receptor antagonist.... Agent: Klarquist Sparkman, LLP

20100184846 - Methods for the formulation and manufacture of artesunic acid for injection: A method for the manufacture of a sterile intravenous or intramuscular formulation of artesunic acid and the formulation are the subject of this invention. First the artesunic acid powder is sterilized with ethylene oxide and placed into a sterile container. The contained sterilized powder is then dissolved in sterile sodium... Agent: Caroline Nash Nash & Titus, LLC

20100184847 - Compositions for skin protection and improvement of skin diseases containing the dibenzo-p-dioxine derivatives: The present invention relates to compositions for skin protection and improvement that contain dibenzo-p-dioxine derivatives as effective components. Since the compositions for skin protection and improvement that contain the dibenzo-p-dioxine derivative according to the present invention have excellent functions such as moisturizing and/or wrinkle prevention which are useful in prevention... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100184848 - Transdermal formulations of synthetic cannabinoids and nano colloidal silica: The present invention relates to pharmaceutical compositions comprising cannabinoids or mimics thereof. In one aspect, the invention provides transdermal formulations comprising cannabinoids or mimics thereof. In another aspect, the invention provides topical formulations comprising cannabinoids or mimics thereof. In one embodiment the formulations and compositions of the invention comprise nano... Agent: David S. Resnick

20100184849 - Urea oligomers, their preparation process and pharmaceutical compositions containing them: A method for treating a cytotoxic disease by administrating compounds having a general formula X-(A)n-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an RaCO, RaOCO, RaNHCO or RaSO2 group, Ra being an alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl group, the groups being substituted or not,... Agent: Young & Thompson

20100184850 - Phenolic extracts of almond peel containing procyanidins, propelargonidins, and prodelphinidins, and method for preparation thereof: The present disclosure concerns phenolic extracts containing procyanidins, propelargonidins and prodelfinidins obtained from peel of the almond [Prunus dulcís (Mili.) D. A. Webb, Prunus amygdalus (L.) Batsch., Amygdalus dulcís (Mili.), Amygdalus communis (L.) or Prunus communis (L.)]. In particular, the objective is to obtain extracts rich in proanthocyanidins with type-A... Agent: Ip Patent Docketing K&l Gates LLP

20100184851 - Inhibition of cell proliferation: Compounds of formula (I) and (II) are provided as modulators of Rb:Raf-1 interactions which are potent, selective disruptors of Rb:Raf-1 binding. Therapeutic methods of using the compounds, for example for treating or ameliorating a cell proliferation disorder such as cancer, are provided.... Agent: Fish & Richardson P.C.

20100184852 - Organic compounds for treatment of disorders connected to impaired neurotransmission: The present invention refers to compounds of the general formula (I) wherein R1 is hydrogen or hydroxy; R2 is butyl or butyryl if R1 is hydroxy, but R2 is butyl if R1 is hydrogen; or R3 and R2 taken together are 1-propylidene or 1-butylidene optionally substituted by hydroxy, methyl, or... Agent: Nixon & Vanderhye, PC

20100184853 - Terpenes with antifungal activity against malassezia yeasts: The present invention relates to the use of some terpenes, for example chlovalicin, ovalicin or fumagillin, as antifungal against Malassezia species and to their use in the manufacture of medicaments for the treatment of human skin diseases caused by these Malassezia species, such as pityriasis versicolor, seborrheic dermatitis, dandruff, atopic... Agent: Hoffmann & Baron, LLP

20100184854 - Platinum (iv) complexes and methods of use thereof: Provided are nitroplatinum(IV) complexes which may be useful treating various forms of proliferative diseases, such as cancer. In some instances the platinum(IV) complexes are relatively stable and may be suitable for oral administration. Also provided are methods of treatment, as well as kits and unit dosages.... Agent: Morrison & Foerster LLP

20100184855 - Hard surface cleaner compositions of sulfonated estolides and other derivatives of fatty acids and uses thereof: Sulfo-estolides and formulations of sulfo-estolides in and as hard surface cleaners, glass cleaners, toilet bowl cleaners, carpet cleaners, all purpose cleaners, floor cleaners, and others are described. Further details of cleaning performance, stability of diluted and concentrated forms and contemplated cleaning applications are provided.... Agent: Mcandrews Held & Malloy, Ltd

20100184856 - Novel compounds and uses thereof for treating inflammation and modulating immune responses: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100184857 - Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity: The invention provides hops (Humulus lupulus) extracts or derivatives thereof for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be of the type chemically induced, environmentally-induced, infection-induced, and/or stress-induced. The invention also provides a pharmaceutical composition comprising an... Agent: Mcdermott Will & Emery

20100184858 - Hepatic fibrosis inhibitor: e

20100184859 - Medicament having promoting action on hepatocyte proliferation: A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20100184860 - Novel carboxylic acid and antidepressant composition containing the same as active ingredient: m

20100184861 - Method and apparatus for dry granulation: The invention provides, inter alia, a method for producing granules from a powder, characterized in that compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the other granules by... Agent: Birch Stewart Kolasch & Birch

20100184862 - Prostacyclin derivatives: This invention relates to novel prostacyclin derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases... Agent: Foley & Lardner LLP

20100184864 - Composite material and method for production thereof: Disclosed are: a material which contains a lipophilic component having a pungent taste or flavor such as a spicy component (e.g., a capsaicin) and a bitter component (e.g., a turmeric extract), in which the pungent taste and/or flavor of the lipophilic component can be reduced effectively, and in which the... Agent: Marshall, Gerstein & Borun LLP

20100184863 - Synthetic spilanthol and use thereof: The present application provides a synthetic spilanthol flavor composition that includes (2E,6Z,8E)-N-(2-methylpropyl)-2,6,8-decatrienamide. The synthetic spilanthol composition can also contain, and at least one of (2E, 6E, 8E)-N-(2-methylpropyl)-2,6,8-decatrienamide and (2E, 6Z, 8Z)-N-(2-methylpropyl)-2,6,8-decatrienamide, the (N-(2-methylpropyl)-2,6,8-decatrienamide being present in amounts effective to impart a salivating or tingle effect while reducing the perception of... Agent: Baker Botts L.L.P.

20100184865 - Use of rr/sr-ractopamine: A method of promoting weight loss in animals or humans by administering thereto a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed.... Agent: Nields, Lemack & Frame, LLC

20100184866 - Dual cation dual anion coordination complexes: Compounds are provided herein which are coordination complexes of the formula, AxByCit2Fz.mH2O, wherein A is a cation selected from certain IA or IIA metal ions in the Periodic Table; B is a cation selected from certain IIA metal ions and certain divalent d-block transition metal ions; A and B are... Agent: Greenlee Winner And Sullivan P C

20100184867 - Use of active agents for stimulating the expression of fn3k and/or fn3k rp for combating ageing of the skin: A cosmetic process for caring for human skin, which is intended for preventing and/or combating at least one sign of ageing of the skin or the ‘orange peel’ appearance of the skin, includes the topical application to the skin of a composition containing at least one active agent for stimulating... Agent: Young & Thompson

20100184868 - Fortification of nutritional products with olive extracts containing hydroxytyrosol and hydroxytyrosol fortified nutritional products.: The present invention relates to nutritional products containing hydroxytyrosol, particularly fond products (i.e: fortified edible oils and fortified edible oil-containing products) and dietary supplements (i.e.: soft gel capsules containing fortified edible oils) with increased antioxidant capacity to be used as a source of hydroxytyrosol for preventing or treating cardiovascular diseases,... Agent: NeifeldIPLaw, PC

20100184869 - Method and kit for determining sirtuin modulating agents, sirtuin modulating procedure, sirtuin modulating compounds and compositions including the same: A kit and a method for determining modulating agents of sirtuins; specifically, the modulation of sirtuin expression, by way of the detection and comparison of mRNAs in the sirtuins and β-actin. A process for modulating the activity of sirtuins, as well as pharmaceutical compounds and compositions capable of modulating the... Agent: Smith, Gambrell & Russell

20100184870 - Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate: A pharmaceutical preparation containing the active substance glyceryl trinitrate having improved storage stability in a container. The improved storage stability is achieved by the addition of a proton-absorbing substance either as part of the preparation as placed into the container or applied to the surface of the preparation's storage container... Agent: K&l Gates LLP

20100184871 - Polyglycerol derivatives: Polyglycerol ethers of sorbitan carboxylic acid, particularly C8 to C22 carboxylic acid, esters are new surfactant compounds, useful as emulsifiers. Desirable compounds are of the formula (I): Sor(R1)(R2)(R3)(R4) where R1, R2, R3, R4 have defined meanings such that at least one group is of the formula (II): -G2CR5, where R5... Agent: Jones Day

  
07/15/2010 > patent applications in patent subcategories. category listing

20100179089 - Compositions and methods to manage the inflammatory basis of chronic disease conditions and maintain an optimal immune response in elderly: Compositions and methods for managing inflammation in the elderly by delivering a selection of amino acids, including arginine and/or citrulline, in a synergistic ratio with omega-3 fatty acids and carbohydrates with a low glycemic index.... Agent: Lewis, Rice & Fingersh, Lc Attn: BoxIPDept.

20100179090 - Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein: The present invention relates to a method for spray-drying of protein solutions and the spray-dried protein product. The invention also relates to pharmaceutical compositions containing such spray-dried protein, to methods of treating diabetes and hyperglycaemia using the spray-dried protein of the invention and to the use of such spray-dried protein... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100179091 - Treatment of conditions related to shock: Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent or combination of therapeutic agents, which is/are able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques.... Agent: Moazzam & Associates, LLC

20100179094 - Bispecific egfr/igfir binding molecules: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative... Agent: Ropes & Gray LLP

20100179092 - Human complement c3 derivatives with cobra venom factor-like function: The invention provides modified human complement C3 proteins, comprising a human C3 protein, wherein amino acid residues in the human C3 protein are substituted with a corresponding portion of a Cobra Venom Factor (CVF) protein, and wherein one or more amino acid residues in the CVF portion of the modified... Agent: Morrison & Foerster LLP

20100179096 - Methods of treating fibrosing diseases by induction of immune tolerance: The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a... Agent: Patton Boggs LLP

20100179093 - Neoropeptide-2-receptor (y-2r) agonists: e

20100179095 - Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa: The invention also relates to pharmaceutical preparations for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing CRP and SAA levels, characterised in that as an active ingredient it comprises at least one compound which is selected from the group consisting of pteroic acid... Agent: Millen, White, Zelano & Branigan, P.C.

20100179097 - Use of kauranes compounds in the manufacture of medicament: This invention relates to the use of kauranes compounds having the structure of formula (I) in the manufacture of a medicament for treating and preventing the diseases such as coronary heart disease, cerebral apoplexy, cerebral ischemia and rhythm disturbance etc. The present compounds also have obvious protective effect against cerebral... Agent: Wen Tan

20100179098 - Furost-5-ene-3, 22, 26-triol glycoside compound for preventing and treatment cancer: A pharmaceutical composition for preventing and treating cancer comprising furost-5-ene-3,22,26-triol glycoside, which can be used to prevent and treat cancer by promoting apoptosis.... Agent: Osha Liang L.L.P.

20100179099 - Insecticidal n-substituted (6-halooalkylpyridin-3-yl)-alkyl sulfoximines: N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100179100 - Medicinal forms of phospholipid preparations and methods for their preparation: A method for producing a pharmaceutical composition comprising a combination of phospholipid and glycyrrhizic acid or a pharmaceutically acceptable salt thereof, which composition is hydratable to produce an injectable medicinal form, said method comprising subjecting a mixture of phospholipid and an aqueous solution of glycyrrhizic acid or a pharmaceutically acceptable... Agent: Intellectual Property / Technology Law

20100179101 - Novel crystalline forms of an antiviral benzimidazole compound: The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H benzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100179212 - Pharmaceutical composition which improves in vivo gene transfer: A pharmaceutical composition which combines a tetrafunctional copolymer with a nucleic acid, said copolymer having formula I (namely a poloxamine), and preferably taking the form of one of the cationic mineral or organic salts thereof. The composition can be used to improve in vivo gene transfer.... Agent: Oliff & Berridge, PLC

20100179213 - Methods and compositions involving mirnas in cancer stem cells: The present invention concerns methods and compositions for treating a patient having, suspected of having, or at risk of developing cancer by targeting cancer stem cells.... Agent: Fulbright & Jaworski L.L.P.

20100179102 - Injectable cross-linked polymeric preparations and uses thereof: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic... Agent: Hoffmann & Baron, LLP

20100179103 - Curcumin cyclodextrin combination for preventing or treating various diseases: Curcumin has shown anti-inflammatory and anti-angiogenic properties that could be useful in treating various diseases such as those of rheumatology and oncology. However, curcumin is very poorly absorbed and has a very low bioavailability. This patent describes a method of increasing the delivery of curcumin by complexing it with cyclodextrins.... Agent: Ketan Desai

20100179104 - Synthetic nutritional formulations: The present invention provides a synthetic nutritional formulation comprising a substantially pure free N-acetyl glucosamine in concentrations effective for enhancing organ development, enhancing an immune response, or increasing tissue repair or healing in a subject. A synthetic nutritional formulation of the invention may optionally comprise one or both of substantially... Agent: Clark & Brody

20100179105 - Keratin materials make-up kit comprising reactive silicone compounds and a compatible oil: The invention provides a make-up kit comprising at least two compositions which are packaged separately, —the kit comprising at least one compound X, at least one compound Y and at least one catalyst or one peroxide, at least one of the compounds, X or Y, being a silicone compound, —with... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100179106 - Mitochondrial compositions and uses thereof: Compositions and methods for treating mitochondrial disorders are provided. The compositions include compounds having a mitochondrial targeting moiety, for example a lipophilic cation. Certain compounds are effective for increasing the ratio of phosphocreatine/creatine in a host, for example a mammal. Other compounds decrease the ratio of phophocreatine/creating in a host.... Agent: Pabst Patent Group LLP

20100179107 - N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids: Pharmaceutical, cosmetic and dietetic compositions and functional foods, constituted by: A) phospholipid mixtures containing N-acyl-phosphatidyl-ethanolamines (NAPEs) and/or B) phospholipid mixtures containing N-acyl-ethanol amines (NAEs) together with phosphatidic acids (PAs) and/or lysophosphatidic acids (LPAs) with the proviso that said N-acyl-phosphatidyl-ethanolamines (NAPEs) do not include N-oleoyl-phosphatidyl-ethanolamine. New phosphobioflavonic complexes of NAPE or... Agent: Pearne & Gordon LLP

20100179108 - Synthesis of sodium narcistatin and related compounds: The present invention involves use of the compounds narciclasine (2a) and 7-deoxy-narciclasine (2c), which are obtained via isolation from the medicinal plant species Narcissus (Amaryllidaceae), as precursors in a novel synthesis method in which each of these compounds are selectively hydrogenated to produce trans-dihydronarciclasine (1a) and 7-deoxy-trans-dihydronarciclasine (1c). Also described... Agent: Mcandrews Held & Malloy, Ltd

20100179109 - Renin inhibitors: Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100179110 - Composition containing a bisphosphonic acid in combination with vitamin d: The present invention relates to pharmaceutical compositions containing a bisphosphonic acid in combination with a non-activated metabolite of vitamin D for oral administration. The compositions of the invention either do not contain or contain only low concentrations of a glidant. Also provided are methods for preparing such compositions and methods... Agent: Greenlee Winner And Sullivan P C

20100179111 - Sigma-1 receptor ligands and methods of use: The invention provides compounds of formula I and compositions thereof. The invention further provides methods of using the compounds and compositions. The compounds of the invention can provide high affinity binding to sigma-1 receptors in a mammal. The compounds can exhibit selectivity for the sigma-1 receptor over the sigma-2 receptor.... Agent: Schwegman Lundberg & Woessner/warf

20100179112 - Nutritional intervention for improving muscular function and strength: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Davis Brown Tower

20100179113 - Stanol composition and the use thereof: A stanol composition containing in addition to sitostanol as the main component, also a substantial amount of at least 10% campestanol has been found to effectively lower serum cholesterol levels when incorporated in edible commodities. Upon esterification the composition is especially useful in edible fats and oils and in fat-containing... Agent: Arent Fox LLP

20100179114 - S-isomer of 2- piperidine and other dermal anesthetic agents: The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.... Agent: Nields, Lemack & Frame, LLC

20100179115 - Use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2: The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment.... Agent: Townsend And Townsend And Crew, LLP

20100179116 - Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof: The present invention relates to arene connected polyamine macrocyclic derivatives represented by general formula I, pharmaceutically acceptable salts or hydrates thereof which have anti-HIV activities, in which the definitions of substituents are as defined in the description; to preparation methods of the compounds of formula I; to pharmaceutical compositions containing... Agent: Macmillan Sobanski & Todd, LLC

20100179117 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases: The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.... Agent: Alcon

20100179119 - Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold: Novel compounds inhibiting the integrin α2β1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin α2β1/GPIa-IIa-mediated activity.... Agent: Woodcock Washburn LLP

20100179121 - 1,3-dihydroxy substituted phenylamide glucokinase activators: Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is alkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; R2 is alkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; R5 is as... Agent: Louis J. Wille Bristol-myers Squibb Company

20100179120 - Novel amide derivative for inhibiting the growth of cancer cells: The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase,... Agent: Sughrue Mion, PLLC

20100179118 - Cyclic aminoalkylcarboxamide derivative: wherein R1 and R2 are the same or different and each is an optionally substituted aryl group and the like, R3 is a hydrogen atom, a C1-6 alkyl group and the like, R4 and R5 are the same or different and each is a hydrogen atom, a halogen atom, a... Agent: Leydig Voit & Mayer, Ltd

20100179122 - Non-nucleoside reverse transcriptase inhibitors: Compounds of Formula (I): are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis,... Agent: Merck

20100179124 - Thieno-pyridine derivatives as mek inhibitors: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.... Agent: Feldman Gale, P.A.

20100179123 - Thienopyrimidines useful as aurora kinase inhibitors: wherein R1, R2, X1, X2, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of... Agent: Choate, Hall & Stewart LLP

20100179125 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis: This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.... Agent: Edwards Angell Palmer & Dodge LLP

20100179126 - Thiolactams and uses thereof: i

20100179127 - Pyrimidine derivatives:

20100179129 - Compositions of an anticonvulsant and mirtazapine to prevent weight gain: Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further... Agent: Cooley LLP Attn: Patent Group

20100179128 - Xanthine derivatives as selective hm74a agonists: The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing these active compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100179130 - Use of piperine and derivatives thereof for the therapy of neurological conditions: The present invention relates to the use of piperine and derivatives thereof for the preparation of a pharmaceutical composition for treating and/or preventing a neuronal condition where there is a need of neuroprotection and/or neuroregeneration. The invention furthermore relates to the use of piperine and derivatives thereof for the in... Agent: Birch Stewart Kolasch & Birch

20100179131 - Combination treatment for diabetes mellitus: The invention relates to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.... Agent: Nath & Associates PLLC

20100179132 - Carboline derivatives useful in the inhibition of angiogenesis: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor... Agent: Jones Day

20100179133 - Compositions, articles and methods comrising tspo ligands for preventing or reducing tobacco-associated damage: Articles of manufacturing (such as tobacco products), methods, devices and compositions for preventing or reducing tobacco-associated damage and/or disorders associated with oxidative stress in a subject, and which utilize a TSPO receptor ligand (such as diazepam), are disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100179135 - 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives: Antibacterial compounds including 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives are provided, and methods of treatment or prevention of bacterial infection with such compounds are provided.... Agent: Hunton & Williams LLP Intellectual Property Department

20100179134 - Pyrimidinediamine kinase inhibitors: The present invention provides pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also provided are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation,... Agent: Weaver Austin Villeneuve & Sampson LLP

20100179136 - N-amino tetrahydrothiazine derivatives, method of manufacture and use: This invention comprises the innovative synthesis of N-amino tetrahydrothiazine free bases and their salts. This invention further comprises the use of the derivatives and their therapeutic application as anticancer agents. Further this invention comprises their manufacture and use.... Agent: Cserr Patents & Strategic Counseling

20100179138 - Isozazole compounds as inhibitors of heat shock proteins: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—,... Agent: Banner & Witcoff, Ltd.

20100179137 - Pyridone compound: [Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100179139 - Pyrrolopyridine compounds, process for their preparation, and their use as medicaments: o

20100179140 - Indenoisoquinolinone analogs and methods of use thereof: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100179141 - Novel jnk inhibitors: Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR5. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0.... Agent: Merck Patent Department (k-6-1, 1990)

20100179142 - Cancer combination therapy comprising azd2171 and zd1839: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20100179143 - Naphthyridine, derivatives as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using naphthyridine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100179144 - Quinazoline derivatives as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100179147 - Benzimidazole compounds and their use as anticancer agents: v

20100179146 - Indolinone compounds as kinase inhibitors:

20100179145 - Pharmaceutical combinations: or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from... Agent: Frommer Lawrence & Haug

20100179149 - Aryl ether pyridazinone derivatives: Compounds of the formula I, in which R1, R2, R3, R4, R5 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100179148 - Pyridazinone derivatives: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100179150 - Antibacterial piperdine derivatives: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20100179151 - Transdermal application of triazines for controlling infections with coccidia: The present invention relates to the transdermal application of triazines such as toltrazuril or ponazuril for controlling infections with coccidia in humans and animals.... Agent: Bayer Healthcare LLC

20100179152 - Novel use for pde5 inhibitors: The present invention is concerned with the use of PDE5 inhibitors in medicine.... Agent: Nath & Associates PLLC

20100179154 - 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof: e

20100179155 - Activators and therapeutic applications thereof: The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family... Agent: Birch Stewart Kolasch & Birch

20100179153 - Bicyclic s1p receptor modulators: e

20100179156 - Antimicrobial compositions: The present invention is directed to providing antimicrobial surfaces containing 1,4-diazoniabicyclo[2.2.2]octane and hydrocarbon groups and/or chains. More specifically, the present invention is directed to antimicrobial compositions wherein the hydroxyl groups on polyols are replaced by 1,4-diazoniabicyclo[2.2.2]octane. The invention is also directed to methods of making antimicrobial compositions containing polyols.... Agent: Hoffmann & Baron, LLP

20100179157 - Therapeutic agent for cerebral infarction: The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-α, IL-1β, IL-6 and MCP-1... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100179158 - Inhibitors of cyclic amp phosphodiesterases: Recombinant fission yeast cells and methods of using them are described, which provide for identification of chemical and biological inhibitors or activators of a target exogenous phosphodiesterase (PDE). The invention provides, in some aspects, compounds that inhibit cAMP PDE activity and compositions that include such compounds. The invention, in part,... Agent: Wolf Greenfield & Sacks, P.C.

20100179159 - Method for the production of a medicament containing tadalafil: The invention relates to a method for producing a medicament containing tadalafil. In said method, tadalafil is mixed with suitable adjuvants and is heated to a temperature of about 100° C. to about 200° C., preferably about 150° C. to about 200° C., especially about 200° C.... Agent: Clark & Elbing LLP

20100179160 - Organic compounds: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I) wherein the substituents are as defined in the specification and to processes for their production to pharmaceutical compositions comprising them and to their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and... Agent: Fanelli Strain & Haag PLLC

20100179161 - Pyrazoline derivatives for the treatment of turberculosis: Compounds of the formula (I) and pharmaceutically acceptable salts or in vivo hydrolysable esters thereof, useful in the treatment of Mycobacterium tuberculosis (M.tb).... Agent: Astrazeneca R&d Boston

20100179162 - Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide: Crystalline forms of the sulfate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the sulfate salt are characterized by a variety of properties and physical measurements. As well, methods of producing the sulfate salts, and using such salts to... Agent: Millennium Pharmaceuticals, Inc.

20100179164 - 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders: 2,4-Pyrimidinediamine compounds represented by formula (I), methods for preparing the same and methods for treating an inflammatory disorder and for inhibiting the production of IL-23 and/or stimulating the production of IL-10 using the same:... Agent: Rigel Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20100179165 - Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds: Methods for treating an inflammatory disorder and for inhibiting the production of IL-23 using 2,4-pyrimidinediamine compounds represented by formula (I):... Agent: Rigel Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20100179163 - Nol3 is a predictor of patient outcome: The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100179166 - Carboxamide heterocyclic cgrp receptor antagonists: wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to... Agent: Merck

20100179167 - Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids: A method for treating a subject having an inflammatory or auto-immune disease with a substituted isoxazolo pyridinone. Also, a method for administering a substituted isoxazolo pyridinone to a cell to retain or increase glucocorticoid receptor transrepression activity with only minimal glucocorticoid receptor transactivation activity.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20100179169 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of... Agent: Cantor Colburn, LLP

20100179168 - Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists: The present invention therefore provides compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100179170 - Heterogeneously configured multiparticulate gastrointestinal drug delivery system: This invention relates to a heterogeneously configured multiparticulate drug delivery system for gastrointestinal delivery of at least one or a combination of active pharmaceutical compositions. The system comprises a multiplicity of enterosoluble or gastrosoluble multiparticulates loaded with the active pharmaceutical composition or compositions for the site-specific delivery of said active... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100179171 - Pharmacological treatment of parkinson's disease: The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.... Agent: Medlen & Carroll, LLP Suite 350

20100179172 - N-phenyl-methanamine derivative and pesticide containing it: wherein R1 is alkyl which may be substituted, etc.; each of R2, R3, R4 and R6 which are independent of one another, is hydrogen, halogen, alkyl which may be substituted, etc.; R5 is haloalkyl or halogen; each of R7 and R8 which are independent of each other, is hydrogen, cyano,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100179173 - Substituted fused pyrimidines as antagonists of gpr105 activity: Fused pyrimidine compounds of structural formula (I) are effective as antagonists of the biological activity of the GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis,... Agent: Merck

20100179174 - Substituted azaquinazolines having an antiviral action: This invention relates to substituted azaquinazolines, to a process for their preparation, to pharmaceutical compositions containing them, and to their use for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100179175 - Use of pkc inhibitors in ocular diseases: The present invention pertains to the use of a PKC inhibitor in the treatment of an ocular disorder.... Agent: Novartis Corporate Intellectual Property

20100179176 - V3 antagonists for the treatment or prevention of chronic pain: The present invention relates to a V3 antagonist for use in the treatment of chronic pain, in particular neuropathic pain.... Agent: Organon Usa, Inc. C/o Merck

20100179177 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20100179179 - Inhibitors of the mutant form of kit: The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT is administered.... Agent: Novartis Corporate Intellectual Property

20100179178 - Pyrimidine derivatives as posh and posh-ap inhibitors: Pyrimidine deriviatives are ubiquination inhibitors that inhibit the ubiquitin ligase activity, particularly of POSH polypeptides, are useful for the treatment of viral infections and neurological disorders.... Agent: Ropes & Gray LLP

20100179180 - Crystalline irinotecan hydrochloride and methods for its preparation: Disclosed is a crystalline form of irinotecan hydrochloride (I) and processes for the preparation thereof from crude irinotecan hydrochloride or another polymorphic form of irinotecan. Said crystalline form is particularly suitable for industrial use, because it is easily filtered and possesses characteristics of high stability and purity.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100179181 - Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates: A camptothecin/polymer dual phase drug release system is described that is stable in both liquid and lyophilized states. The polymer contains acetals and/or ketals.... Agent: Wilmerhale/boston

20100179182 - Pharmaceutical formulation: The present invention provides processes for making and forms of solid dispersions of pharmaceutical active ingredients.... Agent: Novartis Corporate Intellectual Property

20100179183 - Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100179184 - Article of manufacture for prasugrel: An article of manufacture comprising packaging prasugrel tablets, caplets, capsule or other solid form of prasugrel in an air and/or moisture impervious container under a positive liquid gas pressure.... Agent: Eli Lilly & Company

20100179185 - Novel aminothienopyridinone derivatives processes for preparing them and pharmaceutical compositions thereof: The present invention concerns novel 3-aminothienopyridinone derivatives of the formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100179186 - Use of a novel alpha-7 nachr antagonist to suppress pathogenic signal transduction in cancer and aids: This application provides a method for the use of select quaternary ammonium antagonists to alpha-7 nAChR for the treatment of cancer and HIV and AIDS.... Agent: Crowell & Moring LLP Intellectual Property Group

20100179187 - Indolone compounds useful to treat cognitive impairment: This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100179188 - Nitroxide radical as treatment for neurodegeneration: A method of treating or preventing neurodegeneration in a mammal comprising administering to the mammal an effective amount of a stable nitroxide radical, such as Tempo1, as well as related methods.... Agent: Leydig, Voit & Mayer, Ltd.

20100179189 - Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof: Compounds represented by Formula (I) or Formula (II) against cell releasing TNFα, their pharmaceutically acceptable salts or hydrates and preparation methods and uses thereof, in which A and B represent CH2, CO, SO, or SO2; D represents S, NH, or NC1-6 alkyl; R1 represents H, or one or two same... Agent: Matthias Scholl

20100179190 - Bicyclic pyrazolo protein kinase modulators: The present invention provides novel bicyclic pyrazolo kinase modulators and methods of using the novel bicyclic pyrazolo kinase modulators to treat diseases mediated by kinase activity.... Agent: Eli Lilly & Company

20100179191 - Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture: Glucopyranosyl-substituted cyclopropyl-benzene derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100179192 - Use of nitric oxide releasing compounds in the treatment of chronic pain: The present invention relates to nitrooxyderivative of antioxidant compounds of formula (I) and pharmaceutically acceptable salts or stereoisomers thereof for the treatment of chronic pain, in particular chronic neuropathic pain. The invention also describes composition comprising a nitrooxyderivative of a antioxidant compound of formula (I) and an analgesic drugs.... Agent: Arent Fox LLP

20100179193 - Ampa receptor antagonists and zonisamide for neuropathic pain: The invention provides methods for treating and/or preventing neuropathic pain by administering to patients therapeutically effective amounts of AMPA receptor antagonists and zonisamide. The neuropathic pain may be diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and zonisamide. The AMPA... Agent: Clark & Elbing LLP

20100179194 - Insecticidal aryl isoxazoline derivatives: e

20100179195 - Isoxazoline insecticides:

20100179196 - Compositions and methods for deploying a transgenic refuge as a seed blend: Methods and compositions for deploying refuge seeds together with transgenic crop seeds are provided. The refuge seeds can be non-transgenic seeds of a similar variety to that of the transgenic crop seeds, or the refuge seeds can be a transgenic variety.... Agent: Sonnenschein Nath & Rosenthal LLP

20100179197 - Multi-substituted pyridyl sulfoximines and their use as insecticides: Multi-substituted pyridyl sulfoximines are useful as insecticides.... Agent: Dow Agrosciences LLC

20100179198 - Use of homo- and copolymers for stabilizing active ingredient formulations: The present invention relates to the use of specific homo- and copolymers P for the stabilizing of organic active compounds in aqueous compositions or formulations comprising surface-active substances.... Agent: Brinks, Hofer, Gilson & Lione

20100179199 - Ethanamine compounds and methods of using the same 545: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100179200 - 2-oxothiazolidine 4-carboxylic acid compounds for promoting desquamation of the skin: e

20100179201 - Novel thiazole-based compound and inhibitor of t-type calcium channel containing the same: The present invention relates to novel thiazole-based compounds and T-type calcium channel inhibitors containing the compound. The T-type calcium channel inhibitor of the present invention is useful as a treating agent for disease associated with overexpression of T-type calcium channel.... Agent: LexyoumeIPGroup, LLC

20100179202 - Orally disintegrating composition of zolmitriptan: A composition containing Zolmitriptan in the form of oral disintegrating tablet for the acute treatment of migraines is disclosed. The said composition comprises (a) Zolmitriptan, a salt or solvate or polymorph thereof as active ingredient, (b) mannitol, and (c) calcium silicate, and (d) optionally, one or more polysaccharides along with... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100179203 - Novel pyrazole derivatives useful as potassium channel modulators: This invention relates to novel pyrazole derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100179204 - Co-crystals of propiconazole: The present invention relates to co-crystals of propiconazole and a co-crystal forming compound.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100179205 - Composition for enhanced antiparasitic activity: The invention relates to antiparasitic compositions comprising a combination of atipamezole or its pharmaceutically acceptable salt and amitraz and their use in a method to control ectoparasite infestations on animals.... Agent: Traskbritt, P.C.

20100179206 - Control of ectoparasites: Disclosed is a method of controlling ectoparasites that infest companion and livestock animals by applying to the animal an effective amount of 4-tert-butylphenethyl quinazolin-4-yl ether or 4-chloro-5-ethyl-2-methyl-N-[(4-tert-butylphenyl)methyl]pyrazole-3-carboxamide or 5-chloro-N-[2-[4-(2-ethoxyethyl)-2,3-dimethylphenoxy]ethyl]-6-ethyl-4-pyrimidinamine or 4-chloro-3-ethyl-1-methyl-N-[4-(p-tolyloxy)benzyl]pyrazole-5-carboxamide... Agent: Fish & Richardson PC

20100179207 - Compounds: The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example Clostridium infection, such as C. perfringens, C. difficile, C. tetani, and/or C. botulinum, in particular C. difficile, especially infection of the... Agent: Morgan Lewis & Bockius LLP

20100179209 - Pactimibe medicaments for preventing/treating a disease due to sebaceous gland dysfunction in humans or animals: or pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, is useful for preventing or treating a disorder due to a sebaceous gland dysfunction in humans or animals, for example acne and/or any state or pathological condition related to an overproduction of sebum, e.g., seborrhoeic dermatitis, greasy skin or a greasy... Agent: Buchanan, Ingersoll & Rooney PC

20100179208 - Use of hdac inhibitors for the treatment of bone destruction: The present invention relates to the use of HDAC inhibitors for the treatment of bone destruction caused by cancer, inflammatory diseases and osteoporosis.... Agent: Novartis Corporate Intellectual Property

20100179210 - Novel enantiomerically pure compounds for the treatment of proliferative disorders: The present invention relates to an enantiomerically pure (+)-trans-enantiomer of a compound represented by the following formula (I): wherein R1, R2, R3, R4 and R9 are as defined in the specification; enantiomerically pure intermediates thereof, to processes for the preparation of the enantiomerically pure compound and its intermediates, and to... Agent: Frommer Lawrence & Haug

20100179211 - Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission: The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.... Agent: Birch Stewart Kolasch & Birch

20100179215 - Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders: The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders... Agent: Knobbe Martens Olson & Bear LLP

20100179214 - Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders: The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders... Agent: Knobbe Martens Olson & Bear LLP

20100179216 - Amine compound and pharmaceutical use thereof: e

20100179217 - Therapeutic compounds: The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. Compounds of the invention are... Agent: Viksnins Harris & Padys Pllp

20100179218 - Oculoselective drugs and prodrugs: e

20100179219 - Plane tree cream, method for the production thereof and use: In order to prevent betulinic acid from crystallizing in a galenic preparation containing water, a plane tree cream in the form of a stable emulsion containing oil and water is proposed, which is characterized by a content of 2 to 10% by weight of a plane tree extract obtained from... Agent: Hayes Soloway P.C.

20100179220 - Method for the treatment of tinnitus: Acamprosate, a drug used in the treatment of alcoholism, is a safe and successful alternative for neurossensorial tinnitus' treatment.... Agent: Arent Fox LLP

20100179221 - Fluorine-substituted amphetamines and amphetamine derivatives and use thereof: where at least one of the residues R1 or R2 is different from H and Ph is a phenyl ring, which is substituted with fluorine in at least one position or the residues R1 and R2 independently of one another are H or are different from H and Ph is... Agent: Ip Group Of Dla Piper LLP (us)

20100179222 - Compositions comprising jasmonic acid derivatives and use of these derivatives: e

20100179223 - Compounds, compositions, and methods for the treatment of synucleinopathies: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.... Agent: Proteotech, Inc.

20100179224 - Acyclic sulfamide derivatives: The present invention is related to acyclic sulphamide derivatives of formula (I), wherein R1 and R2 may be the same or different, when R1 and R2 are different, R1 is a linear C12-C20 alkyl group or a linear C12-C20 alkenyl group comprising 1, 2, 3 or 4 double bonds; and... Agent: King & Spalding

20100179225 - Poi prevention: A method is provided, comprising administering at least one guanylhydrazone or salt thereof or a combination thereof to a subject to prevent or ameliorate in said subject at least one of postoperative intestinal inflammation, postoperative ileus, ischemia reperfusion injury, or a combination thereof.... Agent: Law Office Of John K. Pike, PLLC

20100179226 - Topical dosage form comprising tri-substituted glycerol compounds: The present invention relates to pharmaceutical dosage forms for topical administration comprising a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof. The invention also relates to a corresponding method for preparing such dosage forms as well as to their use as medicaments for the treatment of cancer and immune... Agent: K&l Gates LLP

20100179227 - Production method of hop preparation, hop preparation, anti-inflammatory agent, food product and beverage, and oral product: e

20100179228 - Novel oil-based adjuvant composition: The present invention provides compositions comprising oil, surfactants and ammonium salts suspended therein which may be added to agrochemical compositions, improving their activity.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100179229 - Method for modulating the taste of material compositions containing at least one high intensity sweetener (his): Process for modulation of a taste and/or aftertaste in foods, articles consumed for pleasure, animal feeds, sweeteners and cosmetics comprising at least one high intensity sweetener HIS by addition of a taste modulator comprising at least one polyoxyethylene sorbitan fatty acid ester which is suitable for food, and use of... Agent: Connolly Bove Lodge & Hutz, LLP

  
07/08/2010 > patent applications in patent subcategories. category listing

20100173823 - Alpha2c adrenoreceptor agonists: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such... Agent: Merck Patent Department (k-6-1, 1990)

20100173822 - Composition comprising saccarides & peptides & uses thereof: The present invention relates to a composition comprising saccharides and peptides in unique proportion for improving the endurance capability of the human body in motion, promoting recovery after motion, reducing body fat, and alleviating fatigue of central nerves during motion. The composition can further comprise vitamins, minerals, flavoring materials and... Agent: The Coca-cola Company Patent & Technology Dept--nat 19

20100173824 - Azepinoindole derivatives as pharmaceutical agents: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20100173825 - Heteroaryl benzamide derivatives: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of... Agent: Morgan Lewis & Bockius LLP

20100173827 - Role of proline rich peptides in cellular communication mechanisms and treatment of diseases: The present invention includes peptide compositions for improving cellular communication mechanisms, repairing metabolic errors, and for treatment of AD, dementia and other neurological conditions. The proline rich peptide complexes (PRPC) of the present invention are isolated from colostrinin and can be added in nutritional and other food supplements. Additionally, the... Agent: Chalker Flores, LLP

20100173826 - Smooth muscle relaxation: The invention relates to methods of inducing smooth muscle relaxation, for example, a method of inducing relaxation of a vascular or a non-vascular muscle or a method of inducing relaxation of the microvasculature, in a subject in need thereof by promoting the accumulation of protoporphyrin IX in the smooth muscle.... Agent: Nada Jain, P.C.

20100173828 - Aß(x - 38 .. 43) oligomers, and processes, compositions, and uses thereof: The present invention relates to an Aβ(X-38 . . . 43) oligomer having a high molecular weight, or a derivative thereof, a process for preparing the oligomer or derivative, compositions comprising the oligomer or derivative, and uses of the oligomer or derivative such as its use for treating or preventing... Agent: Paul D. Yasger Abbott Laboratories

20100173830 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Marshall, Gerstein & Borun (baxter)

20100173831 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Marshall, Gerstein & Borun (baxter)

20100173829 - Glycoproteins having lipid mobilizing properties and therapeutic uses thereof: The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions... Agent: Dla Piper LLP (us)

20100173832 - Anticancerous polymeric agents: Methods and pharmaceutical compositions for treating cancer, particularly MDR cancer, which utilize polymeric compounds that are composed of a plurality of amino acid residues and one or more hydrophobic moieties are disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100173834 - Cyclic peptide melanocortin receptor ligands: The present invention is directed to compounds according to formula, (R2R3)-A0A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, wherein the definitions of A1 to A10 and R1 to R3 are provided in the application, and pharmaceutically-acceptable salts thereof, that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to... Agent: Alan F. Feeny, Esq.

20100173833 - Methods and composition for use of cyclic analogues of histatin: Provided are novel compositions and therapeutic methods for treating bacterial and fungal disease with cyclic analogues of histatin. The cyclic analogues of histatin are advantageously more potent but less toxic than currently used anti-microbial agents. In addition, compositions comprising the cyclic analogue with other anti-microbial agents such as azole compounds... Agent: Valentine A Cottrill Susan Tandan

20100173837 - Dosing forms and regimens comprising 3-[(r)-2-(n,n-dimethylamino)ethylthio-sar]-4-(gammahydroxymethylleucine)cyclosporine: Provided herein are specific doses of, and dosing regimens for, using SCY-635 in treating or preventing diseases, in particular hepatitis C virus (HCV) infection.... Agent: Buchanan, Ingersoll & Rooney PC

20100173836 - Novel macrocycles: o

20100173838 - Novel process for the preparation of cyclosporin derivatives: The invention concerns a novel method for preparing an intermediate polyanion for preparing cyclosporin derivatives by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide. The treated cyclosporin has one or several free hydroxy groups and/or non-methylated nitrogen atoms in position α and/or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100173835 - Peptides for treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100173841 - Highly purified type a botulinum toxin preparation from infant botulism pathogen: A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100173846 - Magnesium ammonium phosphate cement composition: This invention relates to a cement, which comprises in its main phase of microcrystalline magnesium ammonium phosphate and nanoapatite after hardening and thus at the same time has considerable strength. The material is biologically degradable and is suitable for application in tooth cements, as bone replacement, as bone filler, as... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100173840 - Pharmaceutical composition for treating autoimmune, allergic and inflammatory diseases and delivery method thereof: Disclosed herein are a novel pharmaceutical composition for inhibiting autoimmune diseases, allergic diseases and inflammatory diseases, which contains a conjugate of Foxp3 and PTD (protein transduction domain), and a delivery method thereof. According to the disclosed invention, Foxp3-PTD treats and inhibits autoimmune diseases by effectively inhibiting the activation of T... Agent: Quarles & Brady LLP

20100173839 - Stabilized insulin-like growth factor polypeptides: The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100173844 - Stable formulations of peptides: Stable pharmaceutical composition comprising insulinotropic peptide.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100173843 - Tissue adhering compositions: A method mixes a first component, a second component, and a buffer material. The first component includes an electrophilic polymer material comprising poly(ethylene glycol) having a functionality of at least three. The second component includes a nucleophilic material comprising a natural or synthetic protein at a concentration of about 25%... Agent: Pepper Hamilton LLP

20100173845 - Use of fertirelin and delta-endorphin as therapeutic agents: The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100173842 - Vaccine for staphylococcal infections: The invention relates to a method of preparation and use of a polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.... Agent: Matthias Scholl

20100173847 - Tfpi inhibitors and methods of use: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.... Agent: Marshall, Gerstein & Borun (baxter)

20100173848 - Methods of inhibiting chemokine binding to chemokines receptors: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100173849 - Neo-tryptophan: Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75,... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100173850 - Improved peptide composition: A peptide sequence of the form: X(Lys,Arg)XXXXX(Arg,Lys)X, wherein Lys and Arg arc replaceable and X is preferably one or more of the following amino acids: hydrophobic amino acid residues (eg Pro, Leu. Met, Ile), basic amino acid residues or threonine; and wherein the sequence is capable of engaging Λβ and... Agent: Mcandrews Held & Malloy, Ltd

20100173851 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these... Agent: Vertex Pharmaceuticals Inc.

20100173852 - Use of agents that down-regulate expression of tanis and/or p21 waf1/cip1/sd1 genes, and use of agents that inhibit, degrade, sequester or prevent the neurotoxicity of gene product proteins of tanis and p21 waf1/cip1/sd1 genes: The present invention provides compositions and methods for treating glaucoma, ocular hypertension, and age-related macular degeneration. More specifically, the present invention describes the use of agents that down-regulate expression of tanis and/or p21Waf1/Cip1/Sd1 genes to treat such disorders of the eye.... Agent: Alcon

20100173853 - Combination of monosaccharides with ascorbic acid and use thereof: Composition containing a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one additional compound chosen from ascorbic acid, an analogue thereof and a mixture thereof. The present invention also relates to the use of such a composition for combating the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100173854 - Microfluidized oil-in-water emulsions and vaccine compositions: This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.... Agent: Pharmacia & Upjohn

20100173855 - Dermatological formulations: Aqueous preparations of substantially equimolor amounts of a zinc salt and clindamycin phosphate form a polymer useful in the topical treatment of acne and rosacea, with very low systemic levels of clindamycin.... Agent: Fish & Richardson PC

20100173856 - Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances: Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal,... Agent: Knobbe Martens Olson & Bear LLP

20100173857 - Spinosyns for wound healing: A spinosyn or a physiologically acceptable derivative or salt thereof for promoting or accelerating wound healing in humans.... Agent: Eli Lilly & Company

20100173858 - Compositions to treat bacterial and inflammatory affections in pet animals dosage form and method to treat pet animals: Compositions comprising at least one bactericidal antibiotic from the group of macrolides and a non-steroid anti-inflammatory with selective inhibiting activity for cycloxygenase 2 (COX-2). The present invention also refers to a dosage form of said compositions, as well as a method to treat pet animals, particularly dogs and cats. Compositions... Agent: Smith, Gambrell & Russell

20100173859 - Pharmaceutical formulation for the production of rapidly disintergrating tablets: m

20100173860 - Purifications of pomegranate ellagitannins and their uses thereof: Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds... Agent: Bozicevic, Field & Francis LLP

20100173861 - Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants: Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also... Agent: Venable LLP

20100173862 - Injectable, injection solution, and injection kit preparation: Provided is an injectable comprising: an anthracycline antineoplastic antibiotic; and at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide.... Agent: Sughrue Mion, PLLC

20100173975 - Expressed pseudogene regulates gene expression: Selective expression of a pseudogene of myosin light chain kinase is found in cancer cells and tissues but not in normal cells and tissues. The pseudogene is expressed, and when expressed it inhibits expression of the ancestral myosin light chain kinase. This widespread expression among cancer cell types and the... Agent: Banner & Witcoff, Ltd.

20100173973 - Extended dicer substrate agents and methods for the specific inhibition of gene expression: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a pattern... Agent: Edwards Angell Palmer & Dodge LLP

20100173974 - Extended dicer substrate agents and methods for the specific inhibition of gene expression: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a pattern... Agent: Edwards Angell Palmer & Dodge LLP

20100173971 - Genetic changes in atm and atr/chek1 as prognostic indicators in cancer: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to... Agent: Baker Botts L.L.P.

20100173972 - Methods and uses related to rhbdl4: The invention relates to a method of identifying a modulator of RHBDL4, said method comprising (i) providing a first and second sample of cells; (ii) contacting said first sample of cells with a candidate modulator of RHBDL4; (iii) measuring epidermal growth factor receptor (EGFR) transactivation in said first and second... Agent: Nixon Peabody, LLP

20100173976 - Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of stromal cell-derived factor-1 (SDF-1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and... Agent: Merck

20100173980 - Antiviral oligonucleotides targeting rsv: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for... Agent: Ogilvy Renault LLP

20100173977 - Crystal: The present invention relates to a crystal. In particular the present invention relates to a crystal of the N-domain of ACE protein. The present invention also relates to methods, processes, domain specific modulators, pharmaceutical compositions and uses of the N-domain crystal and the structure co-ordinates thereof.... Agent: Marshall, Gerstein & Borun LLP

20100173979 - Gene therapy for lysosomal storage diseases: This disclosure provides methods and compositions for treating lysosomal storage diseases in a subject. In one aspect of the invention, a transgene product is delivered to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region... Agent: Genzyme Corporation Legal Department

20100173978 - Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor: The invention refers to a fully human miniantibody (scFv), called Erbicin, specific for the receptor ErbB2, with a pharmacological, in particular antitumour, activity. It has been obtained from a larger fagmidic library (Griffin 1.) (19) of human synthetic scFv by panning (affinity selection on antigen) carried out on live cells... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100173863 - 2-fluoronucleosides: e

20100173864 - Compositions including triciribine and one or more platinum compounds and methods of use thereof: This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.... Agent: Morgan Lewis & Bockius LLP

20100173865 - Anti-cancer agent-hyaluronic acid conjugate compositions and methods: Methods of making conjugates comprising an anti-cancer agent and hyaluronic acid, together with mixtures of reaction products comprising such conjugates and methods of using such conjugates in therapeutic and research applications are disclosed.... Agent: NielsenIPLaw LLC

20100173866 - Apparatus and method for ocular treatment: The invention provides tools, materials and related methods to surgically access the suprachoroidal space of an eye for the purpose of performing minimally invasive surgery or to deliver drugs to the eye. The invention provides a flexible microcannula or microcatheter device (11, 13) that may be placed into the suprachoroidal... Agent: Weaver Austin Villeneuve & Sampson LLP

20100173867 - Injectable cross-linked polymeric preparations and uses thereof: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic... Agent: Hoffmann & Baron, LLP

20100173868 - Composition and method for healing tissues: The composition and method for healing tissues is a medicinal composition for facilitating the growth, protection and healing of tissues and cells in animals and humans. The composition is formulated as a either a powder, gel, paste, film, fluid injectable, rehydratable freeze-dried paste or sponge, sprayable solution, topically applied patch... Agent: Litman Law Offices, Ltd.

20100173869 - Treatment of surfactants: e

20100173870 - Phosphonate compounds: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.... Agent: Dla Piper LLP (us)

20100173871 - Phosphorylated dendrimers as antiinflammatory drugs: A method for treating inflammatory diseases through an anti-inflammatory type activation of monocytes, the method includes the administration to a patient in need thereof of an effective quantity of at least one dendrimer with mono- or biphosphonic terminations.... Agent: Young & Thompson

20100173872 - Method and composition for treating alzheimer's disease and dementias of vascular origin: A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans.... Agent: Marshall, Gerstein & Borun LLP

20100173873 - Treatment of metastasized tumors: Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt... Agent: Foley & Lardner LLP

20100173874 - Delivery of modulators of glutamate-mediated neurotransmission to the inner ear: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.... Agent: Durect Corporation Thomas P. Mccracken

20100173875 - Formulation of aspirin that is stable and showing minimal hydrolysis for parenteral adminstration for the treatment of cardiovascular and other disease states: Disclosed herein are ways to solubilize aspirin for parenteral administration containing aspirin and a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of acute coronary syndromes as well as other disease states. The solution so constituted is stable at room temperature for prolonged periods without decomposition and avoids significant hydrolysis of... Agent: John C. Somberg, Md

20100173876 - Oil-based nsaid compositions and methods for making and using same: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to... Agent: Jackson Walker LLP

20100173877 - Multi-phase contraceptive preparation based on a natural estrogen: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting... Agent: Millen, White, Zelano & Branigan, P.C.

20100173880 - Alkaloid aminoester derivatives and medicinal composition thereof: Alkaloid aminoester compounds which act as muscarinic receptor antagonists are useful for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100173881 - Compositions for the treatment of inflammatory disorders: The invention features methods and compositions for the treatment of immunonflammatory disorders.... Agent: Clark & Elbing LLP

20100173878 - Organic compounds: 2-benzyl-3-(optionally hetero)arylamino-[2H]-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-diones, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors.... Agent: Hoxie & Associates LLC

20100173879 - Use of a compound antagonist to the nk2 receptors of neurokinin a for the preparation of drugs useful for preventing and treating of sexual dysfunction: The invention relates to the use of a compound antagonist to the NK2 receptors of A neurokinine for the preparation of drugs useful for preventing and treating sexual dysfunction.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100173883 - 7-hydroxyepiandrosterone having neuroprotective activity: 3-Hydroxy-7β-hydroxy steroids and 3-oxo-7β-hydroxy steroids and pharmaceutically acceptable esters thereof are useful for protection against neuronal damage.... Agent: Dechert LLP

20100173882 - Steroidal compositions: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro-... Agent: Wilson, Sonsini, Goodrich & Rosati

20100173884 - Use of a phytosterol containing composition for the treatment of luts: The invention relates to the use of a composition comprising an oil-extract and a water-soluble extract, wherein said extracts are obtainable from plant materials and said extracts comprise phytosterols, for the manufacturing of a medicament for the treatment of females suffering from LUTS as a consequence of Interstitial Cystitis and/or... Agent: Merchant & Gould PC

20100173885 - Organometeallic compounds: The present invention relates to novel organometallic compounds for use as a medicine, in particular in photodynamic therapy against various diseases, such as cancer or inflammatory and/or immune disorders. The compounds comprise a central porphyrin or phtalocyanine backbone to which ligand linkers coordinated to at least one transition metal are... Agent: Krieg Devault LLP

20100173887 - Bactericidal anti-mrsa active pharmaceutical composition containing carbapenems: e

20100173888 - Nicotinamide derivatives:

20100173889 - Substituted pyrimidine and triazine compounds: wherein R1, R2, R3, R4a, R4b, R5a, R5b, R7, R8, R9a, R9b, R10, R11, A, a, b, s, t, V, W1, W2 and W3 have defined meanings, pharmaceutical compositions comprising such compounds, a process for preparing such compounds, and the use of such compounds and compositions to treat or inhibit... Agent: Crowell & Moring LLP Intellectual Property Group

20100173886 - Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.... Agent: Osi Pharmaceuticals, Inc.

20100173890 - Compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity a: The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in the treatment of 5-HT6 mediated disorders such... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100173891 - Heterocyclic compounds, methods for the preparation thereof, and uses thereof: e

20100173892 - Enantioselective synthesis of 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1h]-one and zilpaterol: This invention relates to a process for the hydrogenation of a ketooxime to selectively form an aminoalcohol stereoisomer, and, in particular, to a process for the hydrogenation of 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7[1H]-trione-6-oxime or a salt thereof to selectively form a stereoisomer of 6-amino-7-hydroxy-4,5,6, 7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one or a salt thereof. This invention also relates to... Agent: Traskbritt, P.C.

20100173893 - Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation: i

20100173894 - Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases: The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.... Agent: Arena Pharmaceuticals Inc./finnegan Henderson LLP

20100173895 - Imidazolopyrimidines and imidazolotriazine derivatives as inhibitors of poly(adp-ribose)polymerase(parp): The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative... Agent: Merck

20100173896 - Organic compounds: The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, to the manufacture and to the use thereof.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100173897 - Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof: Wherein R, R1, R2, R3 and R4 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100173898 - Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof: Wherein R, R1, R2, R3 and R4 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100173899 - Dipeptide analogs as coagulation factor inhibitors: e

20100173900 - Strobilurins for increasing the resistance of plants to abiotic stress: The present invention relates to a method for increasing the resistance of a plant or of a plant's seed to abiotic stress which method comprises treating the seed from which the plant is to grow with at least one strobilurin. The invention further relates to the use of at least... Agent: Brinks, Hofer, Gilson & Lione

20100173902 - Bicyclic amide derivatives for enhancing glutamatergic synaptic responses: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in cognitive abilities related to memory impairment, such... Agent: Henry D Coleman

20100173903 - Bicyclic amide derivatives for the treatmet of respiratory disorders: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin. In a particular aspect, the invention relates to bicyclic amide compounds useful... Agent: Henry D Coleman

20100173901 - Substituted heterocyclic compounds: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases... Agent: Pepper Hamilton LLP

20100173904 - Topical composition, topical composition precursor, and methods for manufacturing and using: A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at... Agent: Attn: Dennis R. Daley Merchant & Gould P.C.

20100173905 - Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome: The invention discloses a new use of a class of heptacyclic compounds in the preparation of formulations for the prevention and treatment of diabetes and metabolic syndromes; the present invention also discloses a new class of heptacyclic compounds; the present invention also discloses a process for preparing the heptacyclic compounds... Agent: Baker Botts LLP C/o Intellectual Property Department

20100173906 - Substituted 3,4,6,7-tetrahydro-5h-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods: Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalene-9-amines, pharmaceutical compositions containing the compounds or salts thereof, intermediates, methods of making the compounds or salts thereof, and methods of use of these compounds or salts thereof or pharmaceutical compositions as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic... Agent: Pfizer Inc. Patent Department

20100173907 - Method of treatment of aggression: The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.... Agent: Foley And Lardner LLP Suite 500

20100173908 - Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof: Wherein R, R1, R2, R3, R4 and R5 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100173909 - Piperidine compounds and uses thereof - 596: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20100173910 - Triaminopyrimidine cyclobutenedione derivatives used as phosphatase cdc25 inhibitors: m

20100173911 - 3-(imidazolyl)-pyrazolo[3,4-b]pyridines: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP

20100173912 - Novel compound: m

20100173913 - Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents:

20100173914 - Pharmaceuticals, compositions and methods of making and using the same: Compounds that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.... Agent: Steptoe & Johnson LLP

20100173915 - Pharmaceutical compositions for the treatment of chronic heart failure comprising pyrazolopyrimidinone derivative compound: Disclosed herein is a therapeutic agent for chronic heart failure comprising, as an effective ingredient, 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyl-ethylamidosulfonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one. The compound inhibits phosphodiesterase-5 (PDE-5), which catalyzes the intracellular degradation of cyclic guanosine monophosphatase (cGMP), thereby mitigating several signs of chronic heart failure, that is, thereby preventing left ventricular dilatation, decreasing ventricular wall thinning,... Agent: Lucas & Mercanti, LLP

20100173916 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions: s

20100173917 - Urea derivatives as abl modulators: The invention provides methods and compositions for treating conditions mediated by Bcr-Abl. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.... Agent: Jones Day

20100173918 - Methods and compositions for determining the efficacy of breast cancer therapeutics: The present disclosure relates to a method, kit and controls for detecting phosphorylated Tyr1248 in the c-erbB-2 protein as a predictor of breast cancer progression and as a predictor of therapeutic efficacy of drugs that inhibit both epidermal growth factor receptor and erbB2 protein kinases.... Agent: K&l Gates LLP

20100173919 - Pharmaceutical composition using aliskiren and avosentan: The present invention relates to a pharmaceutical composition and method of achieving a therapeutic effect including, but not limited to, the treatment of hypertension, kidney or heart disease in an animal, preferably a mammal including a human subject, using (i) SPP100/aliskiren or a pharmaceutically acceptable salt thereof in combination with... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100173920 - Polymorphs of 3-(e)-2--3-methoxyacrylate: The present invention relates to novel crystalline polymorphic and amorphous forms of the compound (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxy-acrylate(azoxystrobin). Infrared Raman spectra, X-ray powder diffraction pattern and differential scanning calorimetry thermogram of two polymorphs “A” and “B” are provided. Further, the present invention also provides methods for preparing the novel polymorphic forms “A” and... Agent: Cantor Colburn, LLP

20100173921 - Antiretroviral solid oral composition: The present invention provides an antiretroviral solid oral composition comprising one or more antiretroviral drugs, for example protease inhibitors such as lopinavir, ritonavir or a combination thereof with one or more excipients. The invention provides a composition which is smaller for a given amount of said active substance and possesses... Agent: Conley Rose, P.C.

20100173922 - Polymorphisms for predicting disease and treatment outcome: The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest... Agent: Foley & Lardner LLP

20100173923 - 4 (pyrrolopyridinyl)pyrimidinyl-2-amine derivatives: Compounds of the formula I in which R1, R2, R3, R4 and R5 are each as defined in claim 1 are inhibitors of cell proliferation/cell vitality and can be used to treat tumors.... Agent: Millen, White, Zelano & Branigan, P.C.

20100173924 - Novel heterocycle compounds and uses thereof: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): which penetrate the blood-brain barrier, inhibit the formation and accumulation of beta-amyloid, and are useful in the treatment of neurodegenerative diseases, particularly Alzheimer's disease. Further, the compounds of the present invention inhibit certain kinases, thereby... Agent: Hoxie & Associates LLC

20100173925 - Oxyindole derivatives: A, R1, R2, R3, R4 and R5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal... Agent: Pfizer Inc Mary J Hosley

20100173926 - Methods for regulating neurotransmitter systems by inducing counteradaptations: The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100173927 - Beloxepin and analogs for the treatment of pain: This present disclosure provides methods of treating pain with beloxepin and/or beloxepin analogs.... Agent: Dechert LLP

20100173928 - Phosphorylation and regulation of akt/pkb by the rictor-mtor complex: In certain aspects, the invention relates to methods for identifying compounds which modulate Akt activity mediated by the rictor-mTOR complex and methods for treating or preventing a disorder that is associated with aberrant Akt activity.... Agent: Ropes & Gray LLP

20100173929 - Tricyclic n-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof:

20100173930 - Certain chemical entities, compositions and methods: Provided are certain chemical entities, and methods of use to modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100173931 - Harmine derivatives for reducing body weight: The present invention provides a method of reducing body weight in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of obesity and disorders related to obesity and higher than... Agent: Townsend And Townsend And Crew, LLP

20100173932 - Sub-type selective amides of diazabicycloalkanes: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100173933 - Antibacterial agents: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R1)— or ═N—; R1 is hydrogen or an optional substituent and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2—, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; R3 is a... Agent: Banner & Witcoff, Ltd.

20100173934 - Combinations of therapeutic agents for treating cancer: The invention relates to a combination comprising a microtubule active agent; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.... Agent: Novartis Corporate Intellectual Property

20100173935 - Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia: Compounds of Formula IA, or pharmaceutically acceptable salts thereof: IA wherein G1, G2, G3, G4, R1, R2, X, Y, Z and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100173936 - Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system-related disorders: Compositions are provided which can be useful in treating a renin-angiotensin aldosterone system-related disorder. These compositions include renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, as well as other therapeutic agents, and are useful in treating hypertension, stroke, metabolic syndrome, or other renin-angiotensin aldosterone system-related disorders in a subject. The... Agent: Stites & Harbison PLLC

20100173937 - Use of tetrakis-quaternary ammonium salts as pain modulating agents: Provided are methods of modulating, treating, reversing and/or preventing pain using tetrakis quaternary ammonium compounds, especially regarding pain of central and/or peripheral origin and/or pain which is nociceptive, neuropathic, somatic, visceral, and/or inflammatory in nature.... Agent: Crowell & Moring LLP Intellectual Property Group

20100173938 - Nerve cell death inhibitor: o

20100173939 - Antiviral compounds:

20100173940 - Non-mucoadhesive film dosage forms: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100173941 - Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia: Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, R5, R6, R7, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100173942 - Phosphodiesterase 4 inhibitors: m

20100173943 - Insecticidal compositions with improved action: The present invention relates to enhancement of the action of crop protection compositions comprising enaminocarbonyl compounds by the addition of ammonium salts and/or phosphonium salts or by the addition of ammonium or phosphonium salts and penetrants, to the corresponding compositions, to processes for their production and to their use in... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100173946 - Benzimidazolylidene propane-1,3-dione derivative or salt thereof: Compounds useful as GnRH receptor antagonists are provided. The present inventors have further examined propane-1,3-dione derivatives and confirmed as a result that a propane-1,3-dione having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene), or a compound which has benzene or thiophene ring substituted with a group derived from 1-hydroxymethyl, shows excellent availability, in addition to its excellent... Agent: Sughrue-265550

20100173945 - Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof: Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain.... Agent: Abelman, Frayne & Schwab

20100173944 - Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion: s

20100173947 - New indications for direct thrombin inhibitors: The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the CNS and other fields.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100173948 - Animal pest control method: e

20100173949 - Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof: Wherein R, R1, R2, R3 and R4 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100173950 - Heteroaryl (substituted)alkyl n-substituted sulfoximines as insecticides: N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100173952 - Metalloprotein inhibitors: wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said... Agent: Schwegman, Lundberg & Woessner, P.A.

20100173951 - Novel methods: The invention relates to the novel chemical compounds of the formula (I): (I) in free or salt form, its use in the treatment of NET and/or SERT mediated conditions, e.g., depression, vasomotor symptoms, e.g., hot flashes and other diseases or conditions mediated by NET and/or SERT.... Agent: Hoxie & Associates LLC

20100173953 - 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate: The present invention relates to 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.... Agent: Millen, White, Zelano & Branigan, P.C.

20100173954 - Treatment of cancers having resistance to chemotherapeutic agents: e

20100173955 - 4-substituted phenoxyphenylacetic acid derivatives: Compounds of Formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.... Agent: Viksnins Harris & Padys Pllp

20100173956 - Use of quaternary pyridinium salts as vasoprotective agents: wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100173957 - Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy: The invention relates to the use of nicotinic acid alkyl esters, especially myristyl nicotinate, to inhibit side effects associated with retinoic acid therapy. Also a part of the invention is a method for improving skin cell differentiation by administering the nicotinic acid alkyl ester in an amount sufficient to increase... Agent: Fulbright & Jaworski, LLP

20100173958 - Compounds for the inhibition of dgat1 activity: e

20100173959 - Method of protecting a plant propagation material, a plant, and/or plant organs: A method of controlling or preventing pest damage in a plant propagation material, a plant, and/or plant organs that grow at a later point in time, which comprises applying on the plant propagation material or locus thereof a compound I or II represented by formula (I) and (II) wherein R1... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100173961 - Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors: The invention relates to benzooxazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100173960 - The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases: The invention relates generally to novel compositions and methods comprising one or more cyclohexanehexol and one or more NSAID. The compositions and methods provide beneficial effects in the treatment and prevention of diseases involving a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence, in particular... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100173962 - Heteroaryl (substituted)alkyl n-substituted sulfoximines as insecticides: N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100173963 - Compound: wherein R3, R4, R5, R6 and R7 are independently selected from H and —Y—R8; wherein each R8 is independently selected from —OH, hydrocarbyl groups, oxyhydrocarbyl groups, cyano (—CN), nitro (—NO2), H-bond acceptors, and halogens; wherein at least one of R3, R4, R5, R6 and R7 is —Y—R8 wherein R8 is... Agent: Frommer Lawrence & Haug

20100173964 - Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor: The present patent application relates to a pharmaceutical composition for oral administration that includes a certain pyrrolidine derivative as DPP-IV inhibitor, and a pharmaceutically acceptable excipient. More particularly, the present invention contemplates pharmaceutical compositions that include melogliptin and a pharmaceutically acceptable excipient as well as to processes for preparing the... Agent: Kaplan Gilman & Pergament LLP

20100173965 - Antifungal composition: e

20100173966 - Pyrazole carboxylic acid amides useful as microbiocides: Compounds of the formula (I), in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100173967 - Use of spiro-oxindole compounds as therapeutic agents: This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for... Agent: SeedIPLaw Group PLLC

20100173968 - Sub-type selective azabicycloalkane derivatives: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide, ketone, and ester compounds prepared from certain azabicycloalkane carboxylic acids. The resulting compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the... Agent: Womble Carlyle Sandridge & Rice PLLC Targacept

20100173969 - Therapeutic agent: Provided are agents and methods for use in depleting serum amyloid P component (SAP) from a patient in need thereof.... Agent: Frommer Lawrence & Haug

20100173970 - C-nitroso-derived nitroxyl donors: o

20100173981 - Therapeutic compounds: Disclosed herein is a compound according to one of the formulas or a pharmaceutically acceptable salt thereof, medicaments for the treatment of glaucoma or ocular hypertension and compositions related thereto, as further elaborated herein.... Agent: Allergan, Inc.

20100173982 - Novel method for the asymmetric synthesis of beta-lactone compounds: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These... Agent: Catalyst Law Group, Apc

20100173984 - Epigallocatechin-3-gallate crystal compositions: Crystalline epigallocatechin-3-gallate compositions and methods of use.... Agent: Bryan Cave LLP

20100173983 - Method for inducing autophagy: The present invention relates to methods for inducing or promoting autophagy in a cell, the method comprising exposing to the cell an effective amount of a compound of formula I as described herein. The invention also relates to methods for treating or preventing diseases and disorders by administering to subjects... Agent: Pearl Cohen Zedek Latzer, LLP

20100173985 - Polyphenol proteasome inhibitors, synthesis, and methods of use: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100173986 - Sesquiterpenes and derivatives thereof for use as feed additives: The present invention relates to the use of sesquiterpenes and derivatives thereof as components of animal feed or feed additives for the improvement of animal performance as well as to the corresponding animal feed or feed additives containing them.... Agent: Nixon & Vanderhye, PC

20100173987 - Active agent combinations with insecticidal and acaricidal properties: The novel active compound combinations consisting, firstly, of cyclic ketoenols and, secondly, of beneficial species (natural enemies) have very good insecticidal and/or acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100173988 - Oxaliplatin active substance with a very low content of oxalic acid: The present invention relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, and to a process of preparing the active substance.... Agent: Sanofi - Aventis / Finnegan Henderson LLP

20100173989 - Antiwrinkle agent and skin cosmetic composition: e

20100173992 - Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use: Levodopa dimethyl-substituted diester prodrugs pharmaceutical, compositions comprising levodopa dimethyl-substituted diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100173991 - Method for the synthesis of a-ring aromatized acetyl minocyclines: wherein R1 to R5=acetyl and/or H, which can also be used on an industrial scale, is achieved in that minocycline hydrochloride is reacted with acetanhydride in the presence of a proton catcher, the reaction product is subjected to chromatographic filtration using a carrier material and an eluant, the eluant is... Agent: Jordan And Hamburg LLP

20100173990 - Transglutaminase inhibitor comprising chlorogenic acid and a method for producing thereof: The present invention relates to a transglutaminase inhibitor comprising chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof. More particularly, the present invention relates to a transglutaminase inhibitor comprising chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof which effectively inhibits the activity of transglutaminase, the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100173993 - Controlled release biocidal salts: A controlled release biocidal salt of a first component comprises a cation of a Nα—(C1-C22)alkanoyl di-basic amino acid alkyl(C1-C22)ester cationic biocidal molecule and a second component comprising an anion of a monomeric anionic molecule having insignificant biocidal activity. The salt is characterized such that when the salt is exposed to... Agent: Law Offices Of Jack Matalon

20100173994 - Synthesis of triethylenetetramines: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.... Agent: Duane Morris LLP - San Diego

20100173995 - Use of ppar-alpha activator as inflammatory skin disease-treating agent and method for treating skin diseases using the same: t

20100173996 - Synergistic mixtures of opp and dgh: Ortho phenylphenol or its sodium salt is shown to form synergistic antimicrobial mixtures with nitrogen and aldehyde-containing microbiocides.... Agent: Beck & Thomas, P.C. Suite 100

20100173997 - 2,4,6-trisubstituted phenols having anesthetic properties: Trisubstituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.... Agent: Edwards Angell Palmer & Dodge LLP

20100173998 - Odor controlled personal care compositions containing hydroxypropyl trialkylammonium salts: A personal care composition is provided which includes from 0.1 to 30% of a dihydroxypropyltri(C1-C3 alkyl) ammonium salt by weight of the composition; from 0.0001 to 0.005% of a tri(C1-C3 alkyl)amine or protonated form thereof by weight of the ammonium salt; from 0.002 to 15% of an aluminum salt by... Agent: Unilever Patent Group

20100173999 - 2,5-di- and 2,2,5-trisubstituted di- and tetrahydrofuran derivatives and their use for the production of perfumes: Di-/trisubstituted furans of the formula (I) and their use as odorants wherein R1 is hydrogen or methyl; R2 is ethyl, propyl or isopropyl; the bond between C-3 and C-4 is a single bond, or the dotted line together with the bond between C-3 and C-4 represents a double bond; and... Agent: Parfomak, Andrew N. Norris Mclaughlin & Marcus Pa

20100174000 - Carrier in the form of oil-in-water emulsion notably intended for ophthalmic or dermocosmetic use: -

20100174001 - Antioxidant for food: The present invention relates to the technical field of additives or adjuncts, especially additives that have an antioxidant effect and antioxidants, for food products, animal feed, cosmetics, and pharmaceuticals. The present invention above all provides an improved antioxidant agent for food products, animal feed, cosmetics, and pharmaceuticals and also provides... Agent: Dickstein Shapiro LLP

  
07/01/2010 > patent applications in patent subcategories. category listing

20100167982 - Barrier integrity in hiv patients: The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.... Agent: Foley And Lardner LLP Suite 500

20100167983 - Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a... Agent: Cooper & Dunham, LLP

20100167981 - Encapsidation of heterologous entities into virus-like particles: Methods are provided for the utilization of bacterial cell-free extracts in the synthesis of high yields of virus like particles with encapsidated cargo.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100167980 - Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation: Provided herein are methods for reducing or preventing neutrophilic inflammation in a subject comprising selecting a subject with or at risk for neutrophilic inflammation and administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase. Provided herein are also methods for treatment or prevention of... Agent: Fish & Richardson P.C.

20100167979 - Rheumatoid arthritis-preventive agent for oral intake: There is provided a rheumatoid arthritis inhibitor for oral intake that has an inhibitory effect on rheumatoid arthritis and is excellent in safety. The rheumatoid arthritis inhibitor for oral intake of the present invention contains, as an active component, a casein hydrolysate containing free amino acids and peptides obtained by... Agent: Sughrue Mion, PLLC

20100167984 - Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation: It more particularly relates to the use of a complex according to the invention in the preparation of a human insulin formulation at a concentration of approximately 600 μM (100 IU/ml), the onset of action of which is less than 30 minutes, preferably less than 20 minutes and more preferably... Agent: Oliff & Berridge, PLC

20100167985 - Oral insulin composition and methods of making and using thereof: A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100167986 - Cholesteryl ester transfer protein inhibitors: Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused... Agent: Merck

20100167988 - Ethoxyphenylmethyl inhibitors of sglt2: The present invention relates to new ethoxyphenylmethyl modulators of SGLT2, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100167989 - Isopropoxyphenylmethyl inhibitors of sglt2: The present invention relates to new isopropoxyphenylmethyl inhibitors of SGLT2, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100167987 - Methods and pharmaceutical compositions for healing wounds: A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected... Agent: Fulbright & Jaworski, LLP

20100167990 - Pharmaceutical formulations comprising an insulin derivative: The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100167992 - Phenyl ester side chains to increase polymer resorptivity: The present invention relates to polymers modified to increase their resorbability. In particular, the polymers of the invention have phenyl ester side chains which are good leaving groups and which thereby increase the resorption rate of the polymer relative to the same polymer, for example, bearing a comparable amount of... Agent: Cooley LLP Attn: Patent Group

20100167991 - Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative: The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates... Agent: Oliff & Berridge, PLC

20100167993 - Compounds for enhancing p21 expression and methods of use thereof: The present invention relates to a method for identifying a drug candidate for enhancing expression of p21ctpl/wafl in a human patient suffering from a medical condition that can be treated by enhancing expression of p21Cφl/wafl. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises... Agent: Hoffmann & Baron, LLP

20100167994 - Targeting of ews-fli1 as anti-tumor therapy: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.... Agent: Knobbe Martens Olson & Bear LLP

20100167996 - 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection: p

20100167995 - Peptoid compounds: The invention relates to new peptoid compounds of formula (I), as well as their use in the treatment of bacterial infections, such as those caused by vancomycin resistant microorganisms, and to compositions thereof.... Agent: Seed Intellectual Property Law Group PLLC

20100168003 - Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof: (2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100168027 - Bpc-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells: Described is a novel gene and its encoded secreted tumor antigen, termed BPC-1, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express BPC-1, particularly including prostate cancer and bladder cancer. In human normal tissues, BPC-1 is only expressed in certain tissues of... Agent: Agensys C/o Morrison & Foerster LLP

20100168010 - Compositions and methods of modulating cell growth and motility: A method of modulating cell growth and motility in subject includes administering to a cell expressing GTPase an amount of an ARHGAP4 regulating agent effective to regulate the growth and motility of the cell.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100168028 - Compositions and methods of using crmp-1 and its fragments for treating cancer: Active fragments of hcrmp1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer and methods of using the same for treating cancer are disclosed. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. Vectors capable of expressing an... Agent: Ipc Intellectual Property Connections, Inc.

20100168016 - Diagnosis and treatment of diseases caused by misfolded proteins: In certain aspects, the disclosure relates to methods and compositions for diagnosing and treating diseases caused by misfolded proteins that comprise monitoring ANKRD 16 expression and altering the activity of ANKRD 16 protein. In certain embodiments, the diseases are neurodegenerative diseases. In certain embodiments, the diseases are proteopathies. In certain... Agent: David S. Resnick

20100168024 - Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials: The present invention includes compositions and methods for making and using a drug conjugated to a peptide or protein that binds specifically to a ligand in vivo, wherein the conjugate binds to its ligand in vivo and increases the half-life of the drug.... Agent: Chalker Flores, LLP

20100168018 - Factor viii formulations: A Factor VIII (FVIII) composition formulated such that NaCl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized FVIII.... Agent: Marshall, Gerstein & Borun (baxter)

20100168017 - Functional serum protein product for use in infant food and therapeutic compositions and methods for the preparation thereof: The invention relates to a serum protein product, suitable as an ingredient for foods and therapeutic compositions, in particular infant and baby foods. The invention also provides a method for the preparation of the serum protein product, based on micro filtration of milk. The invention provides a method for the... Agent: Morrison & Foerster LLP

20100167998 - Growth-stimulating polypeptides for use in fish and crustaceans: The present invention is related with polypeptides which show an increased activity compared with tilapia growth hormone. These polypeptides are able to stimulate growth, survival and the quality of fish and crustaceans larvae. Also, they increase the defences against pathogens and stimulate parameters related with the immune system of aquatic... Agent: Hoffmann & Baron, LLP

20100168012 - Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture: The present invention provides methods for inhibiting tumor associated angiogenesis by administering a mutant protective antigen protein comprising a matrix metalloproteinase-recognized cleavage site in place of the native protective antigen furin-recognized site in combination with a lethal factor polypeptide comprising a protective antigen binding site. Upon cleavage of the mutant... Agent: Townsend And Townsend And Crew, LLP

20100168006 - In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins: The present invention encompasses a method for the production of Apolipoproteins in dimeric and/or oligomeric forms (comprising three or more units) of muteins of the human ApoA-1 protein in plant seeds, novel variants of these proteins having an increased stability and capacity to transport cholesterol compared to the native ApoA-1... Agent: Nixon & Vanderhye, PC

20100167999 - Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a... Agent: Greenberg Traurig LLP (la)

20100168023 - Injectable botulinum toxin formulations: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized... Agent: King & Spalding

20100168026 - Insulin secretion inducer, and accelerator for increasing the number of pancreatic beta-cells: Disclosed are: an insulin secretion inducer; an insulin secretion-inducing composition; a process for the production of the composition; an accelerator for increasing the number of pancreatic β-cells; a composition for increasing the number of pancreatic β-cells; a process for the production of the composition; and a viral vector for gene... Agent: Dilworth & Barrese, LLP

20100168001 - Method for preventing and/or treating articles or media contaminated with bacteria of the legionelle genus: The present invention relates to peptides that are active against bacteria of the Legionella genus, characterized in that they correspond to the amino acid sequence corresponding to SEQ ID No. 1: MQFITDLIKKAVDFFKGLFGNK, or to any other similar sequences. The invention also relates to the use of such peptides for preventing... Agent: Nixon & Vanderhye, PC

20100167997 - Method for stimulation collagen synthesis and/or kgf expression: The present invention relates to a method for stimulating collagen synthesis and/or KGF expression, and more particularly, to a method for stimulating collagen synthesis and/or KGF expression using the AIMP1 or its fragment. The AIMP1 or its fragment can be effectively used for the stimulation of collagen synthesis and/or KGF... Agent: Seed Intellectual Property Law Group PLLC

20100168008 - Method of use of epiregulin protein and nucleic acid encoding the same in inflammatory conditions: The present invention relates to nucleotide and protein sequences of epiregulin and epiregulin like proteins and nucleotides and methods employing them as a drug response marker in inflammatory conditions. The invention also provides epiregulin protein for treatment of inflammatory conditions like psoriasis and rheumatoid arthritis alone or in combination with... Agent: Merchant & Gould PC

20100168004 - Methods and compositions for the synergistic activation of latent hiv: The present invention provides methods and compositions useful for the elimination of latent HIV reservoirs that persist despite HAART. The methods and compositions overcome this latent barrier by inducing the replication of HIV in latently infected T cells while preventing the spread of the newly produced virions to uninfected cells... Agent: Townsend And Townsend And Crew, LLP

20100168029 - Methods for treating bone tumors: The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.... Agent: Ropes & Gray LLP

20100168013 - Neuromedin and fn-38 peptides for treating psychiatric diseases: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100168000 - Octanoate-reduced human albumin: The invention relates to the improvement of the transport properties of albumin which is produced on an industrial scale, e.g. via the Cohn process or by means of recombinant processes, and is mixed, during the production process, with substances that saturate the binding points on the albumin and thus affect... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100168019 - Peptide conjugated anti-cancer prodrugs: The present invention relates to prodrug molecules comprising conjugates of an antiproliferative drug, a protease specific cleavable peptide, and, optionally, a targeting peptide, with the prodrugs being substantially inactive prior to degradation of the cleavable sequence by proteolytic enzymes abundant within or in close proximity to the target cancer cell.... Agent: Winston & Strawn LLP Patent Department

20100168015 - Peptides with capacity for binding with interleukine 10 (il-10): The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.... Agent: Moore & Van Allen PLLC

20100168009 - Pha1b toxin, cdna of pha1b toxin gene, pharmaceutical composition containing pha1b toxin, process and product: Methods and compositions for blocking calcium channels with a spider toxin from Phoneutria nigriventer are provided. For easy identification the toxin will be sometimes generally referred to as Phα-1B herein. The toxin comprises a 55-amino acid sequence having a molecular weight of approximately 6,017. This Phα-1B spider toxin was found... Agent: Nixon & Vanderhye, PC

20100168011 - Pharmaceutical formulations and methods for making the same: In certain embodiments, the invention relates to pre-lyophilization formulations, lyophilized compositions, reconstituted formulations, kits comprising the same, and methods for preparing, storing and using the same.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100168005 - Pyridin-3-yl derivatives as immunomodulating agents: The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5; R6 and A are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent: Hoxie & Associates LLC

20100168014 - Screening method: The present inventors have found that relaxin-3 has a feeding-stimulating activity, a body weight increasing activity, and fat weight increasing activity by intracerebroventricularly administering relaxin-3 to rats and observing the amount of feeding, body weight and fat weight, and so on after the administration. According to the present invention, a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100168020 - Stabilized receptor polypeptides and uses thereof: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and... Agent: Amgen Inc. Law Department

20100168025 - Stroke-generated angiogenesis enhancers and uses thereof: The present invention is drawn to methods of stimulating or enhancing angiogenesis in a patient comprising, administering to said patient a therapeutically effective amount of an endorepellin protein, wherein said endorepellin protein has an amino acid sequence of domain V of perlecan or fragments or derivatives, analogs thereof; and stimulating... Agent: Benjamin Aaron Adler Adler & Associates

20100168007 - Systems and methods for applying cross-linked mechanical barriers: A delivery device applies a biocompatible and biodegradable barrier material to a tissue region, e.g., to seal a vascular puncture site. The material comprises two liquid components, which are pre-packaged in individual dispensers. Upon mixing, the liquid components cross-link to create a barrier matrix. A holder attaches to the delivery... Agent: Pepper Hamilton LLP

20100168002 - Therapeutic peptides: The present invention provides a ligand isolated from Moraxella catarrhalis outer membrane protein which binds to CEACAM receptors, said ligand comprising a receptor binding domain comprising an amino acid sequence selected from the group disclosed, or a fragment, homologue, functional equivalent, derivative, degenerate or hydroxylation, sulphonation or glycosylation product or... Agent: Edwards Angell Palmer & Dodge LLP

20100168021 - Urocortin proteins and uses thereof: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related... Agent: Seed Intellectual Property Law Group PLLC

20100168022 - Use of in-vitro culture to design or test personalized treatment regimens: Provided herein are methods of assessing responsiveness to an agent, methods of customizing treatments, methods of screening agents, and methods of treatment. Also provided are systems and kits for carrying out the methods contemplated herein. An exemplary aspect includes a method of assessing whether a subject having a condition, disorder,... Agent: Swanson & Bratschun, L.L.C.

20100168030 - Methods and compositions for treatment of organophosphate-caused pathology: A method of treating an organophosphate toxin-caused cardiac abnormality is described which includes administering a pharmaceutical composition including a therapeutically effective amount of a chloride current modulator to an individual subject having a cardiac abnormality caused by intoxication with an organophosphate toxin. The chloride current modulator is effective to modulate... Agent: U S Army Research Laboratory Attn: Rdrl-loc-i

20100168031 - Lat peptides and their use in assays for identifying immunosuppressants: The invention relates to novel peptides and their use in assays for identifying novel immunosuppressants. More particularly the present invention provides methods and compositions for identifying compounds that will modulate the interaction of protein tyrosine kinase substrates with their intracellular ligands, as well as between their intracellular ligands and other... Agent: Novartis Institutes For Biomedical Research, Inc.

20100168032 - Smart pro-drugs of serine protease inhibitors: The present invention relates to prodrugs of protease inhibitors, such as inhibitors of the proteosome, DPP IV, FAPα and the like. These “pro-inhibitors” are activated, i.e., cleaved, by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100168033 - Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders: An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells.... Agent: Darby & Darby P.C.

20100168036 - Growth factor: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.... Agent: Morgan, Lewis & Bockius LLP (sf)

20100168034 - Peptide having cell membrane penetrating activity: The present invention provides a peptide having cell membrane penetrating activity, a transmembrane carrier comprising the peptide having cell membrane penetrating activity as an effective component, a transmembrane complex consisting of the peptide having cell membrane penetrating activity combined with a target substance, a transfection kit comprising the peptide having... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100168035 - Subcutaneous implants containing a degradation-resistant polylactide polymer: The present invention refers to compositions comprising a LH-RH-analogue and/or pharmaceutically acceptable salts thereof in a low-dose and a degradation-resistant polylactide suitable for the preparation of subcutaneous implants. Sterilisation of the polylactide via gamma-radiation as well as temperature stress result in a negligible decomposition of less than 1000 Dalton.... Agent: Foley & Lardner LLP

20100168037 - Peptides comprising aromatic d-amino acids and methods of use: Disclosed are D-peptides and libraries of D-peptides comprising aromatic D-amino acids. Also disclosed are methods for identifying small D-peptides comprising aromatic D-amino acids that bind to proteins of interest... Agent: Barnes & Thornburg LLP

20100168038 - Use of compounds in combination with gamma-irradiation for the treatment of cancer: TPP II (tripeptidyl peptidase inhibitors are useful in enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells. Suitable compounds comprise tripeptide compounds of general formula RN1RN2N-A1-A2-A3-CO—RC1 wherein RN1, RN2, A1, A2, A3 and RC1 are as defined herein, and which include for... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100168040 - Muscle fatigue remedy: A muscle fatigue remedy that for persons with the symptoms of muscle pain attributed to strenuous exercise, lassitude in the arms and legs attributed to acute exercise, lower back pain and stiffness in the shoulder attributed to taking of a certain posture over a prolonged period of time, etc., relieves... Agent: Darby & Darby P.C.

20100168039 - Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions: Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.... Agent: Pepper Hamilton LLP

20100168041 - Combination of monosaccharides and desquamating agents, and use thereof: The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one desquamating agent. The present invention also relates to the use of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100168042 - Active agent combinations with insecticidal and acaricidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, cyclic ketoenols or other acaricidally active compounds and, secondly, further insecticidally active compounds from the group of the anthranilamides, which combinations are highly suitable for controlling animal pests, such as insects and unwanted acarids.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100168043 - Method for the protection of trees: The present invention provides a method for the prevention/treatment of hark beetle and/or wood borer infestation of trees comprising treatment of the tree with a composition comprising a macroyclic lactone.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100168044 - Superparamagnetic nanoparticle encapsulated with stimuli responsive polymer for drug delivery: The current invention is a novel superparamagnetic site-targeting nanoparticle comprising superparamagnetic nanoparticles encapsulated with a smart polymer. The superparamagnetic site-targeting nanoparticle comprises a functionalized superparamagnetic core that is conjugated with a therapeutic agent and then encapsulated with a smart polymer. The smart polymer can be any polymer that exhibits a... Agent: Kean, Miller, Hawthorne, D'armond, Mccowan & Jarman, L.L.P.

20100168045 - Novel polyunsaturated compounds, method for preparing same and compositions containing the same: The invention concerns novel polyunsaturated compounds of formula (I) wherein: R1 represents a R′1, -A-R′1 group, R′1 being selected from —COOH, —COOR3, —CONH2, —CONHR3, —CONR3, R4, —CHO, —CH2OH, —CH2OR5, and A represents a C2-C16 alkylene, alkenylene or alkynylene; R2 represents: an optionally substituted aryl group or an optionally substituted heteroaryl... Agent: Birch Stewart Kolasch & Birch

20100168046 - Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases: Disclosed are methods of treating infectious diseases comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent.... Agent: Knobbe Martens Olson & Bear LLP

20100168047 - Inhibition of apoptosis-specific eif-5a (\"eif-5a1\") with antisense oligonucleotides and sirna as anti-inflammatory therapeutics: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100168203 - Adenylyl cyclases as novel targets for antibactrial interventions: The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount... Agent: Kenyon & Kenyon LLP

20100168209 - Apoptosis inducer for cancer cell: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or... Agent: Seed Intellectual Property Law Group PLLC

20100168207 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Pepper Hamilton LLP

20100168206 - Gnaq targeted dsrna compositions and methods for inhibiting expression: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.... Agent: Alnylam/fenwick

20100168205 - Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules: Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by... Agent: Alnylam/fenwick

20100168202 - Rad 9 as a diagnostic,prognostic,and therapeutic tool for prostate cancer: This disclosure provides a method of treating a human subject having a cancer which comprises administering to the subject a nucleic acid so as to inhibit expression of human RAD9 protein in a cell of the cancer so as to thereby treat the human subject. This disclosure also provides methods... Agent: Cooper & Dunham, LLP

20100168208 - Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded... Agent: Merck

20100168210 - T-cell cytokine-inducing surface molecules and methods of use: The invention provides cytokine modulators and methods for using the same to modulate cytokine production in monocyte lineage-derived cells. In particular, cytokine modulators of the invention selectively bind to a T-cell cytokine-inducing surface molecule (TCISM)-ligand of T lymphocytes or the corresponding TCISM-receptor of monocyte lineage-derived cells, thereby modulating cytokine production... Agent: Don D. Cha

20100168204 - Therapeutic uses of inhibitors of rtp801l: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.... Agent: Cooper & Dunham, LLP

20100168211 - Hereditary cataract status in canines based on hsf4 gene marker: The invention provides methods for assessing the Hereditary cataract (HC) status of a canine mammal, which methods comprise use of an HSF4 marker to assess the status. Preferred canine mammals are dogs selected from the following breeds: Staffordshire bull terrier, Boston terrier, French bulldog, Mastiff, Bulldog, Boxer, Bullmastiff, Miniature bull... Agent: Michael Best & Friedrich LLP

20100168215 - Methods and compositions for the treatment of neurological disease: The present invention relates to a method for delivering a nucleic acid sequence encoding neuropeptide Y, or a derivative or functional fragment thereof, to a mammalian nervous system target cell. The expression of exogenous NPY, or a derivative or a functional fragment thereof in the target cell(s) provides therapeutic benefit... Agent: Nutter Mcclennen & Fish LLP

20100168214 - Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer: A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene... Agent: Agensys C/o Morrison & Foerster LLP

20100168212 - Oligomers: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce... Agent: Banner & Witcoff, Ltd.

20100168213 - Protein-coding rna to correct mitochondrial dysfunction: The present invention provides compositions and methods for using correctional RNA, with a proteinaceous carrier, to stimulate respiration of the cells, tissues, organs or the whole organism of normal or diseased subjects. In one embodiment of the invention, the signal-tagged correctional RNA is one or more protein-coding RNAs (pcRNA) that... Agent: Reed Smith LLP

20100168049 - Combination of monosaccharides and adenosine and use thereof: The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one additional compound chosen from adenosine, an analogue thereof and a mixture... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100168048 - Method of stabilizing s-adenosyl-l-methionine and stabilized composition: Provided are a process for producing a S-adenosyl-L-methionine-containing composition which is very excellent in a stability by adding at least ascorbic acids or salts thereof to a composition liquid containing S-adenosyl-L-methionine and then drying the above composition liquid or separating and drying a crystallized deposit obtained from the above composition... Agent: Antonelli, Terry, Stout & Kraus, LLP

20100168050 - Compounds having antiangiogenic activity: The use of o-ATP as a pharmacological agent useful for the treatment of diseases in whose onset or progression angiogenesis is involved.... Agent: Young & Thompson

20100168051 - Altered mitochondrial activity in diseases resulting from oxidative stress: The present invention relates to the identification of a subject having or at risk of developing a disease resulting from oxidative stress in the body. The present invention also relates to the identification of a diabetic subject having or at risk of developing microvascular disease, kidney disease, and/or cardiovascular disease.... Agent: Marshall, Gerstein & Borun LLP

20100168052 - Treatment of ebv and khsv infection and associated abnormal cellular proliferation: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or... Agent: Merchant & Gould PC

20100168053 - Oral delivery system for methylcobalamin to treat disorders: A method of treating a disorder by lollipop administering methylcobalamin, with or without folinic acid by direct delivery to the trigeminal nerve. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dyslexia,... Agent: Fulbright And Jaworski LLP

20100168055 - Combination of monosaccharide with c-glycoside derivative and use thereof: Composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, at least one of mannose, and rhamnose and at least one additional compound chosen from C-glycosides and C-glycoside derivatives. Use of such a composition, and also a device containing it.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100168054 - Functionalized beta 1,6 glucosamine disaccharides and process for their preparation: The present invention relates to a novel process for the chemical synthesis of β-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention relates to compositions comprising the compounds and the use of the compounds in the synthesis of disaccharides... Agent: The Webb Law Firm, P.C.

20100168056 - Dietary fiber formulation and method of administration: The invention provides dietary fiber formulation and related methods for its administration. In one embodiment, the invention provides a dietary fiber formulation comprising: partially-hydrolyzed guar gum (PHGG); and fructooligosaccharides (FOS), wherein the dietary fiber formulation exhibits a prebiotic potential greater than a prebiotic potential of PHGG and FOS individually.... Agent: Nestle Healthcare Nutrition

20100168057 - Fungal growth inhibitor: A very safe and useful agent for inhibiting fungal growth and the like are provided by the present invention. Specifically, the present invention provides (1) an agent for inhibiting fungal growth comprising hyaluronic acid or a salt thereof excluding a heavy metal salt as the active ingredient, and a method... Agent: Sughrue-265550

20100168059 - Hyaluronic acid nutritional supplements and methods of using the same: Hyaluronic acid nutritional supplements and methods of using the same. In at least one embodiment of a nutritional supplement of the present disclosure, the nutritional supplement comprises a quantity of a hyaluronic acid, or a salt or digest thereof, and a food acceptable carrier.... Agent: Ice Miller LLP

20100168058 - Novel antagonists of the toll-like receptor 4: The present invention relates to a novel antagonist of the Toll-like receptor 4 (TLR-4). More specifically, the present invention relates to a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana as a novel antagonist of the Toll-like receptor 4 (TLR-4). Further, the present invention relates to the use of said... Agent: Bozicevic, Field & Francis LLP

20100168060 - Salts of benzimidazolyl pyridyl ethers and formulations thereof: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.... Agent: Novartis Corporate Intellectual Property

20100168061 - Method for preparing enzymatically highly branched-amylose and amylopectin cluster: The present invention relates to a method for preparing enzymatically highly branched-amylose and amylopectin cluster. Alpha-glucanotransferase or branching enzyme hydrolyzes the linkage of the segment between amylopectin clusters in starch, producing amylopectin cluster, and simultaneously branching enzyme attaches the branched side-chain to amylose, producing branched amylose, and subsequently treating the... Agent: Law Offices Of Khalilian Sira, LLC

20100168062 - Quinoxaline derivatives as tyrosine kinase activity inhibitors: e

20100168063 - Bicyclic pyrimidinones and uses thereof: The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a... Agent: Darby & Darby P.C.

20100168064 - Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents: 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant... Agent: Bacon & Thomas, PLLC

20100168065 - Quinolinone derivatives as parp and tank inhibitors: a

20100168067 - Biomarkers for bisphosphonate-responsive bone disorders: This invention relates to the finding that the presence of polymorphisms in and around the farnesyl diphosphate synthase (FDPS) gene is predictive of the densitometric response of patients with bone disorders, such as osteoporosis, subsequent to commencing treatment with amino-bisphosphonates. Methods relating to the identification of individuals having bone disorders... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100168066 - Novel insecticides: Compounds of formula (I) wherein the substituents are as defined in claim (1), and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as agrochemical active ingredients and can be prepared in a manner known per se.... Agent: Syngenta Crop Protection, Inc., Patent And Trademark Department

20100168068 - Mao-b inhibitors useful for treating obesity: m

20100168069 - Insect repellent: The invention provides an insect repellent composition that repels flies, gnats, mosquitoes, lice, ticks, and fleas. The insect repellent composition includes an effective amount of a phosphorous containing compound having the formula (RO)3P=Ox or (RO)2P=Ox(OH) alone or in synergistic combination with any one or more compounds selected from a group... Agent: Nixon & Vanderhye, PC

20100168070 - Compounds for the treatment of alzheimer's disease: e

20100168071 - Extended estrogen dosing contraceptive regimen: A contraceptive kit comprising a package containing daily dosages of: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22... Agent: Fitzpatrick Cella Harper & Scinto

20100168072 - Drug combinations for the treatment of duchenne muscular dystrophy: Combinations comprising (or consisting essentially of) one or more compounds of the formula (I) or (II) with one or more ancillary compounds, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of... Agent: Jones Day

20100168073 - Method for treating and/or preventing retinal diseases with sustained release corticosteroids: The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from... Agent: Ropes & Gray LLP

20100168074 - Freezable unit dosage delivery system and method of preparation: A freezable unit dosage delivery system, method of preparation, a solid unit dosage, method of treating symptoms and conditions, and kit is disclosed. The freezable unit dosage delivery system includes a composition, preferably containing one or more medicinal ingredients, having a freezing point less than 5° C.; a storage container... Agent: Sunstein Kann Murphy & Timbers LLP

20100168075 - Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions: The application relates to novel 2-azetidinone derivatives of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds are cholesterol absorption inhibitors and are useful in the treatment of hyperlipidaemic conditions, including atherosclerosis, Alzheimers' disease and cholesterol associated tumours. The application also relates to pharmaceutical formulations comprising such... Agent: Pepper Hamilton LLP

20100168079 - Biaryl benzylamine derivatives: The present invention relates to biaryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100168078 - S1p receptor modulators for treating multiple sclerosis: e

20100168076 - Diphenyl substituted alkanes: The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.... Agent: Merck

20100168077 - Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof: The present invention concerns 2-amino pyridine derivatives of formula 1 processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100168080 - Novel compounds useful as cc chemokine receptor ligands: The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100168081 - Galantamine as a neuroprotective drug for retinal ganglion cells: The present invention relates to the use of galantamine for neuroprotection of retinal ganglion cells.... Agent: Smart & Biggar

20100168082 - Heterobicyclic carboxamides as inhibitors for kinases: and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative... Agent: Novartis Institutes For Biomedical Research, Inc.

20100168083 - Adamantane derivatives for the treatment of the metabolic syndrome: Novel substituted adamantane based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly... Agent: High Point Pharmaceuticals, LLC

20100168084 - Therapeutic compounds and related methods of use: Methods of using compounds that are HAT inhibitors are described herein.... Agent: Lando & Anastasi, LLP

20100168086 - 7,8,10,10a-tetrahydro-6h-benzo[c]chromen-9(6ah)-one modulators of cannabinoid receptors: The present invention relates to new 7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one modulators of cannabinoid receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100168085 - Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells: Compositions and methods for modulation of the suppressive activity of CD4+CD25+regulatory T cells (Treg) on CD4+CD25− effector T cells (Teff) are provided. An agent selected from: (i) dopamine; (ii) a dopamine precursor; (iii) a D1-R agonist; (iv) a D2-R antagonist; (v) a combination of (i) and (ii); or (vi) a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100168087 - Benzo[1,2,3]thiadiazine derivates: The present invention relates to new benzo[1,2,3]thiadiazine-1,1-dioxide derivatives of the general Formula (I), medicaments containing such compounds and the use thereof in the medicine. Benzo[1,2,3]thiadiazine-1,1-dioxide derivatives of the general Formula (I) are suitable for the prevention or treatment of the diseases of the central nervous system.... Agent: Kf Ross PC

20100168088 - Pyrrolidine derivatives as nk-3 receptor antagonists: or to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100168089 - Utilization of tace inhibitors for the treatment of acne: An in vitro method of screening for candidate compounds for the preventive or curative treatment of acne entails determination of the ability of a compound to inhibit the expression or the activity of TACE, and also to the administration of inhibitors of the expression or of the activity of this... Agent: Buchanan, Ingersoll & Rooney PC

20100168090 - Active ingredient combinations with insecticidal and acaricidal properties: The novel active compound combinations comprising compounds of the formula (I-1) or (I-2) and the agonists or antagonists of nicotinergic acetylcholine receptors listed in the description have very good insecticidal and/or acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100168091 - Imidazole amines as inhibitors of beta-secretase: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated 3-amyloid deposits or 3-amyloid levels in a patient.... Agent: Wyeth LLC Patent Law Group

20100168092 - Pharmaceutical composition with anti-diabetic action: The invention relates to medicine, in particular to searching and developing novel medicinal agent for treating pancreatic diabetes. The invention is based on the development of more effective and less toxic medicinal agents based on indole derivatives which exhibit antidiabetic, hypolipidemic, hypoglycemic, hypocholesterolemic activity and insulin resistance-improving actions and the... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20100168094 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.... Agent: Vertex Pharmaceuticals Inc.

20100168095 - Multi-cyclic cinnamide derivatives: or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and... Agent: Birch Stewart Kolasch & Birch

20100168093 - Substituted 3-amino-4 -hydroxy pyrrolidines compounds, their preparation and use as medicaments: The present invention relates to substituted pyrrolidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animal.... Agent: Cooper & Dunham LLP

20100168096 - Acylguanidine derivative or salt thereof: [Means for Resolution] It was found that an acylguanidine derivative having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having antagonism to both of the receptors showed superior pharmacological action in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100168097 - Non-nucleoside reverse transcriptase inhibitors: Compounds of Formula I: Formula (I); are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in... Agent: Merck

20100168099 - 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions: The invention provides new 1H-quinolin-4-one compounds of formula (I), wherein R1, R2, R3, R4 and R5 have different meanings, and pharmaceutically acceptable salts and hydrates thereof. Compounds of formula (I) are useful for treating or preventing diseases associated with GABAA receptors modulation, anxiety, epilepsy, sleep disorders including insomnia, and for... Agent: Birch Stewart Kolasch & Birch

20100168101 - Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps): The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100168100 - Quinoline derivatives as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100168098 - Viral polymerase inhibitors: The present invention relates to compounds represented by formula (I) wherein A, B, D, E, R2, R3, R4, R5, R6, R9, a, b, d and e are as defined herein, their salt or ester and pharmaceutical compositions thereof useful in the treatment of hepatitis C viral (HCV) infection. Said compounds... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100168102 - Amide derivatives as kinase inhibitors: The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar1, Ar2, R1, R3, p and n have the meaning defined in the claims In particular, the... Agent: Wolf Greenfield & Sacks, P.C.

20100168103 - Diaryl piperidine compounds as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of diaryl piperidine compounds are disclosed of the general formula (I) where X is a linker and Y may be C, O, S or N.... Agent: Morrison & Foerster LLP

20100168106 - Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation: t

20100168104 - Hiv inhibiting 5-amido substituted pyrimidines:

20100168107 - Imidazole compounds for the treatment of neurodegenerative disorders: wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising... Agent: Pfizer Inc

20100168105 - Spirocyclopropyl piperidine derivatives: Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100168109 - Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent: Jones Day

20100168108 - Phenyl derivatives and methods of use: Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related... Agent: Feldman Gale, P.A.

20100168110 - Novel compounds: The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low... Agent: Jacobson Holman PLLC

20100168111 - Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide: A polymorphic form of rivaroxaban, 5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxa-zolidin-5-yl]-methyl}thiophene-2-carboxamide (termed form APO-A), processes for the preparation thereof, and compositions and formulations comprising form APO-A are provided. Also provided are compositions comprising a crystalline form of rivaroxaban and solvents selected from C3 to C6 ketones, C3 to C4 amides and mixtures thereof.... Agent: Apotex, Inc.

20100168112 - 2-substituted and 4-substituted aryl nitrone compounds: The present invention provides aryl nitrones, compositions comprising the same and methods of their use for the treatment or prevention of oxidative, ischemic, ischemia/reperfusion-related and chemokine mediated conditions.... Agent: Klauber & Jackson

20100168114 - Invertebrate acetylcholinesterase inhibitors: Methods for determining invertebrate- and insect-specific, such as mosquito-specific, residues of acetylcholinesterases are provided herein. The methods can be used to design pesticides and insecticides that are specific for the invertebrate or insect (e.g., mosquito) enzymes, resulting in reduced toxicity concerns for mammals. Compositions for inhibiting invertebrate and insect (e.g.,... Agent: Fish & Richardson P.C.

20100168113 - Pharmaceutical compounds: This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.... Agent: Foley & Lardner LLP

20100168115 - Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect: The present patent application relates to the use of triazine derivatives as cicatrising or angiogenic agents, wherein the triazine is a molecule of formula (I).... Agent: Millen, White, Zelano & Branigan, P.C.

20100168116 - 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases: Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.... Agent: Alcon

20100168117 - A process for the preparation of the stable, amorphous calcium salt of (6s)-n(5)-methyl-5,6,7,8-tetrahydrofolic acid: A process for the preparation of an aqueous solution of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid, whereby (6S)-5,6,7,8-tetrahydrofolic acid having a content of the corresponding (6R)-diastereoisomer in the range from 4% by weight to 8% by weight is methylated in water comprises: treating the methylated reaction mixture with calcium chloride;... Agent: Buchanan, Ingersoll & Rooney PC

20100168118 - Methods to treat cancer with 10-propargyl-10-deazaaminopterin and methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin: The present invention relates to a method for assessing the sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the... Agent: Larson & Anderson, LLC Re: Msk

20100168119 - Compositions and methods for minimizing or reducing agonist-induced desensitization: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that... Agent: Sutherland Asbill & Brennan LLP

20100168120 - Salts of pyridazine compounds: The invention relates to stable and substantially purified synthetic pharmaceutically acceptable acid addition salts of pyridazine compounds of the formula I wherein R10 is hydrogen, hydroxyl, alkyl, alkoxy, alkenyl, alkynyl, alkylene, aryl, heteroaryl, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, =0, ═S, carboxyl, carbonyl,... Agent: Millen, White, Zelano & Branigan, P.C.

20100168121 - Compounds with 5-ht1a activity useful for treating disorders of the outer retina: Compositions and methods for treating disorders of the outer retina with compounds with 5-HT1A agonist activity are disclosed.... Agent: Alcon

20100168122 - Xanthine derivatives as selective hm74a agonists: The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100168123 - Akt protein kinase inhibitors: e

20100168125 - Indolizines and aza-analog derivatives thereof as cns active compounds: The present application relates to indolizine-based compounds of the general formula (I) and aza-analogs thereof, which have medical utility, for example as antipsychotics.... Agent: Mccarter & English, LLP Boston

20100168124 - Novel heterocyclic substituted pyridine compounds with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft... Agent: Merck Patent Department (k-6-1, 1990)

20100168126 - Cosmetic use of 1-aroyl-n-(2-oxo-3-piperidinyl)-2-piperazine carbomamides and related compounds: Cosmetic compositions comprising 1-aroyl-N-(2-oxo-3-piperidinyl)-2-piperazine carboxamides and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The 1-aroyl-N-(2-oxo-3-piperidinyl)-2-piperazine carboxamides are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging.... Agent: Avon Products, Inc.

20100168127 - Cosmetic use of 1-aroyl-n-(2-oxo-3-piperidinyl)-2-piperazine carbomamides and related compounds: Cosmetic compositions comprising 1-aroyl-N-(2-oxo-3-piperidinyl)-2-piperazine carboxamides and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The 1-aroyl-N-(2-oxo-3-piperidinyl)-2-piperazine carboxamides are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging.... Agent: Avon Products, Inc.

20100168128 - Small-molecule inhibitors of the androgen receptor: wherein R1, R2, R3 and R8 are each independently hydrogen or C1-6 alkyl. R4 is absent or is hydrogen, C1-6 alkyl or C1-6 alkyl-OH. R5 is hydrogen, C1-6 alkyl or —NR6R7. R6 and R7 are each independently hydrogen or C1-6 alkyl, or are combined with the nitrogen to which they... Agent: Townsend And Townsend And Crew, LLP

20100168129 - Drugs with anticholestatic activity: e

20100168130 - Diarylmethyl piperazine derivatives, preparations thereof and uses thereof:

20100168131 - Novel compounds: Disclosed are N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100168132 - Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists: Compounds of Formula (I) ; in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and... Agent: Novartis Corporate Intellectual Property

20100168133 - Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases: the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the above compounds and one or more other... Agent: Philip S. Johnson Johnson & Johnson

20100168134 - Pyridyl piperidine orexin receptor antagonists: The present invention is. directed to pyridyl piperidine compounds of formula (I) which are antagonists of orexin receptors, and which are useful' in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these... Agent: Merck

20100168135 - Method of inducing cleavage of amyloid precursor protein to form a novel fragment: The present invention provides a method of inducing cleavage of amyloid precursor protein to produce an approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein in a subject, the method comprising administering a heterocyclic compound or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100168136 - Alkylsulfone derivatives: [wherein, R1 represents a C1-C6 alkyl group which may have 1 to 6 halogen atoms as substituent groups, a C2-C6 alkenyl group which may have 1 to 6 halogen atoms as substituent groups, or a C3-C7 cycloalkyl group which may have 1 to 6 halogen atoms as substituent groups; R2... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100168137 - Combination for use in the treatment of inflammatory disorders: There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) ramatroban, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosclerosis and related conditions.... Agent: Ryan Kromholz & Manion, S.c.

20100168138 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Paul D. Yasger Abbott Laboratories

20100168139 - Inhibitors of human phosphatidylinositol 3-kinase delta: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K... Agent: Morrison & Foerster LLP

20100168140 - Easily absorbable oral preparations of xanthine derivatives: An object of the present invention is to provide an easily absorbable oral preparation containing a xanthine derivative or a pharmaceutically acceptable salt thereof and a fatty acid or a fatty acid derivative for the purpose of providing an easily absorbable oral preparation containing the xanthine derivative of which absorbability... Agent: Edwards Angell Palmer & Dodge LLP

20100168141 - Azetidine analogues nucleosidase and phosphorylase inhibitors: Azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors having the general formula (I), the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds wherein W and... Agent: Amster, Rothstein & Ebenstein LLP

20100168143 - Quinazoline derivatives: The invention provided a compound of formula (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also processes for the preparation of such compounds, as well... Agent: Astrazeneca R&d Boston

20100168142 - Salts of 4-aniline quinazoline derivative: The present invention relates to salt forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide, methods for preparation thereof, pharmaceutical compositions comprising the same and their use thereof. The salt forms of the present invention, which possess excellent tumor inhibitory activity, good bioavailability and low toxicity in an animal body, are suitable for the use of... Agent: Myers Bigel Sibley & Sajovec

20100168144 - Inhibitors of protein kinases: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least... Agent: Olson & Cepuritis, Ltd.

20100168146 - Composition comprising (r)-spiro[l-azabicyclo[2.2.2]octane-3,2'(3'h)-furo[2,3-b]pyridine (azd0328) and its use in the treatment of alzheimer's disease, adhd or cognitive dysfunction: A pharmaceutical composition comprising (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine (AZD0328) and its use in the treatment of subjects suffering from schizophrenia, Alzheimer's disease or other conditions with impaired cognitive function.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100168145 - Fused imidazole derivatives and use thereof as aldosterone synthase inhibitors: The patent application relates to new heterocyclic compounds of the general formula (I) in which A, R, R1, R2, X, Y, Z, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100168147 - Medicinal compositions comprising buprenorphine and naloxone: There is provided a composition for the treatment of pain in human patients wherein said composition comprises buprenorphine to naloxone in a ratio by weight of from 2.1:1 to 8:1, the amount of buprenorphine and naloxone being suitable to provide analgesia, the composition being in a transdermal or transmucosal dosage... Agent: Troutman Sanders LLP 5200 Bank Of America Plaza

20100168148 - Pharmaceutical formulation containing gelling agent: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Agent: Mcdermott Will & Emery LLP

20100168149 - Camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them: s

20100168150 - Camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them.:

20100168151 - Novel processes for preparing 6-(difluoromethoxy)[1]benzofuro[3,2-c]pyridine-9-carbaldehyde, a novel intermediate for the synthesis of pde iv inhibitors: The present invention relates to novel processes for preparing 6-(difluoromethoxy)[1] benzofuro[3,2-c]pyridine-9-carbaldehyde, which is a novel and useful intermediate for preparing compounds with PDE4 inhibitory activity, such as 3,5-dichloro-4-(6-difluoromethoxybenzo[4,5]furo[3,2-c]pyridin-9-ylcarboxamido)-1-pyridiniumolate.... Agent: Glenmark Pharmaceuticals S.a. C/o Blank Rome

20100168152 - Fat regulation: The present invention provides methods and compounds for regulating fat metabolism and achieving fat homeostasis in a subject. Methods and compound for regulating body weight, reducing body fat, and inducing weight loss are also provided, as are methods and compounds for treating or preventing obesity and for preventing or treating... Agent: Fibrogen, Inc.

20100168154 - 1-substituted tetrahydroisoquinoline compound: Provided is a compound useful as an N-type Ca2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100168153 - Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile: The invention relates to particular crystalline forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, its hydrates and solvates, its salts and hydrates and solvates of its salts, certain processes for their preparation, pharmaceutical compositions containing these crystalline forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans,... Agent: Novartis Corporate Intellectual Property

20100168155 - Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics: e

20100168158 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20100168156 - Novel benzoxathiine derivative: This compound is useful for treatment of obesity, diabetes and the like. [In the formula (I), Ar represents a benzene ring or the like; X1 represents a nitrogen atom, a sulfur atom or the like; R1 represents an aryl group or the like; X2 represents a group represented by the... Agent: Merck

20100168157 - Preventive and therapeutic medicament for gastroesophageal reflux disease: wherein R1 and R2 independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100168159 - Hetero compound: Since the compound of the invention has an S1P1 agonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or... Agent: Fitzpatrick Cella Harper & Scinto

20100168160 - Genipin derivatives and uses thereof: Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100168161 - Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta2 adrenergic receptor: n

20100168162 - Selective inhibitors of akt and methods of using same: The present invention describes an improved method for screening compounds for activity in inhibiting the enzymatic activity of Akt1 protein kinase, also known as Protein Kinase B, an enzyme that is believed to play a key role in the inhibition of apoptosis and thus in the etiology of cancer and... Agent: Catalyst Law Group, Apc

20100168163 - Cyclic-alkylamine derivatives as inhibitors of the interaction between mdm2 and p53: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, t, R1, R2, R3, R4, R5, R6, R7, Q, Y and Z have defined meanings.... Agent: Philip S. Johnson Johnson & Johnson

20100168164 - Antidiabetic oxazolidinediones and thiazolidinediones: Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.... Agent: Merck

20100168165 - Method of treating disease involving myelin and/or axonal loss: e

20100168166 - Method of providing an antihistaminic effect in a hepatically impaired patient:

20100168167 - Piperidinones useful in the treatment of inflammation: There is provided compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, m and n have meanings given in the description, and pharmaceutically acceptable derivatives thereof, which compounds are useful in the treatment of diseases and conditions associated with inflammation.... Agent: K&l Gates LLP

20100168168 - Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands: The present invention provides aminoaryl sulphonamide derivatives of formula (I), useful in the treatment of a CNS disorder related to or affected by the 5-HT6 receptor. Pharmacological profiles of these components include high affinity binding with 5-HT6 receptors along with good selectivity towards the receptor. The present invention also includes... Agent: Iphorgan, Ltd.

20100168169 - Substituted 1,3-dioxanes useful as ppar modulators: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100168171 - Piperidinone carboxamide derivatives as p2x7 modulators: The compounds or salts modulate P2X7 receptor function and are capable of interfering with the effects of ATP at the P2X7 receptor. The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders mediated by the P2X7 receptor, for... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100168170 - Piperidinones useful in the treatment of inflammation: There is provided compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, m, n, q and r have meanings given in the description, and pharmaceutically acceptable derivatives thereof, which compounds are useful in the treatment of diseases and conditions associated with inflammation.... Agent: K&l Gates LLP

20100168172 - Heteroaryl (substituted)alkyl n-substituted sulfoximines as insecticides: N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100168173 - Heterocycles substituted pyridine derivatives and antifungal agent containing thereof: wherein R1 represents a hydrogen atom, a halogen atom, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group or a C1-6 alkoxy C1-6 alkyl group; R2 represents a hydrogen atom, a C1-6 alkyl group, an amino group or a di C1-6 alkylamino group; one of X and Y... Agent: Birch Stewart Kolasch & Birch

20100168174 - Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain: The invention provides methods for treating and/or preventing neuropathic pain by administering to patients in need thereof therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The neuropathic pain may be painful diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective... Agent: Clark & Elbing LLP

20100168175 - Atpenins: The present invention relates to processes for preparing certain 2-pyridones and 2-pyridinols, to novel compounds of these two types and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection, in the medicinal field and in the protection of materials.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100168179 - 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations: This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R1a, R1b, R2a, R3a, R3b, R4, R5, R6, R7, A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli... Agent: Millen, White, Zelano & Branigan, P.C.

20100168176 - Novel compounds, pharmaceutical compositions containing same, and methods of use for same: Compounds having the following general formula, pharmaceutical compositions comprising the compounds, and methods of treating cancer, obesity, and microbial infections using such compositions: wherein: R1=H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, cyanomethyl, —OCH3, OC(O)CH3 or OC(O)CF3 R2=-OCH2C(O)NHNH—R5, where R5 is (a) phenyl, optionally substituted with one or more... Agent: Fox Rothschild LLP

20100168177 - Stable insecticide compositions: Insect controlling compositions including an N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximine compound and an organic acid or a salt thereof exhibit increased stability.... Agent: Dow Agrosciences, LLC

20100168178 - Stable insecticide compositions and methods for producing same: Insect controlling compositions including an N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximine compound exhibiting increased stability, along with methods for preparing same, are disclosed.... Agent: Dow Agrosciences, LLC

20100168181 - Benzimidazole amido derivatives, their manufacture and use as pharmaceutical agents: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100168180 - Novel compounds: R9, R10, R11, R12 and R13 are independently H, halo, lower alkyl or —O— lower alkyl, provided that at least one is —O-lower alkyl; or at least one pair of R9 to R13, the members of which pair are adjacent to one another on the ring, are conjoined to form... Agent: Mintz Levin Cohn Ferris Glovsky And Popeo, P.C.

20100168182 - Compounds and compositions as kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly TrkA, TrkB, TrkC, PDGFR and c-kit.... Agent: Genomics Institute Of The Novartis Research Foundation

20100168184 - Small molecule bcl-x1/bcl-2 binding inhibitors: Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject... Agent: Calfee Halter & Griswold, LLP

20100168183 - Subsituted cyclic compound, its preparation process and its medical use: l

20100168185 - Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi: The present invention relates to the use of known 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi in plants and parts of plants, and also to methods for controlling phytopathogenic fungi in plants and parts of plants in crop protection, and also to crop protection compositions comprising these 5-pyridin-4-yl-1,3-thiazoles.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100168186 - Pre-mixed, ready-to-use pharmaceutical compositions: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100168187 - Therapeutic combination: This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects... Agent: Connolly Bove Lodge & Hutz, LLP

20100168188 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone... Agent: Merck

20100168189 - Therapeutic substituted lactams: Therapeutic compounds, compositions, methods, and medicaments related thereto are disclosed herein.... Agent: Allergan, Inc.

20100168190 - Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv): The present invention relates to novel heterocyclic compounds, including oxadiazole compounds, pharmaceutical compositions and their use in the inhibition of reverse transcriptase and the treatment of HIV (1 and 2) infections, AIDS and ARC and other viral infections.... Agent: Coleman Sudol Sapone, P.C.

20100168191 - Pharmaceutical formulation comprising pramipexole: The present invention refers to the use of a medicament for the paediatric treatment of RLS and/or Tic Disorder and/or Tourette's Syndrom.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100168192 - Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions: This invention relates to novel benzisoxazole derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels e.g. a respiratory disease, epilepsy or convulsions.... Agent: Birch Stewart Kolasch & Birch

20100168193 - Therapeutic use of imidazole-5-carboxylic acid derivatives: The invention discloses the use of 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxycarbonyl)oxy] methyl ester and the pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of the damage of a target organ caused by hypertension. It particularly discloses the use of this compound in the manufacture of a medicament... Agent: Connolly Bove Lodge & Hutz, LLP

20100168194 - Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase: The present invention provides compounds and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.... Agent: Wyeth LLC Patent Law Group

20100168195 - Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists: e

20100168196 - N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them: This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100168198 - Mitochondria-targeted antioxidant prodrugs and methods of use: The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20100168197 - Muscarinic receptor antagonists: This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed... Agent: Ranbaxy Inc.

20100168200 - Antifungal pharmaceutical composition: Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1), 50 to 95 mass % of an alcohol such as ethanol, 0.1 to 35 mass % of water or the like, and 0.01 to 5 mass % of a... Agent: Knobbe Martens Olson & Bear LLP

20100168199 - Kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent: Allergan, Inc.

20100168201 - Polymorphs of [r-(r*, r*) ]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid magnesium salt (2:1): Crystalline and amorphous polymorphic forms of Atorvastatin magnesium and processes for their preparation are claimed.... Agent: Ballard Spahr LLP

20100168216 - Prostaglandin pharmaceutical compositions: The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension.... Agent: Schneck & Schneck

20100168217 - Sulfamatobenzothiophene derivatives: The invention relates to novel compound of the general formula (I), in which R has the meanings indicated in claim 1, to the preparation thereof and to the use thereof as medicaments. The compounds (I) are inhibitors of steroid sulfatase and are used for the treatment of cancer.... Agent: Millen, White, Zelano & Branigan, P.C.

20100168218 - Method of reducing food intake: A method of decreasing the food intake of a subject, comprising the administration of a compound which increases FAO, where the compound does not act in the central nervous system to decrease appetite, where the compound is not a fatty acid, or an NPY-inhibitor, or an FAS inhibitor.... Agent: Fox Rothschild LLP

20100168219 - Chronic inflammation and transplantation: This invention relates to pharmaceutical compositions, particularly pharmaceutical compositions comprising bryostatin-1 and substituted derivatives of bryostatin-1, thereof as pharmaceuticals for inhibition of inflammation, and for use in combating arteriosclerosis, diseases of the cardiovascular system, of the central nervous system and prior to/following organ transplantation, ischemia. The invention relates to methods... Agent: Dr. Trevor P. Castor Ceo, Aphios Corporation

20100168223 - 7-hydroxy chromones as potent antioxidants: The present invention describes the identification and purification of 7-hydroxychromes that exhibit potent antioxidant activity. In one embodiment the present invention includes a method for providing an antioxidant to a host in need thereof, comprising administering an effective amount of a 7-hydroxychrome or a mixture of 7-hydroxychromones. The present invention... Agent: Swanson & Bratschun, L.L.C.

20100168222 - Novel use of sargachromenol: The present invention relates to novel use of sargachromenol, and more particularly, the present invention relates to novel use of sargachromenol for destroying and/or lysing hyperproliferating keratinocyte. Accordingly, since sargachromenol of the present invention has activity in destroying and/or lysing keratinocyte, it may be useful for keratinocyte lysing agents in... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20100168221 - Pharmaceutical composition for treating hepatitis b virus and health food product having hepatitis b virus inhibiting effects: , wherein R1 is OCH3, R2 is OH and R3 is H, or R1 is OH and R2 and R3 both are H, or R1 and R2 both are OH and R3 is H, or R1, R2 and R3 all are OH, and R4 is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar or 3-(β)-O-sugar.... Agent: Lowe Hauptman Ham & Berner, LLP

20100168220 - Plant extract composition for treating hepatitis c: The invention provides a plant extract composition for treating hepatitis C, including an effective amount of the proanthocyanidins oligomer extracted from a plant material, and a pharmaceutically acceptable carrier or salt, wherein the structure of proanthocyanidins is shown as follows:... Agent: Pai Patent & Trademark Law Firm

20100168224 - Hypoglycemic activity of osthole: The present invention relates to a method for controlling blood glucose level and a method for the prophylaxis or treatment of diabetes mellitus and/or its complications. The present invention further relates to an anti-diabetic formulation for controlling blood glucose level and/or for the prophylaxis or treatment of diabetes mellitus and/or... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100168225 - Small-molecule hepatitis c virus (hcv) ns3/4a serine protease inhibitors: Compounds of Formula 5 and prodrug compounds of Formula 5 wherein G1 is H or OH; G2 is H, R′, or CO2R′; G3, G4 and G5, are each independently selected from the group consisting of: H, R′, OH, OR′, F, Cl, Br, I, NH2, NHR′,NR′2, CN, SH, SR′, SO3H, SO3R′,... Agent: Bozicevic, Field & Francis LLP

20100168226 - Spirocyclic tetronic acid derivatives: m

20100168227 - Preventative treatment and remission of allergic diseases: The invention provides the use of at least one plant selected from plants of the family Zingiberaceae in the preparation of a medicament for use in the treatment or prophylaxis of allergic diseases. The plant is optionally selected from the genera Siphonochilus, Kaempferia, Cienkowskia and Cienkowskiella and the species is... Agent: Sheridan Ross PC

20100168228 - Novel chemotherapeutic agents against inflammation and cancer: Novel compounds, their methods of preparation and use in therapies related to cancer and inflammation are provided. Compounds comprise esters of cinnamic acid, vanillic acid and 4-hydroxy cinnamic acid and derivatives and salts thereof. Compounds with novel benzofuran lignan structure as a potent antimitotic agent and inducer of apoptosis are... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100168229 - Process for the preparation of optically active compounds using transfer hydrogenation: A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen... Agent: Novartis Corporate Intellectual Property

20100168230 - Methods for making organozinc salts and compositions containing the same: Organic zinc salts and mixtures thereof, organic zinc salt coated particles, methods of preparing organic zinc salts and organic zinc salt coated particles, and various applications of such coated particles, including applications in rubber, other polymeric materials, and pesticides and/or fungicides are disclosed.... Agent: The Law Offices Of Andrew D. Fortney, Ph.d., P.C.

20100168231 - Target enzyme for the treatment of acne: The use of an enzyme as a research tool for acne, by identifying a compound for the treatment of acne and/or any disorder associated with cutaneous hyperseborrhoea.... Agent: Buchanan, Ingersoll & Rooney PC

20100168232 - Oligomer-anticholinergic agent conjugates: The invention provides anticholinergic agents that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the anticholinergic agent not attached to the water-soluble... Agent: Nektar Therapeutics

20100168234 - Production of peracids using an enzyme having perhydrolysis activity: A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100168235 - Production of peracids using an enzyme having perhydrolysis activity: A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100168236 - Production of peracids using an enzyme having perhydrolysis activity: A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100168237 - Production of peracids using an enzyme having perhydrolysis activity: A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100168233 - Terbinafine formulation: The present invention provides a pharmaceutical composition comprising as the active agent a terbinafine compound, water, and at least one water-soluble or water-miscible nonionic surfactant, wherein the terbinafine compound has at least one form selected from the group consisting of free base form, acid addition salt form, ionic form, and... Agent: Banner & Witcoff, Ltd.

20100168238 - Pharmaceutical composition containing phloroglucinol and paracetamol: The invention relates to a pharmaceutical composition for oral or rectal administration, that contains phloroglucinol and paracetamol in a pharmaceutically acceptable carrier. The inventors have evidenced a synergy developed by these two active ingredients in antispasmodic therapy.... Agent: Woodcock Washburn LLP

20100168239 - Use of rasagiline for the treatment of multiple system atrophy: Disclosed is a method for the treatment of Multiple System Atrophy comprising administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.... Agent: Cooper & Dunham, LLP

20100168240 - Substituted dibenzoic acid derivatives and use thereof: The invention relates to novel substituted dibenzoic acid derivatives of formula (I), wherein A represents a group of formula (II) or (III), to methods for producing the same, and to their use in the treatment and/or prophylaxis of diseases. The invention also relates to the use of said substances in... Agent: Barbara A. Shimei Director, Patents & Licensing

20100168241 - Treatment of acne disease states, notably acne vulgaris: Acne disease states, notably acne vulgaris, are treated with naphthoic acid compounds and particularly adapalene in association/combination with light therapy.... Agent: Buchanan, Ingersoll & Rooney PC

20100168242 - Polymorphs of suberoylanilide hydroxamic acid: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high.... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100168243 - Renin inhibitors: The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100168244 - Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them: e

20100168246 - Amine compounds and inhibiting neurotransmitter reuptake: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.... Agent: Fish & Richardson P.C.

20100168245 - Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure: This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of... Agent: Klarquist Sparkman, LLP

20100168247 - Solid composites of a calcium receptor-active compound: The invention encompasses solid composites of the calcium receptor-active compounds, processes for preparing the solid composites, immediate and controlled-release pharmaceutical formulations comprising the solid composites, and methods of treatment therewith.... Agent: Kenyon & Kenyon LLP

20100168248 - Process for producing enriched fractions of tetrahydroxycurcumin and tetrahydrotetrahdroxy-curcumin from the extracts of curcuma longa: A process for producing an enriched fraction of tetrahydoxycurcumin containing, tetrahydroxycurcumin, demethylcurcumin, demethylmonodemethoxycurcumin and bisd.emethoxycurcumin and colorless tetrahydroderivatives thereof. The process consists of demethylation of natural curcumins, obtained, in turn, from the organic solvent extract of turmeric from Curcuma species. The said enriched fraction of tetrahydroxycurcumin is subjected to hydrogenation... Agent: Kramer & Amado, P.C.

20100168249 - Composition containing reduced coenzyme q10, and method for stabilizing the composition: The invention provides a composition containing reduced coenzyme Q10, which is useful as a pharmaceutical product, food, cosmetic, animal drug, feed, and the like, as well as a stabilization method thereof. The oxidation of reduced coenzyme Q10 into oxidized coenzyme Q10 by molecular oxygen can be suppressed by setting, in... Agent: Leydig Voit & Mayer, Ltd

20100168250 - Use of cyclohexanehexol derivatives in the treatment of ocular disease: The present invention relates to methods of treating ocular diseases in a subject by administering to the subject a therapeutically effective amount of one or more cyclohexanehexol derivatives, or salts thereof, or a medicament comprising a cyclohexanehexol derivative and a pharmaceutically acceptable carrier. More specifically, the invention provides a medicament... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100168251 - Fragrance composition for core shell microcapsules: The invention relates to a core shell microcapsules containing a fragrance composition which comprises, prior to encapsulation: A) 40 to 100% by weight of at least one cyclic aromachemical material with a density between 0.950 g/cm3 and 1.500 g/cm3 and a ClogP value between 1.00 and 6.00; B) 0 to... Agent: Sughrue-265550

20100168252 - Sugar derivatives, method for preparation thereof, their use as surface-active agents: e

20100168253 - Method for selecting perfume ingredient, method for formulating fragrance, and preference-enhancing agent: A hair cleanser comprising (i) an amphoteric surfactant, (ii) a cationic polymer, (iii) an N-acyl-N-methyltaurine-based anionic surfactant, and (iv) one or more selected from the group consisting of galaxolide, ambroxan, manzanate, grapefruit oil, marjoram oil, cinnamon oil, aurantiol, tomato leaf extract, spearmint oil, clove oil, chamomile oil, pepper oil, Triplal,... Agent: Rankin, Hill & Clark LLP

20100168254 - Hydrogel composition for the treatment of dermatological disorders: The present patent application is related to a hydrogel composition which is essentially free of active drugs for the manufacture of a product for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis.... Agent: Millen, White, Zelano & Branigan, P.C.

20100168255 - Method for producing a compound which has at least one ether group: The present invention relates to a process for preparing a compound having at least one ether group, at least one ester group, at least one amino group or at least one urethane group by a1) preparing 1,2-propanediol by means of a process wherein glycerol is hydrogenated in the presence of... Agent: Smith Moore Leatherwood LLP

20100168256 - Use of phosphoric triamides in cleaner and hygiene applications: The present invention describes the use of phosphoric triamides in cleaner and hygiene applications.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.53769 seconds

PATENT INFO